Conduit Pharmaceuticals (CDT) S-4/A 28 Jul 23 Registration of securities issued in business combination transactions (amended) Financial data

Cover

Cover	3 Months Ended
	Mar. 31, 2023
Entity Addresses [Line Items]
Document Type	S-4/A
Amendment Flag	true
Amendment Description	Amendment No. 2
Entity Registrant Name	MURPHY CANYON ACQUISITION CORP
Entity Central Index Key	0001896212
Entity Tax Identification Number	87-3272543
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	4995 Murphy Canyon Road
Entity Address, Address Line Two	Suite 300
Entity Address, City or Town	San Diego
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92123
City Area Code	760
Local Phone Number	471-8536
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Business Contact [Member]
Entity Addresses [Line Items]
Entity Address, Address Line One	4995 Murphy Canyon Road
Entity Address, Address Line Two	Suite 300
Entity Address, City or Town	San Diego
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92123
City Area Code	760
Local Phone Number	471-8536
Contact Personnel Name	Jack K. Heilbron

Condensed Balance Sheets

Condensed Balance Sheets £ in Thousands	Mar. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Current assets:
Prepaid expenses	$ 219,417	$ 300,862	$ 55,608
Cash	90,606	345,777	48,555
Total current assets	310,023	646,639	104,163
Investments held in Trust Account	23,658,838	136,871,183
Deferred offering costs			108,962
Total Assets	23,968,861	137,517,822	213,125
Current liabilities:
Accrued expenses	1,433,289	43,113	15,449
Income taxes payable	224,419	374,862
Note payable – Sponsor	300,000		177,057
Total current liabilities	1,957,708	417,975	192,506
Deferred commission payable	4,628,750	4,628,750
Total Liabilities	6,586,458	5,046,725	192,506
Commitments and Contingencies (Note 6)
Common stock subject to possible redemption at redemption value (13,225,000 shares at $10.34 per share)	22,861,803	136,771,183
Stockholders’ Equity (Deficit)
Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding
Additional paid-in capital			24,669
Accumulated deficit	(5,479,806)	(4,300,492)	(4,381)
Total Stockholders’ Equity (Deficit)	(5,479,400)	(4,300,086)	20,619
Total Liabilities and Stockholders’ Equity (Deficit)	23,968,861	137,517,822	213,125
Common Class A [Member]
Stockholders’ Equity (Deficit)
Common stock value	75	75
Common Class B [Member]
Stockholders’ Equity (Deficit)
Common stock value	331	331	331
Conduit Pharmaceuticals Ltd [Member]
Current assets:
Cash and cash equivalents	8,000
Total current assets	8,000
Intangible assets – research and development	5,000	5,000
Total Assets	13,000	5,000
Current liabilities:
Accrued professional fees	2,419,000	2,246,000
Accrued payroll and other current liabilities	25,000	338,000
Option liability	1,309,000	1,417,000
Total current liabilities	3,753,000	4,001,000
Convertible notes payable, carried at fair value	3,620,000	1,835,000
Deferred revenue	4,173,000	4,083,000
Convertible promissory note payable, carried at cost	805,000
Notes payable	179,000	175,000
Total Liabilities	12,530,000	10,094,000
Commitments and Contingencies (Note 6)
Stockholders’ Equity (Deficit)
Common stock value
Accumulated deficit	(12,929,000)	(10,764,000)
Accumulated other comprehensive loss	412,000	675,000
Total Stockholders’ Equity (Deficit)	(12,517,000)	(10,089,000)
Total Liabilities and Stockholders’ Equity (Deficit)	13,000	5,000
Conduit Pharmaceuticals Ltd [Member] | Common Class A [Member]
Stockholders’ Equity (Deficit)
Common stock value
Conduit Pharmaceuticals Ltd [Member] | Common Class B [Member]
Stockholders’ Equity (Deficit)
Common stock value
Conduit Pharmaceuticals Limited [Member]
Current assets:
Intangible assets – research and development		5,000
Total Assets		5,000
Current liabilities:
Accrued professional fees		2,246,000	1,308,000
Accrued payroll and other current liabilities		338,000	927,000
Option liability		1,404,000
Total current liabilities		3,988,000	2,235,000
Convertible notes payable, carried at fair value		1,835,000	749,000
Deferred revenue		4,083,000	2,958,000
Notes payable		175,000
Total Liabilities		10,081,000	5,942,000
Commitments and Contingencies (Note 6)
Stockholders’ Equity (Deficit)
Common stock value
Accumulated deficit		(10,764,000)	(5,877,000)
Accumulated other comprehensive loss		688,000	(65,000)
Total Stockholders’ Equity (Deficit)		(10,076,000)	(5,942,000)
Total Liabilities and Stockholders’ Equity (Deficit)		$ 5,000

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical)	Mar. 31, 2023 $ / shares shares	Mar. 31, 2023 £ / shares shares	Dec. 31, 2022 $ / shares shares	Dec. 31, 2022 £ / shares shares	Dec. 31, 2021 $ / shares shares
Shares subject to possible redemption	2,187,728	2,187,728	13,225,000	13,225,000
Temporary equity, redemption price | $ / shares	$ 10.45		$ 10.34
Preferred stock, par value | $ / shares	$ 0.0001		$ 0.0001		$ 0.0001
Preferred stock, shares authorized	1,000,000	1,000,000	1,000,000	1,000,000	1,000,000
Preferred stock, shares issued	0	0	0	0	0
Preferred stock, shares outstanding	0	0	0	0	0
Common Class A [Member]
Common stock, par value | $ / shares	$ 0.0001		$ 0.0001		$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000	100,000,000	100,000,000	100,000,000
Common stock, shares issued	754,000	754,000	754,000	754,000	0
Common stock, shares outstanding	754,000	754,000	754,000	754,000	0
Shares subject to possible redemption	2,187,728	2,187,728	13,225,000	13,225,000	13,225,000
Common Class B [Member]
Common stock, par value | $ / shares	$ 0.0001		$ 0.0001		$ 0.0001
Common stock, shares authorized	10,000,000	10,000,000	10,000,000	10,000,000	10,000,000
Common stock, shares issued	3,306,250	3,306,250	3,306,250	3,306,250	3,306,250
Common stock, shares outstanding	3,306,250	3,306,250	3,306,250	3,306,250	3,306,250
Conduit Pharmaceuticals Ltd [Member]
Common stock, par value | (per share)	$ 0.0001	£ 0.0001	$ 0.0001	£ 0.0001
Common stock, shares authorized	400,000,000	400,000,000	400,000,000	400,000,000
Common stock, shares issued	2,000	2,000	2,000	2,000
Common stock, shares outstanding	2,000	2,000	2,000	2,000
Conduit Pharmaceuticals Limited [Member]
Common stock, par value | $ / shares			$ 0.0001		$ 0.0001
Common stock, shares authorized			400,000,000	400,000,000	400,000,000
Common stock, shares issued			2,000	2,000	1,000
Common stock, shares outstanding			2,000	2,000	1,000

Condensed Statements of Operati

Condensed Statements of Operations - USD ($)	2 Months Ended		3 Months Ended		12 Months Ended
	Dec. 31, 2021		Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021
Operating expenses:
General and administrative expenses	$ 4,381		$ 477,406	$ 243,718	$ 1,092,682
Administration fee – related party			30,000	20,000	110,000
Total expenses	4,381		507,406	263,718	1,202,682
Other Income
Interest income – Investments held in Trust Account			664,232	10,182	1,976,183
Total other income			664,232	10,182	1,976,183
Net income (loss) before income taxes	(4,381)		156,826	(253,536)	773,501
Income tax expense			(36,557)		(374,862)
Net income (loss)	$ (4,381)		$ 120,269	$ (253,536)	$ 398,639
Common Class A [Member]
Other Income
Earnings per share, basic			$ 0.01	$ (0.02)	$ 0.03
Earnings per share, diluted			$ 0.01	$ (0.02)	$ 0.03
Weighted average number of shares outstanding, basic			5,762,364	8,167,506	12,558,058
Weighted average number of shares outstanding, diluted			5,762,364	8,167,506	12,558,058
Common Class B [Member]
Other Income
Earnings per share, basic	$ 0		$ 0.01	$ (0.02)	$ 0.03
Earnings per share, diluted			$ 0.01	$ (0.02)	$ 0.03
Weighted average number of shares outstanding, basic	2,875,000	[1],[2]	3,306,250	3,306,250	3,306,250
Weighted average number of shares outstanding, diluted	2,875,000	[1],[2]	3,306,250	3,306,250	3,306,250
Conduit Pharmaceuticals Ltd [Member]
Operating expenses:
General and administrative expenses			$ 2,008,000	$ 291,000
Total expenses			2,008,000	291,000
Loss from operation			(2,008,000)	(291,000)
Other Income
Other expense			(157,000)	(16,000)
Total other income			(157,000)	(16,000)
Net income (loss)			$ (2,165,000)	$ (307,000)
Earnings per share, basic			$ (1,082)	$ (307)
Earnings per share, diluted			$ (1,082)	$ (307)
Weighted average number of shares outstanding, basic			2,000	1,000
Weighted average number of shares outstanding, diluted			2,000	1,000
Comprehensive loss:
Foreign currency translation adjustment			$ (263,000)	$ 140,000
Total comprehensive loss			$ (2,428,000)	$ (167,000)
Conduit Pharmaceuticals Limited [Member]
Operating expenses:
Research and development expenses					$ 37,000	$ 28,000
General and administrative expenses					3,049,000	2,890,000
Funding expenses					74,000	255,000
Total expenses					3,160,000	3,173,000
Loss from operation					(3,160,000)	(3,173,000)
Other Income
Other expense					(1,727,000)	(484,000)
Total other income					(1,727,000)	(484,000)
Net income (loss)					$ (4,887,000)	$ (3,657,000)
Earnings per share, basic					$ (2,444)	$ (3,657)
Earnings per share, diluted					$ (2,444)	$ (3,657)
Weighted average number of shares outstanding, basic					2,000,000	1,000,000
Weighted average number of shares outstanding, diluted					2,000,000	1,000,000
Comprehensive loss:
Foreign currency translation adjustment					$ 753,000	$ 79,000
Total comprehensive loss					$ (4,134,000)	$ (3,578,000)
[1]Excludes an aggregate of up to 431,250 1,006,250 3,306,250

Condensed Statements of Changes

Condensed Statements of Changes in Stockholders' Deficit - USD ($)		Common Stock [Member] Conduit Pharmaceuticals Ltd [Member]	Common Stock [Member] Conduit Pharmaceuticals Limited [Member]	Common Stock [Member] Common Class A [Member]	Common Stock [Member] Common Class B [Member]	Retained Earnings [Member] Conduit Pharmaceuticals Ltd [Member]	Retained Earnings [Member] Conduit Pharmaceuticals Limited [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member] Conduit Pharmaceuticals Ltd [Member]	AOCI Attributable to Parent [Member] Conduit Pharmaceuticals Limited [Member]	Additional Paid-in Capital [Member]	Conduit Pharmaceuticals Ltd [Member]	Conduit Pharmaceuticals Limited [Member]	Common Class A [Member]	Total
Beginning balance, value at Dec. 31, 2020							$ (2,220,000)			$ (144,000)			$ (2,364,000)
Beginning balance, shares at Dec. 31, 2020			1,000
Foreign currency translation adjustment										79,000			79,000
Net income (loss)							(3,657,000)						(3,657,000)
Ending balance, value at Dec. 31, 2021					$ 331		(5,877,000)	$ (4,381)		(65,000)	$ 24,669		(5,942,000)		$ 20,619
Ending balance, shares at Dec. 31, 2021			1,000		3,306,250
Beginning balance, value at Oct. 18, 2021
Beginning balance, shares at Oct. 18, 2021
Net income (loss)								(4,381)							(4,381)
Sale of Private Placement Units, net of offering costs	[1],[2]				$ 331						24,669				25,000
Sale of private placement units, net of offering costs	[1],[2]				3,306,250
Ending balance, value at Dec. 31, 2021					$ 331		(5,877,000)	(4,381)		(65,000)	24,669		(5,942,000)		20,619
Ending balance, shares at Dec. 31, 2021			1,000		3,306,250
Foreign currency translation adjustment												$ 140,000
Net income (loss)								(253,536)				(307,000)			(253,536)
Sale of Private Placement Units, net of offering costs				$ 75							7,520,275				7,520,350
Sale of private placement units, net of offering costs				754,000
Remeasurement of Class A common stock subject to possible redemption								(2,818,567)			(29,462,487)				(32,281,054)
Proceeds allocated to Public Warrants, net of offering costs											21,917,543				21,917,543
Ending balance, value at Mar. 31, 2022				$ 75	$ 331			(3,076,484)							(3,076,078)
Ending balance, shares at Mar. 31, 2022				754,000	3,306,250
Beginning balance, value at Dec. 31, 2021					$ 331		(5,877,000)	(4,381)		(65,000)	24,669		(5,942,000)		20,619
Beginning balance, shares at Dec. 31, 2021			1,000		3,306,250
Foreign currency translation adjustment										753,000			753,000
Net income (loss)							(4,887,000)	398,639					(4,887,000)		398,639
Sale of Private Placement Units, net of offering costs				$ 75							7,520,275				7,520,350
Sale of private placement units, net of offering costs			1,000	754,000
Proceeds allocated to Public Warrants, net of offering costs											21,917,543				21,917,543
Remeasurement of Class A common stock subject to possible redemption upon IPO								(2,818,567)			(29,462,487)				(32,281,054)
Remeasurement of Class A shares to redemption value								(1,876,183)							(1,876,183)
Ending balance, value at Dec. 31, 2022				$ 75	$ 331	$ (10,764,000)	$ (10,764,000)	(4,300,492)	$ 675,000	$ 688,000		(10,089,000)	$ (10,076,000)		(4,300,086)
Ending balance, shares at Dec. 31, 2022		2,000	2,000	754,000	3,306,250
Foreign currency translation adjustment									(263,000)			(263,000)
Net income (loss)						(2,165,000)		120,269				(2,165,000)			120,269
Remeasurement of Class A common stock subject to possible redemption								(158,900)							(158,900)
Accrued excise tax on January 24, 2023 redemptions								(1,140,683)						$ 1,140,683	(1,140,683)
Remeasurement of Class A shares to redemption value														$ (114,068,280)	(114,068,280)	[3]
Ending balance, value at Mar. 31, 2023				$ 75	$ 331	$ (12,929,000)		$ (5,479,806)	$ 412,000			$ (12,517,000)			$ (5,479,400)
Ending balance, shares at Mar. 31, 2023		2,000		754,000	3,306,250
[1]Includes an aggregate of up to 431,250 1,006,250 3,306,250 236,350

Condensed Statement of Cash Flo

Condensed Statement of Cash Flows - USD ($)	2 Months Ended	3 Months Ended		12 Months Ended
	Dec. 31, 2021	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities:
Net income (loss)	$ (4,381)	$ 120,269	$ (253,536)	$ 398,639
Adjustments to reconcile net income (loss) to net cash used in operating activities
Formation costs paid by note payable – Sponsor	3,994
Interest earned on investments held in Trust Account		(664,232)	(10,182)	(1,976,183)
Changes in operating assets and liabilities:
Deferred offering costs			108,962	108,962
Prepaid expenses	(5,608)	81,445	(600,637)	(245,254)
Accrued expenses		13,143	59,033	27,664
Related party payable			3,875
Accrued income taxes payable		(150,443)		374,862
Net cash used in operating activities	(5,995)	(599,818)	(692,485)	(1,311,310)
Cash flows from investing activities:
Extension deposit into the Trust Account		(155,403)
Withdrawals from Trust Account for redemptions		113,831,930
Withdrawals from the Trust Account for taxes		200,050
Cash deposited into Trust Account			(134,895,000)	(134,895,000)
Net cash used in investing activities		113,876,577	(134,895,000)	(134,895,000)
Cash flows from financing activities:
Deferred offering costs	(45,450)
Proceeds from note payable - Sponsor	75,000	300,000
Redemptions of Class A common stock		(113,831,930)
Sale of units in public offering			132,250,000	132,250,000
Sale of private placement units			7,540,000	7,540,000
Payment of offering costs			(3,109,411)	(3,109,411)
Repayment of note payable - Sponsor			(177,057)	(177,057)
Proceeds from issuance of Class B common stock to Sponsor	25,000
Net cash provided by financing activities	54,550	(113,531,930)	136,503,532	136,503,532
Net change in cash	48,555	(255,171)	916,047	297,222
Cash at beginning of period		345,777	48,555	48,555
Cash at end of period	48,555	90,606	964,602	345,777	$ 48,555
Non-cash financing activities:
Deferred commission payable			4,628,750	4,628,750
Accrued excise tax on January 24, 2023 redemptions		1,140,683
Remeasurement of Class A common stock subject to possible redemption		(158,900)
Deferred offering costs included in accrued offering costs	15,449
Prepaid expenses paid by note payable - Sponsor	50,000
Deferred offering costs paid by note payable - Sponsor	47,875
Class A shares subject to redemption				136,771,183
Conduit Pharmaceuticals Ltd [Member]
Cash flows from operating activities:
Net income (loss)		(2,165,000)	(307,000)
Adjustments to reconcile net income (loss) to net cash used in operating activities
Gain on sale of equity securities received for sale of future revenue			(33,000)
Gain on change in fair value of option liability		(136,000)
Loss on sale of equity securities			48,000
Change in fair value of convertible notes payable		280,000	1,000
Change in reserve for uncollectible loan		243,000
Noncash interest expense		5,000
Changes in operating assets and liabilities:
Accrued expenses and other current liabilities		(196,000)	(497,000)
Net cash used in operating activities		(1,969,000)	(788,000)
Cash flows from investing activities:
Loans to related party		(243,000)
Net cash used in investing activities		(243,000)
Cash flows from financing activities:
Issuance of convertible notes payable		786,000
Issuance of convertible notes payable, carried at fair value		1,434,000
Proceeds from sale of equity securities			789,000
Net cash provided by financing activities		2,220,000	789,000
Net change in cash and cash equivalents before effect of exchange rate changes		8,000	1,000
Effect of exchange rate changes on cash and cash equivalents			1,000
Net change in cash		8,000	2,000
Cash at beginning of period
Cash at end of period		8,000	2,000
Non-cash financing activities:
FV of shares received related to the sale of future revenue			1,422,000
Conduit Pharmaceuticals Limited [Member]
Cash flows from operating activities:
Net income (loss)				(4,887,000)	(3,657,000)
Adjustments to reconcile net income (loss) to net cash used in operating activities
Loss on option				1,300,000
Change in loan allowance				331,000
Loss on sale of equity securities				129,000	76,000
Change in fair value of convertible notes payable				265,000	73,000
Changes in operating assets and liabilities:
Accrued expenses and other current liabilities				601,000	1,357,000
Intangible assets				(5,000)
Net cash used in operating activities				(2,266,000)	(2,151,000)
Cash flows from investing activities:
Proceeds from issuance of option				148,000
Loans to related party				(331,000)
Net cash used in investing activities				(183,000)
Cash flows from financing activities:
Proceeds from note payable - Sponsor				179,000
Issuance of convertible notes payable				928,000	688,000
Proceeds from sale of equity securities				1,341,000	1,210,000
Net cash provided by financing activities				2,448,000	1,898,000
Net change in cash and cash equivalents before effect of exchange rate changes				(1,000)	(253,000)
Effect of exchange rate changes on cash and cash equivalents				1,000	1,000
Net change in cash					(252,000)
Cash at beginning of period					252,000
Cash at end of period
Non-cash financing activities:
FV of shares received related to the sale of future revenue				$ 1,471,000	$ 1,286,000

Condensed Statements of Opera_2

Condensed Statements of Operations (Parenthetical) - shares			3 Months Ended
	Feb. 07, 2022	Jan. 26, 2022	Mar. 31, 2023
Subsidiary, Sale of Stock [Line Items]
Stock surrendered and forfeited during period shares			11,037,272
Sponsor [Member]
Subsidiary, Sale of Stock [Line Items]
Stock surrendered and forfeited during period shares		1,006,250
Stock issued during period on hold		3,306,250
Over-Allotment Option [Member] | Common Class B [Member]
Subsidiary, Sale of Stock [Line Items]
Number of option issued for forfeiture	431,250

Condensed Statements of Chang_2

Condensed Statements of Changes in Stockholders' Deficit (Parenthetical) - shares			3 Months Ended
	Feb. 07, 2022	Jan. 26, 2022	Mar. 31, 2023
Stock surrendered and forfeited during period shares			11,037,272
Sponsor [Member]
Stock surrendered and forfeited during period shares		1,006,250
Stock issued during period on hold		3,306,250
Over-Allotment Option [Member] | Common Class B [Member]
Number of option issued for forfeiture	431,250

Nature of the Business, Basis o

Nature of the Business, Basis of Presentation and Summary of Significant Accounting Policies	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Conduit Pharmaceuticals Ltd [Member]
Nature of the Business, Basis of Presentation and Summary of Significant Accounting Policies	1. Nature of the Business, Basis of Presentation and Summary of Significant Accounting Policies Conduit Pharmaceuticals Limited, formerly known as SGS Global Limited (“Conduit” or the “Company”), was incorporated in the Cayman Islands as an exempted company in December 2018. Conduit is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been, or are not being, prioritized by leading biopharmaceutical companies in order to develop pharmaceutical products that meet the unmet medical needs of patients. The Company’s current development pipeline includes a glucokinase activator, which is Phase II ready in autoimmune diseases including uveitis, Hashimoto’s Thyroiditis, preterm labor and renal transplant rejection. The Company’s development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility. Merger Agreement On November 8, 2022, the Company entered into a Merger Agreement (the “Merger Agreement”) with Conduit Merger Sub, Inc. (“Merger Sub”) and Murphy Canyon Acquisition Corp. (“MURF”), a publicly traded blank check special purpose acquisition company. Under the terms of the Merger proposed in the Merger Agreement, a wholly owned subsidiary of Murphy will merge with the Company, with the Company being the surviving company and therefore becoming, upon closing of the Merger Agreement, a wholly owned subsidiary of Murphy. The Business Combination will be accounted for a reverse recapitalization in accordance with U.S. GAAP. Under the reverse recapitalization method, MURF will be treated as the acquired company for financial reporting purposes, and the Company, the accounting acquirer, will be assumed to have issued shares of stock for the net assets of MURF, with no goodwill or other intangible assets recorded. This determination is primarily based on the following predominant factors: (i) post-closing, the Company’s shareholders are expected to have a majority of the voting power of the combined company and ability to elect the members of the combined company’s Board of Directors (“Board”); (ii) the on-going operations post-merger will comprise those of Conduit; and (iii) all of the senior management of the combined company, except for the Chief Financial Officer, will be members of the management of the Company. As a result of the Business Combination, MURF will be renamed “Conduit Pharmaceuticals Inc.” The board of directors of each MURF and Conduit have each approved the Business Combination. The completion of the Business Combination, which is expected to occur in the second quarter of 2023, is subject to a special resolution of the Company’s shareholders and approval of MURF’s stockholders of the respective entities and the satisfaction or waiver of certain other customary closing conditions. Basis of Presentation The accompanying condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the rules and regulations of the Securities and Exchange Commission. The functional currency of the Company is the British pound sterling. The accompanying financial statements are reported in United States Dollars, the reporting currency of the Company. Operating results for the three months ended March 31, 2023 are not necessarily indicative of the results that may be expected through December 31, 2023. The accompanying unaudited condensed financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Registration Statement. Liquidity and Going Concern Since its inception, and in line with its growth strategy, the Company has prepared its financial statements assuming it will continue as a going concern. As of March 31, 2023, and December 31, 2022, the Company had an accumulated deficit of $ 12.9 10.8 2.2 0.3 2.0 0.8 As further discussed in Note 5 – Convertible Notes Payable, in the fourth quarter of 2022 the Company approved approximately $ 3.7 1.8 27 The Company has raised and plans on raising further funds as set out above including through the above-mentioned convertible debt as well as through the transactions contemplated by the Merger Agreement and the related PIPE transaction. There is currently no public market for the Company’s ordinary shares. While the Company believes in the viability of its ability to raise additional funds, there can be no assurances to that effect. These matters raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the issue date of this report. These financial statements have been prepared assuming the Company will continue as a going concern and do not include adjustments to reflect the possible effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty. Risks and Uncertainties The Company is subject to risks common to companies in the pharmaceutical industry including, but not limited to, uncertainties related to commercialization of competitor products, regulatory approvals, dependence on key products, dependence on key customers and suppliers, and protection of intellectual property rights. Clinical assets currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts will require significant amounts of additional capital, adequate personnel, infrastructure, and extensive compliance and reporting capabilities. Even if the Company’s efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. In addition, on March 11, 2020, the World Health Organization declared the Coronavirus Disease 2019 (“COVID-19”) a global pandemic. The pandemic has been a highly disruptive economic and societal event that remains unpredictable. Its duration and extent continue to be dependent on various developments, such as the emergence of variants to the virus that may cause additional strains of COVID-19, the administration and ultimate effectiveness of vaccines, and the eventual timeline to achieve a sufficient level of herd immunity among the general population. Accordingly, the COVID-19 pandemic may continue to have negative effects on the health of the U.S. and other economies for the foreseeable future. As this crisis has unfolded, the Company has continued to monitor conditions and adapt its operations to meet federal, state, and local standards. The Company cannot predict the duration or severity of the COVID-19 pandemic or its ultimate impact on the broader economy or the Company’s operations and liquidity. Due to the pandemic, all clinical trials in the United Kingdom that were not related to COVID-19 were put on hiatus for significant portions of the three months ended March 31, 2022. As a result, during the hiatus, the Company shifted its activities to focus on clinical trials related to COVID-19. Summary of Significant Accounting Policies Cash and Cash Equivalents Cash and cash equivalents are primarily maintained with major financial institutions in the United Kingdom and Switzerland. The Company considers cash equivalents to be short-term, highly liquid investments that (a) are readily convertible into known amounts of cash, (b) are traded and held for cash management purposes, and (c) have original maturities of three months or less at the time of purchase. The Switzerland bank accounts holding cash balances are uninsured. The Company has not experienced any losses on this account through the period ended March 31, 2023. As of March 31, 2023, the Company held immaterial cash equivalents. As of December 31, 2022, the Company did not hold any cash equivalents. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and related disclosures of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting period. Estimates are based on several factors including the facts and circumstances available at the time the estimates are made, historical experience, risk of loss, general economic conditions and trends, and the assessment of the probable future outcome. Subjective and significant estimates include, but are not necessarily limited to, the inputs used to determine the fair value of convertible notes payable, the Cizzle option and the amount to reserve for the related party loan receivable. Actual results could differ materially from such estimates. Estimates and assumptions are reviewed periodically by management and changes in estimates are made as management becomes aware of changes in circumstances surrounding the estimates. The effects of changes are reflected in the financial statements in the period that they are determined. Fair Value Measurements Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurements and Disclosures, defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. Fair value is to be determined based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants. In determining fair value, the Company used various valuation approaches. A fair value hierarchy has been established for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are those that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs reflect the Company’s assumption about the inputs that market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The fair value hierarchy is categorized into three levels, based on the inputs, as follows: ● Level 1—Valuations based on quoted prices for identical instruments in active markets. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these instruments does not entail a significant degree of judgment. ● Level 2— Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for either similar instruments in active markets, identical or similar instruments in markets that are not active, or model-derived valuations whose inputs or significant value drivers are observable or can be corroborated by observable market data. ● Level 3—Valuations based on inputs that are unobservable. These valuations require significant judgment. The Company’s Level 1 assets consist of cash and cash equivalents in the accompanying balance sheets and the value of accrued expenses and other current liabilities approximate fair value due to the short-term nature of these assets and liabilities. As of March 31, 2023, the Company has two financial liabilities, convertible notes that are adjusted to fair value on a recurring basis as well as an option liability for which the fair value is determined based on Level 3 inputs as such inputs are not readily observable. See Note 2, Note 4 and Note 5 for further information on the Company’s financial liability held at fair value. Research and Development and Funding Research and development expenses consist primarily of costs incurred in connection with the research and development of our product candidates and programs. Funding expenses consist primarily of costs incurred in connection with the Company providing funding to St George Street Capital (“SGSC”) to carry out its research and development activities. SGSC holds all licenses to conduct clinical research through third party pharmaceutical companies. The Company expenses research and development costs and intangible assets acquired that have no alternative future use as incurred. These expenses include: ● expenses incurred under agreements with organizations that support the Company’s drug discovery and development activities; ● expenses incurred in connection with the preclinical and clinical development of the Company’s product candidates and programs, including under agreements with contract research organizations, or CROs; ● costs related to contract manufacturing organizations, or CMOs, that are primarily engaged to provide drug substance and product for our clinical trials, research and development programs, as well as investigative sites and consultants that conduct the Company’s clinical trials, nonclinical studies and other scientific development services; ● the costs of acquiring and manufacturing nonclinical and clinical trial materials, including manufacturing registration and validation batches; ● employee-related expenses, including salaries, related benefits and equity-based compensation expense, for employees engaged in research and development functions; ● costs related to compliance with quality and regulatory requirements; ● payments made under third-party licensing agreements; and ● direct and allocated costs related to facilities, information technology, personnel and other overhead. Advance payments that we make for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such amounts are recognized as an expense as the goods are delivered or consumed or the related services are performed, or until it is no longer expected that the goods will be delivered, or the services rendered. General and Administrative Expenses General and administrative expenses consist primarily of salaries and related costs for personnel in executive management, finance, corporate and business development, and administrative functions. General and administrative expenses also include legal fees relating to patent and corporate matters; professional fees for accounting, auditing, tax, and administrative consulting services; insurance costs; administrative travel expenses and other operating costs The Company has incurred increased accounting, audit, legal, regulatory, compliance and director and officer insurance costs as well as investor and public relations expenses associated with being a public company. The Company anticipates that its general and administrative expenses will increase in the future as it increases its headcount to support development of its product candidates and programs and with continued research and development activities. Income Taxes ASC Topic 740, Income Taxes The Company is exempt from income tax in the Cayman Islands. Net Loss per Ordinary Share Attributable to Ordinary Shareholders The Company calculates net loss per share attributable to ordinary shareholders – basic and diluted using the two-class method under ASC Topic 260, Earnings Per Share Investments in Equity Securities Investments in equity securities that have a readily determinable fair value are reported at fair value. Changes in fair value between accounting periods are recorded in other expense, net, in the statements of operations and comprehensive loss. Realized gains or losses upon sale are recorded in other expense, net, in the statements of operations and comprehensive loss. The Company did not hold any available for sale or trading securities at the period ended March 31, 2023 or at the year ended December 31, 2022. Intangible Assets Intangible assets subject to amortization include a developed patent. The Company qualitatively evaluates intangible assets for impairment annually or whenever events or changes in circumstances indicate that it is more likely than not the carrying amount of intangible assets may excess their implied fair values. The company recorded an immaterial amount for the intangible asset and an immaterial amount of amortization expense for the periods ended March 31, 2023 and March 31, 2022. As of March 31, 2023 and December 31, 2022, no indicators of impairment of the intangible asset were identified. Related Party Loan The loan made to a related party is stated at the principal amount of $ 0.6 0.6 Foreign Currency Translation Monetary assets and liabilities in the functional currency are re-measured into the reporting currency at the rates of exchange prevailing at the reporting date. Income and expense transactions in the functional currency are re-measured into the reporting currency at the average exchange rate prevailing during the reporting period. Non-monetary items in functional currency are re-measured into the reporting currency at the historical exchange rate (i.e., the rate of exchange at the date of the transaction). The gains or losses resulting from foreign currency translation are included in the statements of operations and comprehensive loss. Emerging Growth Company Status The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that: (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. If the Business Combination were to be consummated, the surviving company will remain an emerging growth company, as defined by the Jumpstart Our Business Startups act of 2012, until the earliest of (i) the last day of the combined entity’s first fiscal year following the fifth anniversary of the completion of MURF’s initial public offering, (ii) the last day of the fiscal year in which the combined entity has total annual gross revenue of at least $1.235 billion, (iii) the last day of the fiscal year in which the combined entity is deemed to be a large accelerated filer, which means the market value of the combined entity’s common stock that is held by non-affiliates exceeds $700.0 million as of the prior December 31 st
Conduit Pharmaceuticals Limited [Member]
Nature of the Business, Basis of Presentation and Summary of Significant Accounting Policies		1. Nature of the Business, Basis of Presentation and Summary of Significant Accounting Policies Conduit Pharmaceuticals Limited, formerly known as SGS Global Limited (“Conduit” or the “Company”), was incorporated in the Cayman Islands as an exempted company in December 2018. Conduit is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been, or are not being, prioritized by leading biopharmaceutical companies in order to develop pharmaceutical products that meet the unmet medical needs of patients. The Company’s current development pipeline includes a glucokinase activator, which is Phase II ready in autoimmune diseases including uveitis, Hashimoto’s Thyroiditis, preterm labor and renal transplant rejection. The Company’s development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility. Merger Agreement On November 8, 2022, the Company entered into a Merger Agreement (the “Merger Agreement”) with Conduit Merger Sub, Inc. (“Merger Sub”) and Murphy Canyon Acquisition Corp. (“MURF”), a publicly traded blank check special purpose acquisition company. Under the terms of the Merger proposed in the Merger Agreement, a wholly owned subsidiary of Murphy will merge with the Company, with the Company being the surviving company and therefore becoming, upon closing of the Merger Agreement, a wholly owned subsidiary of Murphy. The Business Combination will be accounted for a reverse recapitalization in accordance with U.S. GAAP. Under the reverse recapitalization method, MURF will be treated as the acquired company for financial reporting purposes, and the Company, the accounting acquirer, will be assumed to have issued shares of stock for the net assets of MURF, with no goodwill or other intangible assets recorded. This determination is primarily based on the following predominant factors: (i) post-closing, the Company’s shareholders are expected to have a majority of the voting power of the combined company and ability to elect the members of the combined company’s Board of Directors (“Board”); (ii) the on-going operations post-merger will comprise those of Conduit; and (iii) all of the senior management of the combined company, except for the Chief Financial Officer, will be members of the management of the Company. As a result of the Business Combination, MURF will be renamed “Conduit Pharmaceuticals Inc.” The board of directors of each MURF and Conduit have each approved the Business Combination. The completion of the Business Combination, which is expected to occur in the second quarter of 2023, is subject to a special resolution of the Company’s shareholders and approval of MURF’s stockholders of the respective entities and the satisfaction or waiver of certain other customary closing conditions. Basis of Presentation The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the rules and regulations of the Securities and Exchange Commission. The functional currency of the Company is the British pound sterling. The accompanying financial statements are reported in United States Dollars, the reporting currency of the Company. Liquidity and Going Concern Since its inception, and in line with its growth strategy, the Company has prepared its financial statements assuming it will continue as a going concern. Since its inception, the Company has incurred net losses and negative cash flows from operations. As of December 31, 2022, and 2021, the Company had an accumulated deficit of $ 10.8 5.9 4.9 3.7 2.3 2.2 As further discussed in Note 5 – Convertible Notes Payable, in the fourth quarter of 2022 the Company approved approximately $ 3.6 1.8 27 The Company has raised and plans on raising further funds as set out above including through the above-mentioned convertible debt as well as through the transactions contemplated by the Merger Agreement and the related PIPE transaction. There is currently no public market for the Company’s ordinary shares. While the Company believes in the viability of its ability to raise additional funds, there can be no assurances to that effect. These matters raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the issue date of this report. These financial statements have been prepared assuming the Company will continue as a going concern and do not include adjustments to reflect the possible effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty. Risks and Uncertainties The Company is subject to risks common to companies in the pharmaceutical industry including, but not limited to, uncertainties related to commercialization of competitor products, regulatory approvals, dependence on key products, dependence on key customers and suppliers, and protection of intellectual property rights. Clinical assets currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts will require significant amounts of additional capital, adequate personnel, infrastructure, and extensive compliance and reporting capabilities. Even if the Company’s efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. In addition, on March 11, 2020, the World Health Organization declared the Coronavirus Disease 2019 (“COVID-19”) a global pandemic. The pandemic has been a highly disruptive economic and societal event that remains unpredictable. Its duration and extent continue to be dependent on various developments, such as the emergence of variants to the virus that may cause additional strains of COVID-19, the administration and ultimate effectiveness of vaccines, and the eventual timeline to achieve a sufficient level of herd immunity among the general population. Accordingly, the COVID-19 pandemic may continue to have negative effects on the health of the U.S. and other economies for the foreseeable future. As this crisis has unfolded, the Company has continued to monitor conditions and adapt its operations to meet federal, state, and local standards. The Company cannot predict the duration or severity of the COVID-19 pandemic or its ultimate impact on the broader economy or the Company’s operations and liquidity. Due to the pandemic, all clinical trials in the United Kingdom that were not related to COVID-19 were put on hiatus through a significant portion of the year ended December 31, 2021. During the year ended December 31, 2022, the hiatus As a result, during the hiatus, the Company shifted its activities to focus on clinical trials related to COVID-19. Summary of Significant Accounting Policies Cash and Cash Equivalents Cash and cash equivalents are primarily maintained with major financial institutions in the United Kingdom and Switzerland. The Company considers cash equivalents to be short-term, highly liquid investments that (a) are readily convertible into known amounts of cash, (b) are traded and held for cash management purposes, and (c) have original maturities of three months or less at the time of purchase. The Switzerland bank accounts holding cash balances are uninsured. The Company has not experienced any losses on this account through the year ended December 31, 2022. As of December 31, 2022 and 2021, the Company did not hold any cash equivalents. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and related disclosures of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting period. Estimates are based on several factors including the facts and circumstances available at the time the estimates are made, historical experience, risk of loss, general economic conditions and trends, and the assessment of the probable future outcome. Subjective and significant estimates include, but are not necessarily limited to, the inputs used to determine the fair value of convertible notes payable and the amount to reserve for the related party loan receivable. Actual results could differ materially from such estimates. Estimates and assumptions are reviewed periodically by management and changes in estimates are made as management becomes aware of changes in circumstances surrounding the estimates. The effects of changes are reflected in the financial statements in the period that they are determined. Fair Value Measurements Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurements and Disclosures, defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. Fair value is to be determined based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants. In determining fair value, the Company used various valuation approaches. A fair value hierarchy has been established for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are those that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs reflect the Company’s assumption about the inputs that market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The fair value hierarchy is categorized into three levels, based on the inputs, as follows: ● Level 1—Valuations based on quoted prices for identical instruments in active markets. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these instruments does not entail a significant degree of judgment. ● Level 2— Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for either similar instruments in active markets, identical or similar instruments in markets that are not active, or model-derived valuations whose inputs or significant value drivers are observable or can be corroborated by observable market data. ● Level 3—Valuations based on inputs that are unobservable. These valuations require significant judgment. The Company’s Level 1 assets consist of cash and cash equivalents in the accompanying balance sheets and the value of accrued expenses and other current liabilities approximate fair value due to the short-term nature of these assets and liabilities. As of December 31, 2022 and 2021, the Company has two financial liabilities, convertible notes that are adjusted to fair value on a recurring basis as well as an option liability for which the fair value is determined based on Level 3 inputs as such inputs are not readily observable. See Note 2 and Note 5 for further information on the Company’s financial liability held at fair value. Research and Development and Funding Research and development expenses consist primarily of costs incurred in connection with the research and development of our product candidates and programs. Funding expenses consist primarily of costs incurred in connection with the Company providing funding to St George Street Capital (“St George Street”) to carry out its research and development activities. St George Street holds all licenses to conduct clinical research through third party pharmaceutical companies. The Company expenses research and development costs and intangible assets acquired that have no alternative future use as incurred. These expenses include: ● expenses incurred under agreements with organizations that support the Company’s drug discovery and development activities; ● expenses incurred in connection with the preclinical and clinical development of the Company’s product candidates and programs, including under agreements with contract research organizations, or CROs; ● costs related to contract manufacturing organizations, or CMOs, that are primarily engaged to provide drug substance and product for our clinical trials, research and development programs, as well as investigative sites and consultants that conduct the Company’s clinical trials, nonclinical studies and other scientific development services; ● the costs of acquiring and manufacturing nonclinical and clinical trial materials, including manufacturing registration and validation batches; ● employee-related expenses, including salaries, related benefits and equity-based compensation expense, for employees engaged in research and development functions; ● costs related to compliance with quality and regulatory requirements; ● payments made under third-party licensing agreements; and ● direct and allocated costs related to facilities, information technology, personnel and other overhead. Advance payments that we make for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such amounts are recognized as an expense as the goods are delivered or consumed or the related services are performed, or until it is no longer expected that the goods will be delivered, or the services rendered. General and Administrative Expenses General and administrative expenses consist primarily of salaries and related costs for personnel in executive management, finance, corporate and business development, and administrative functions. General and administrative expenses also include legal fees relating to patent and corporate matters; professional fees for accounting, auditing, tax, and administrative consulting services; insurance costs; administrative travel expenses and other operating costs. The Company has incurred increased accounting, audit, legal, regulatory, compliance and director and officer insurance costs as well as investor and public relations expenses associated with being a public company. The Company anticipates that its general and administrative expenses will increase in the future as it increases its headcount to support the development of its product candidates and programs and with continued research and development activities. Income Taxes ASC Topic 740, Income Taxes The Company is exempt from income tax in the Cayman Islands. Net Loss per Ordinary Share Attributable to Ordinary Shareholders The Company calculates net loss per share attributable to ordinary shareholders – basic and diluted using the two-class method under ASC Topic 260, Earnings Per Share Intangible Assets Intangible assets subject to amortization include a developed patent. The Company qualitatively evaluates intangible assets for impairment annually or whenever events or changes in circumstances indicate that it is more likely than not the carrying amount of intangible assets may excess their implied fair values. The company recorded an immaterial amount for the intangible asset and an immaterial amount of amortization expense for the year ended December 31, 2022. As of December 31, 2022, no indicators of impairment of the intangible asset were identified. Related Party Loan The loan made to a related party is stated at the principal amount of $ 0.3 0.3 Investments in Equity Securities Investments in equity securities that have a readily determinable fair value are reported at fair value. Changes in fair value between accounting periods are recorded in other income, net, in the statements of operations and comprehensive loss. Realized gains or losses upon sale are recorded in other income, net, in the statements of operations and comprehensive loss. The Company did not hold any available for sale or trading securities at the years ended December 31, 2022 and December 31, 2021. Foreign Currency Translation Monetary assets and liabilities in the functional currency are re-measured into the reporting currency at the rates of exchange prevailing at the reporting date. Income and expense transactions in the functional currency are re-measured into the reporting currency at the average exchange rate prevailing during the reporting period. Non-monetary items in functional currency are re-measured into the reporting currency at the historical exchange rate (i.e., the rate of exchange at the date of the transaction). The gains or losses resulting from foreign currency translation are included in the statements of operations and comprehensive loss. Emerging Growth Company Status The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that: (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. If the Business Combination (see Note 1) were to be consummated, the surviving company will remain an emerging growth company, as defined by the Jumpstart Our Business Startups act of 2012, until the earliest of (i) the last day of the combined entity’s first fiscal year following the fifth anniversary of the completion of MURF’s initial public offering, (ii) the last day of the fiscal year in which the combined entity has total annual gross revenue of at least $1.235 billion, (iii) the last day of the fiscal year in which the combined entity is deemed to be a large accelerated filer, which means the market value of the combined entity’s common stock that is held by non-affiliates exceeds $700.0 million as of the prior December 31 st Recently Adopted Accounting Pronouncements Effective January 1, 2021, the Company adopted ASU No. 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40) In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842).” Topic 842 was subsequently amended by ASU 2018-10, “Codification Improvements to Topic 842, Leases” and ASU 2018-11, “Leases (Topic 842)”. The amendments in this update increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. For leases with a term of 12 months or less, the amendments permit lessees to make an accounting policy election by class of underlying assets not to recognize lease assets and lease liabilities. For finance leases, the amendments in this update require a lessee to (1) recognize a right-of-use asset and lease liability, initially measured at the present value of the lease payments, on the balance sheet; (2) recognize interest on the lease liability separately from amortization of the right-of-use asset in the statement of operations; (3) classify repayments of the principal portion of the lease liability within financing activities and payments of interest on the lease liability and variable lease payments within operating activities in the statement of cash flows. For operating leases, the amendments in this update require a lessee to (1) recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments, on the balance sheet; (2) recognize a single lease cost, calculated so that the cost of the lease is allocated over the lease term on a generally straight-line basis; (3) classify all cash payments within operating activities in the statement of cash flows. On October 16, 2019, the FASB approved the proposal to delay the effective date for this standard for private and all other entities. Due to the Company’s extended transition period election, the amendments are effective for fiscal years beginning after December 15, 2020. In June 2020, the FASB issued ASU No. 2020-05, Coronavirus Disease 2019 (“COVID-19”) in response to the pandemic which has adversely affected the global economy and caused significant and widespread business and capital market disruptions. The FASB is committed to supporting and assisting stakeholders during this difficult time. The FASB issued ASU 2020-05 as a limited deferral of the effective dates of certain ASUs, including ASU 2016-02 (including amendments issued after the issuance of the original) to provide immediate, near-term relief for certain entities for whom these ASUs are either currently effective or imminently effective. This update is effective for annual periods beginning January 1, 2022, and interim periods beginning January 1, 2023, with early adoption permitted. The Company is in the process of evaluating its impact. The Company did not have any lease agreements as of the years ended December 31, 2022 and 2021 and does not believe the new standard will have a material impact on the financial statements. The Company adopted the standard on January 1, 2022. The adoption of ASU No. 2016-02 did not have a material impact on the Company’s financial statements. Recent Accounting Pronouncements Not Yet Adopted In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740) In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments

Fair Value

Fair Value	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Conduit Pharmaceuticals Ltd [Member]
Fair Value	2. Fair Value The following table presents as of March 31, 2023 the Company’s liabilities subject to measurement at fair value on a recurring basis (in thousands): Schedule of Liabilities Subject to Measurement at Fair Value on Recurring Basis Fair Value Measurements as of March 31, 2023 In thousands Level 1 Level 2 Level 3 Total Liabilities: Convertible notes payable $ - $ - $ 3,620 $ 3,620 Option liability $ - $ - $ 1,309 $ 1,309 Total Liabilities $ - $ - $ 4,929 $ 4,929 The following table presents as of December 31, 2022 the Company’s liabilities subject to measurement at fair value on a recurring basis (in thousands): Fair Value Measurements as of December 31, 2022 In thousands Level 1 Level 2 Level 3 Total Liabilities: Convertible notes payable $ - $ - $ 1,835 $ 1,835 Option liability $ - $ - $ 1,417 $ 1,417 Total Liabilities $ - $ - $ 3,252 $ 3,252 The following table presents additional information about the financial liabilities subject to measurement at fair value on a recurring basis for which the Company used significant unobservable inputs (Level 3) (in thousands): Schedule of Additional Information About the Financial Liabilities Subject To Measurement at Fair Value Amount Balance as of December 31, 2022 $ 1,835 Issuance of debt 1,459 Change in fair value 280 Foreign currency exchange impact 46 Balance as of March 31, 2023 $ 3,620 The convertible notes payable were valued using the fair value option and are considered Level 3 measured instruments. See Note 5 for additional information. Due to the embedded derivatives included in the convertible notes payable, the Company elected to use the fair value option. The fair value was determined based upon a probability-weighted present value approach under three scenarios that consider the provisions of the convertible notes payable. The following table outlines the range of significant unobservable inputs as of March 31, 2023 and December 31, 2022, respectively: Schedule of Fair Value Significant Unobservable Inputs Assumption Unobservable input - Change of control 2023 2022 Probabilities of conversion provisions 10 90 % 10 90 % Estimated timing of conversion 0.33 1.59 0.25 1.41 Time period to maturity 1.41 1.41 Risk-adjusted discount rate 6.3 % 6.1 % The option liability was valued using public market research to determine the probability of success that similar studies in the respiratory and cardiovascular disease areas and a Black-Scholes pricing model. In reviewing the public market research, the Company determined the phase transition success rates for trials similar to the Covid Asset from Phase I to Phase II was 52.7 2.8 1.3 1.4 1.3 The following table presents additional information about the option liability subject to measurement at fair value on a recurring basis for which the Company used significant unobservable inputs (Level 3) (in thousands): Schedule of Additional Information About the Option Liability Subject to Measurement at Fair Value Amount Balance, beginning of period $ 1,417 Option issued - Change in fair value (136 ) Foreign currency exchange impact 28 Balance, end of period $ 1,309 During the period ended March 31, 2023, there were no transfers between Level 1 and Level 2, nor into or out of Level 3.
Conduit Pharmaceuticals Limited [Member]
Fair Value		2. Fair Value The following tables present as of December 31, 2022 and 2021 respectively, the Company’s liabilities subject to measurement at fair value on a recurring basis (in thousands): Schedule of Liabilities Subject to Measurement at Fair Value on Recurring Basis Fair Value Measurements as of December 31, 2022 In thousands Level 1 Level 2 Level 3 Total Liabilities: Convertible notes payable $ - $ - $ 1,835 $ 1,835 Option liability $ - $ - $ 1,404 $ 1,404 Total Liabilities $ - $ - $ 3,239 $ 3,239 Fair Value Measurements as of December 31, 2021 In thousands Level 1 Level 2 Level 3 Total Liabilities: Convertible notes payable $ - $ - $ 749 $ 749 Total Liabilities $ - $ - $ 749 $ 749 The following table presents additional information about the convertible notes payable subject to measurement at fair value on a recurring basis for which the Company used significant unobservable inputs (Level 3) (in thousands): Schedule of Additional Information About the Financial Liabilities Subject To Measurement at Fair Value Amount Balance, beginning of period $ 749 Notes issued 908 Change in fair value 264 Foreign currency exchange impact (86 ) Balance, end of period $ 1,835 The convertible notes payable were valued using the fair value option and are considered Level 3 measured instruments. See Note 5 for additional information. Due to the embedded derivatives included in the convertible notes payable, the Company elected to use the fair value option. The fair value was determined based upon a probability-weighted present value approach under three scenarios that consider the provisions of the convertible notes payable. The following table outlines the range of significant unobservable inputs used in the third-party valuation of the convertible notes payable as of December 31, 2022 and December 31, 2021, respectively: Schedule of Fair Value Significant Unobservable Inputs Assumption Unobservable input - Change of control 2022 2021 Probabilities of conversion provisions 10 90 5 67.5 Estimated timing of conversion 0.25 1.41 0.75 2.41 Time period to maturity 1.41 2.41 Risk-adjusted discount rate 6.1 % 2.9 % The option liability was valued using public market research to determine the probability of success that similar studies in the respiratory and cardiovascular disease areas and a Black-Scholes pricing model. In reviewing the public market research, the Company determined the phase transition success rates for trials similar to the Covid Asset from Phase I to Phase II was 52.7 2.8 1.4 1.4 The following table presents additional information about the option liability subject to measurement at fair value on recurring basis for which the Company used significant unobservable inputs (Level 3) (in thousands): Schedule of Additional Information About the Option Liability Subject to Measurement at Fair Value Amount Balance, beginning of period $ - Option issued 1,404 Change in fair value - Foreign currency exchange impact - Balance, end of period $ 1,404 The following table presents the inputs to the Black-Scholes model as of December 31, 2022 to determine the fair value of the Covid Asset option (in thousands where applicable): Schedule of Fair Value of the Covid Asset Option Black-Scholes Inputs Assumption Underlying asset price $ 2,812 Strike Price $ 3,960 Volatility 90 % Risk-free rate 4.68 % Dividend yield 0 % Option term .71 During the years ended December 31, 2022 and 2021, there were no transfers between 1evel 1 and Level 2, nor into or out of Level 3.

Accrued Expenses

Accrued Expenses	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Conduit Pharmaceuticals Ltd [Member]
Accrued Expenses	3. Accrued Expenses Accrued expenses consisted of the following as of March 31, 2023 and December 31, 2022 (in thousands): Schedule of Accrued Expenses March 31, December 31, 2023 2022 Accrued expenses: Professional service fees $ 2,419 $ 2,246 Payroll 25 338 Total accrued expenses and other current liabilities $ 2,444 $ 2,584
Conduit Pharmaceuticals Limited [Member]
Accrued Expenses		3. Accrued Expenses Accrued expenses consisted of the following as of December 31, 2022 and 2021 (in thousands): Schedule of Accrued Expenses 2022 2021 December 31, 2022 2021 Accrued expenses: Professional service fees $ 2,246 $ 1,308 Payroll 338 921 Other current liabilities: Other - 6 Total accrued expenses and other current liabilities $ 2,584 $ 2,235

Liability Related to the Sale o

Liability Related to the Sale of Future Revenue	3 Months Ended
	Mar. 31, 2023
Conduit Pharmaceuticals Ltd [Member]
Liability Related to the Sale of Future Revenue	4. Liability Related to the Sale of Future Revenue Indirect Investment Regarding the Covid Asset On June 3, 2020, the Company entered into an agreement with SGSC for an indirect investment in the AZ Covid Asset. Under the terms of the agreement, SGSC agreed to pay the Company a royalty of 30 24.5 19.2 0.3 Vela Technologies PLC The Company entered into an Agreement with SGSC to approve an Indirect Investment from Vela Technologies PLC (“Vela”) on October 20, 2020, whereby Vela agreed to provide funding to the Company for an indirect investment in an asset related to COVID-19 (the “Covid Asset”) for use in the field in exchange for 8 2.9 2.35 1.6 1.25 1.1 1.3 1.6 1.25 Cizzle PLC On February 11, 2022, the Company entered into an agreement with Cizzle PLC (“Cizzle”) whereby Cizzle agreed to purchase a percentage of future revenue earned in the Covid Asset, should it reach the commercialization stage. Total consideration under the agreement is specified as $ 1.6 1.2 25.0 22.0 22.0 1.4 The payments received for the sale of future revenue will be classified as deferred income. Under ASC 470-10-25, a seller of future revenue should evaluate whether the proceeds received should be accounted for as debt or deferred income. In assessing the factors that created rebuttable presumption of debt within the guidance, the Company determined that there were factors present to overcome the debt presumption and deferred income classification to be appropriate. The main factors the Company considered were that the transactions in form were sales, and not debt transactions. Each agreement does not guarantee a return to each purchaser, the return is based solely on future performance of the AZ Covid Asset should it reach commercialization, with neither purchaser having an involvement in generating future cash flows from the AZ Covid Asset. The following table presents as of March 31, 2023 the Company’s liability for the sale of future revenue (in thousands): Schedule of Liability for the Sale of Future Revenue Liability related to the sale of future royalties December 31, 2022 $ 4,083 Sale of future royalties - Foreign currency exchange impact 90 March 31, 2023 $ 4,173 On December 15, 2022, the Company entered into an agreement with Cizzle whereby the Company granted Cizzle the option, but not the obligation, to sell its economic interest in the Covid Asset back to the Company. The agreement contained an option period of nine months from the date of the agreement for Cizzle to notify the Company of its intent to exercise the option to sell its economic interest in the Covid Asset. Upon closing of the agreement, Cizzle agreed to pay the Company an option fee of $ 0.1 0.1 3.9 3.25

Convertible Notes Payable

Convertible Notes Payable	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Conduit Pharmaceuticals Ltd [Member]
Convertible Notes Payable	5. Convertible Notes Payable On May 27, 2021, the Company approved a Master Convertible Loan Note Instrument (the “2021 Convertible Loan Note Instrument”), permitting the Company to issue convertible notes in a maximum aggregate principal amount of up to $ 1.4 1.0 5 On August 26, 2022, under the terms of the 2021 Convertible Loan Note Instrument, the Company issued a $ 0.5 0.4 On October 6, 2022, under the terms of the 2021 Convertible Loan Note Instrument, the Company issued a $ 67 50 1.3 950,000 On November 1, 2022, the Company approved a master Convertible Loan Note Instrument (the “2022 Convertible Loan Note Instrument”), permitting the Company to issue convertible notes payable for a maximum aggregate principal amount of up to $ 3.3 3.0 5 On November 16, 2022, under the terms of the 2022 Convertible Loan Note Instrument, the Company issued convertible notes payable with an aggregate principal amount of $ 0.4 0.3 During January and February 2023, under the terms of the 2022 Convertible Loan Note Instrument, the Company issued convertible notes payable with an aggregate principal amount of $ 0.9 0.8 As discussed in Note 10 – Related Party Transactions, during January and February 2023, under the terms of the 2022 Convertible Loan Note Instrument, the Company issued convertible notes payable with an aggregate principal amount of $ 0.5 0.4 The Company elected to fair value the convertible notes payable issued under the 2021 and 2022 Convertible Loan Note Instruments. At the end of each reporting period, the Company calculates the fair value of the convertible notes payable, and any changes in fair value are reported in other income, net, in the current period’s statement of operations and comprehensive loss. There has been no change in fair value from a change in credit quality. For the year period ended March 31, 2023, the Company recorded a loss from the change in fair value of convertible notes payable of $ 0.3 Convertible Promissory Notes Payable During March 2023, the Company issued a promissory convertible note payable with an aggregate principal amount of $ 0.8 20 The Company notes that this issuance was outside of the terms of the 2022 Convertible Loan Note Instrument.
Conduit Pharmaceuticals Limited [Member]
Convertible Notes Payable		5. Convertible Notes Payable On May 27, 2021, the Company approved a Master Convertible Loan Note Instrument (the “2021 Convertible Loan Note Instrument”), permitting the Company to issue convertible notes in a maximum aggregate principal amount of up to $ 1.4 1.0 5 20 The Company issued $ 0.3 0.25 0.5 0.4 67 50 1.1 950,000 67 50 On November 1, 2022, the Company approved a master Convertible Loan Note Instrument (the “2022 Convertible Loan Note Instrument”), permitting the Company to issue convertible notes payable for a maximum aggregate principal amount of up to $ 3.3 3.0 5 20 On November 16, 2022, under the terms of the 2022 Convertible Loan Note Instrument, the Company issued convertible notes payable with an aggregate principal amount of $ 0.4 0.3 The Company elected to fair value the convertible notes payable issued under the 2021 and 2022 Convertible Loan Note Instruments. At the end of each reporting period, the Company calculates the fair value of the convertible notes payable, and any changes in fair value are reported in other income, net, in the current period’s statement of operations and comprehensive loss. There has been no change in fair value from a change in credit quality. For the year ended December 31, 2022, the Company recorded a loss from the change in fair value of convertible notes payable of $ 0.3 0.1

Loans Payable

Loans Payable	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Conduit Pharmaceuticals Ltd [Member]
Loans Payable	6. Loans Payable On May 1, 2022, the Company entered into Loan Agreements (the “Loans”) with two lenders, totaling $ 0.2 The Loans mature two years from the date of the agreement 33 30 33 30 28 25 0.2 0.2 0.2
Conduit Pharmaceuticals Limited [Member]
Loans Payable		6. Loans Payable On May 1, 2022, the Company entered into Loan Agreements (the “Loans”) with two lenders, totaling $ 0.2 The Loans mature two years from the date of the agreement 33 30 33 30 28 25 0.2 0.2

Ordinary Shares

Ordinary Shares	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Subsidiary or Equity Method Investee [Line Items]
Ordinary Shares	NOTE 7 — STOCKHOLDERS’ DEFICIT Preferred Stock 1,000,000 0.0001 no Class A Common Stock 100,000,000 0.0001 Holders of Class A common stock are entitled to one vote for each share 754,000 2,187,728 13,225,000 11,037,272 114,068,280 10.33 Class B Common Stock 10,000,000 0.0001 3,306,250 Only holders of the Class B common stock will have the right to vote on the election of directors prior to the Business Combination. Holders of Class A common stock and holders of Class B common stock will vote together as a single class on all matters submitted to a vote of our shareholders except as otherwise required by law. In connection with our initial business combination, we may enter into a stockholders agreement or other arrangements with the stockholders of the target or other investors to provide for voting or other corporate governance arrangements that differ from those in effect upon completion of this offering. The shares of Class B common stock will automatically convert into Class A common stock at the time of a Business Combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment. In the case that additional shares of Class A common stock, or equity-linked securities, are issued or deemed issued in excess of the amounts issued in the Initial Public Offering and related to the closing of a Business Combination, the ratio at which shares of Class B common stock shall convert into shares of Class A common stock will be adjusted (unless the holders of a majority of the then-outstanding shares of Class B common stock agree to waive such adjustment with respect to any such issuance or deemed issuance) so that the number of shares of Class A common stock issuable upon conversion of all shares of Class B common stock will equal, in the aggregate, on an as-converted basis, 20% of the sum of the total number of all shares of common stock outstanding upon the completion of Initial Public Offering plus all shares of Class A common stock and equity-linked securities issued or deemed issued in connection with a Business Combination (net of the number of shares of Class A common stock redeemed in connection with a Business Combination), excluding any shares or equity-linked securities issued or issuable to any seller of an interest in the target to us in a Business Combination. Only holders of the Class B common stock will have the right to vote on the election of directors prior to the Business Combination. Holders of Class B common stock will vote together as a single class on all matters submitted to a vote of our shareholders except as otherwise required by law. In connection with our initial business combination, we may enter into a stockholders agreement or other arrangements with the stockholders of the target or other investors to provide for voting or other corporate governance arrangements that differ from those in effect upon completion of this offering. Warrants The Company will not be obligated to deliver any shares of Class A common stock pursuant to the exercise of a warrant and will have no obligation to settle such warrant exercise unless a registration statement under the Securities Act covering the issuance of the shares of Class A common stock issuable upon exercise of the warrants is then effective and a current prospectus relating to those shares of Class A common stock is available, subject to the Company satisfying its obligations with respect to registration, or a valid exemption from registration is available. No warrant will be exercisable for cash or on a cashless basis, and the Company will not be obligated to issue any shares to holders seeking to exercise their warrants, unless the issuance of the shares upon such exercise is registered or qualified under the securities laws of the state of residence of the exercising holder, or an exemption from registration is available. The Company has agreed that as soon as practicable, but in no event later than 15 business days after the closing of a Business Combination, the Company will use its commercially reasonable efforts to file, and within 60 business days following a Business Combination to have declared effective, a registration statement covering the issuance of the shares of Class A common stock issuable upon exercise of the warrants and to maintain a current prospectus relating to those shares of Class A common stock until the warrants expire or are redeemed. Notwithstanding the above, if the Class A common stock is at the time of any exercise of a warrant not listed on a national securities exchange such that it satisfies the definition of a “covered security” under Section 18(b)(1) of the Securities Act, the Company may, at its option, require holders of Public Warrants who exercise their warrants to do so on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act and, in the event the Company so elects, the Company will not be required to file or maintain in effect a registration statement, but will use its commercially reasonable efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. Redemption of Warrants When the Price per Share of Class A Common Stock Equals or Exceeds $18.00 ● in whole and not in part; ● at a price of $ 0.01 ● upon a minimum of 30 days’ prior written notice of redemption, or the 30-day redemption period to each warrant holder; and ● if, and only if, the last reported sale price of the Class A common stock equals or exceeds $ 18.00 If and when the warrants become redeemable by the Company, the Company may exercise its redemption right even if it is unable to register or qualify the underlying securities for sale under all applicable state securities laws. If the Company calls the Public Warrants for redemption, as described above, its management will have the option to require any holder that wishes to exercise the Public Warrants to do so on a “cashless basis,” as described in the warrant agreement. The exercise price and number of common stock issuable upon exercise of the Public Warrants may be adjusted in certain circumstances including in the event of a stock dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation. However, except as described below, the Public Warrants will not be adjusted for issuances of common stock at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the Public Warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of Public Warrants will not receive any of such funds with respect to their Public Warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with respect to such Public Warrants. Accordingly, the Public Warrants may expire worthless. The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering. The Private Placement Warrants and Public Warrants are recorded in stockholders’ equity (deficit) as they qualify for equity treatment under ASC 815. The key assumptions used to value the Public Warrants, which was determined to be $ 23,276,000 ● Term – 5 ● Volatility – 22 ● Dividends – 0 ● Discount rate – 1.76	NOTE 7 — STOCKHOLDERS’ EQUITY (DEFICIT) Preferred Stock 1,000,000 0.0001 no Class A Common Stock 100,000,000 0.0001 Holders of Class A common stock are entitled to one vote for each share. 754,000 zero 13,225,000 Class B Common Stock 10,000,000 0.0001 3,306,250 Only holders of the Class B common stock will have the right to vote on the election of directors prior to the Business Combination. Holders of Class A common stock and holders of Class B common stock will vote together as a single class on all matters submitted to a vote of our shareholders except as otherwise required by law. In connection with our initial business combination, we may enter into a stockholders agreement or other arrangements with the stockholders of the target or other investors to provide for voting or other corporate governance arrangements that differ from those in effect upon completion of this offering. The shares of Class B common stock will automatically convert into Class A common stock at the time of a Business Combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment. In the case that additional shares of Class A common stock, or equity-linked securities, are issued or deemed issued in excess of the amounts issued in the Initial Public Offering and related to the closing of a Business Combination, the ratio at which shares of Class B common stock shall convert into shares of Class A common stock will be adjusted (unless the holders of a majority of the then-outstanding shares of Class B common stock agree to waive such adjustment with respect to any such issuance or deemed issuance) so that the number of shares of Class A common stock issuable upon conversion of all shares of Class B common stock will equal, in the aggregate, on an as-converted basis, 20% of the sum of the total number of all shares of common stock outstanding upon the completion of Initial Public Offering plus all shares of Class A common stock and equity-linked securities issued or deemed issued in connection with a Business Combination (net of the number of shares of Class A common stock redeemed in connection with a Business Combination), excluding any shares or equity-linked securities issued or issuable to any seller of an interest in the target to us in a Business Combination. Only holders of the Class B common stock will have the right to vote on the election of directors prior to the Business Combination. Holders of Class B common stock will vote together as a single class on all matters submitted to a vote of our shareholders except as otherwise required by law. In connection with our initial business combination, we may enter into a stockholders agreement or other arrangements with the stockholders of the target or other investors to provide for voting or other corporate governance arrangements that differ from those in effect upon completion of this offering. Warrants The Company will not be obligated to deliver any shares of Class A common stock pursuant to the exercise of a warrant and will have no obligation to settle such warrant exercise unless a registration statement under the Securities Act covering the issuance of the shares of Class A common stock issuable upon exercise of the warrants is then effective and a current prospectus relating to those shares of Class A common stock is available, subject to the Company satisfying its obligations with respect to registration, or a valid exemption from registration is available. No warrant will be exercisable for cash or on a cashless basis, and the Company will not be obligated to issue any shares to holders seeking to exercise their warrants, unless the issuance of the shares upon such exercise is registered or qualified under the securities laws of the state of residence of the exercising holder, or an exemption from registration is available. The Company has agreed that as soon as practicable, but in no event later than 15 business days after the closing of a Business Combination, the Company will use its commercially reasonable efforts to file, and within 60 business days following a Business Combination to have declared effective, a registration statement covering the issuance of the shares of Class A common stock issuable upon exercise of the warrants and to maintain a current prospectus relating to those shares of Class A common stock until the warrants expire or are redeemed. Notwithstanding the above, if the Class A common stock is at the time of any exercise of a warrant not listed on a national securities exchange such that it satisfies the definition of a “covered security” under Section 18(b)(1) of the Securities Act, the Company may, at its option, require holders of Public Warrants who exercise their warrants to do so on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act and, in the event the Company so elects, the Company will not be required to file or maintain in effect a registration statement, but will use its commercially reasonable efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. Redemption of Warrants When the Price per Share of Class A Common Stock Equals or Exceeds $18.00 ● in whole and not in part; ● at a price of $ 0.01 ● upon a minimum of 30 days’ prior written notice of redemption, or the 30-day redemption period to each warrant holder; and ● if, and only if, the last reported sale price of the Class A common stock equals or exceeds $ 18.00 If and when the warrants become redeemable by the Company, the Company may exercise its redemption right even if it is unable to register or qualify the underlying securities for sale under all applicable state securities laws. If the Company calls the Public Warrants for redemption, as described above, its management will have the option to require any holder that wishes to exercise the Public Warrants to do so on a “cashless basis,” as described in the warrant agreement. The exercise price and number of common stock issuable upon exercise of the Public Warrants may be adjusted in certain circumstances including in the event of a stock dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation. However, except as described below, the Public Warrants will not be adjusted for issuances of common stock at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the Public Warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of Public Warrants will not receive any of such funds with respect to their Public Warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with respect to such Public Warrants. Accordingly, the Public Warrants may expire worthless. The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering. The Private Placement Warrants and Public Warrants are recorded in stockholders’ equity (deficit) as they qualify for equity treatment under ASC 815. The key assumptions used to value the Public Warrants, which was determined to be $ 23,276,000 ● Term – 5 ● Volatility – 22 ● Dividends – 0 ● Discount rate – 1.76
Conduit Pharmaceuticals Ltd [Member]
Subsidiary or Equity Method Investee [Line Items]
Ordinary Shares	7. Ordinary Shares As of March 31, 2023 and December 31, 2022, the Company has authorized the issuance of up to 400,000,000 0.0001 On November 4, 2022, the Company issued 1,000 775 As of March 31, 2023 and December 31, 2022, 2,000 no Holders of the Ordinary Shares are entitled to one vote per share, and to receive dividends, on and if declared by the board of directors and, upon liquidation or dissolution, are entitled to receive all assets available for distribution, subordinate to the rights, preferences, and privileges of any outstanding preferred shares (if any) with respect to dividends and in connection with liquidation, winding up and dissolution of the Company. The holders have no preemptive or other subscription rights.
Conduit Pharmaceuticals Limited [Member]
Subsidiary or Equity Method Investee [Line Items]
Ordinary Shares		7. Ordinary Shares As of December 31, 2022 and 2021, the Company has authorized the issuance of up to 400,000,000 0.0001 As of December 31, 2022 and December 31, 2021, 2,000 1,000 1,000 No no Holders of the Ordinary Shares are entitled to one vote per share, and to receive dividends, on and if declared by the board of directors and, upon liquidation or dissolution, are entitled to receive all assets available for distribution, subordinate to the rights, preferences, and privileges of any outstanding preferred shares (if any) with respect to dividends and in connection with liquidation, winding up and dissolution of the Company. The holders have no preemptive or other subscription rights.

Net Loss Per Share Attributable

Net Loss Per Share Attributable to Ordinary Shareholders	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Conduit Pharmaceuticals Ltd [Member]
Net Loss Per Share Attributable to Ordinary Shareholders	8. Net Loss Per Share Attributable to Ordinary Shareholders The following table presents the calculation of basic and diluted net loss per share attributable to holders of the Ordinary Shares (in thousands, except share amounts and per share data): Schedule of Basic and Diluted Net Loss Per Share 2023 2022 March 31, 2023 2022 Numerator: Net loss and comprehensive loss $ (2,165 ) $ (307 ) Denominator: Weighted average number of ordinary shares outstanding - basic and diluted 2,000 1,000 Net loss per share - basic and diluted $ (1,082 ) $ (307 ) Since the Company was in a loss position for all periods presented, basic net loss per share attributable to holders of the Ordinary Shares is the same as diluted net loss per share attributable to holders of the Ordinary Shares for all periods presented as the inclusion of all potential Ordinary Shares outstanding would have been anti-dilutive. Potentially dilutive securities (upon conversion) that were not included in the diluted per share calculations because they would have been anti-dilutive were as follows: Schedule of Potentially Dilutive Securities March 31, 2023 Ordinary Shares potentially issuable upon conversion of convertible notes payable 3,070,000 Total 3,070,000 March 31, 2022 Ordinary Shares potentially issuable upon conversion of convertible notes payable 500,000 Total 500,000
Conduit Pharmaceuticals Limited [Member]
Net Loss Per Share Attributable to Ordinary Shareholders		8. Net Loss Per Share Attributable to Ordinary Shareholders The following table presents the calculation of basic and diluted net loss per share attributable to holders of the Ordinary Shares (in thousands, except share amounts and per share data): Schedule of Basic and Diluted Net Loss Per Share 2022 2021 December 31, 2022 2021 Numerator: Net loss $ (4,887 ) $ (3,657 ) Denominator: Weighted-average shares outstanding used in calculating net loss per share – basic and diluted 2,000 1,000 Net loss per share attributable to ordinary shareholders – basic and diluted $ (2,444 ) $ (3,657 ) Since the Company was in a loss position for all periods presented, basic net loss per share attributable to holders of the Ordinary Shares is the same as diluted net loss per share attributable to holders of the Ordinary Shares for all periods presented as the inclusion of all potential Ordinary Shares outstanding would have been anti-dilutive. Potentially dilutive securities (upon conversion) that were not included in the diluted per share calculations because they would have been anti-dilutive were as follows: Schedule of Potentially Dilutive Securities December 31, 2022 Ordinary Shares potentially issuable upon conversion of convertible notes payable 1,250,000 Total 1,250,000 December 31, 2021 Ordinary Shares potentially issuable upon conversion of convertible notes payable 500,000 Total 500,000

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Commitments and Contingencies	NOTE 6 — COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Registration Rights The holders of the Founder Shares, Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans (and any shares of common stock issuable upon the exercise of the Private Placement Warrants or warrants issued upon conversion of the Working Capital Loans and upon conversion of the Founder Shares) will be entitled to registration rights pursuant to a registration rights agreement to be signed prior to or on the effective date of Initial Public Offering requiring the Company to register such securities for resale. The holders of these securities will be entitled to make up to three demands, excluding short form registration demands, that the Company register such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to completion of a Business Combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. However, the registration rights agreement provides that the Company will not be required to effect or permit any registration or cause any registration statement to become effective until the securities covered thereby are released from their lock-up restrictions. The Company will bear the expenses incurred in connection with the filing of any such registration statements. Underwriting Agreement The Company granted the underwriters a 45-day option from the date of Initial Public Offering to purchase up to 1,725,000 February 7, 2022 The underwriters were paid a cash underwriting discount of $ 0.20 2,645,000 0.35 4,628,750 In addition to the underwriting discount, the Company paid the underwriters $ 50,000 150,000 50,000	NOTE 6 — COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Registration Rights The holders of the Founder Shares, Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans (and any shares of common stock issuable upon the exercise of the Private Placement Warrants or warrants issued upon conversion of the Working Capital Loans and upon conversion of the Founder Shares) will be entitled to registration rights pursuant to a registration rights agreement to be signed prior to or on the effective date of Initial Public Offering requiring the Company to register such securities for resale. The holders of these securities will be entitled to make up to three demands, excluding short form registration demands, that the Company register such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to completion of a Business Combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. However, the registration rights agreement provides that the Company will not be required to effect or permit any registration or cause any registration statement to become effective until the securities covered thereby are released from their lock-up restrictions. The Company will bear the expenses incurred in connection with the filing of any such registration statements. Underwriting Agreement The Company granted the underwriters a 45-day option from the date of Initial Public Offering to purchase up to 1,725,000 February 7, 2022 The underwriters were paid a cash underwriting discount of $ 0.20 2,645,000 0.35 4,628,750 In addition to the underwriting discount, the Company paid the underwriters $ 50,000 150,000 50,000
Conduit Pharmaceuticals Ltd [Member]
Commitments and Contingencies	9. Commitments and Contingencies Legal Proceedings From time to time, the Company may become involved in legal proceedings or other litigation relating to claims arising in the ordinary course of business. The Company intends to accrue a liability for such matters when it is probable that future expenditures will be made and that such expenditures can be reasonably estimated. Significant judgment is required to determine both probability and estimated exposure amount. Legal fees and other costs associated with such proceedings are expensed as incurred. The Company is not presently a party to any litigation such that the ultimate resolution is reasonably expected to have a material effect on the Company’s financial statements.
Conduit Pharmaceuticals Limited [Member]
Commitments and Contingencies		9. Commitments and Contingencies Legal Proceedings From time to time, the Company may become involved in legal proceedings or other litigation relating to claims arising in the ordinary course of business. The Company intends to accrue a liability for such matters when it is probable that future expenditures will be made and that such expenditures can be reasonably estimated. Significant judgment is required to determine both probability and estimated exposure amount. Legal fees and other costs associated with such proceedings are expensed as incurred.

Related Party Transactions

Related Party Transactions	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Related Party Transactions	NOTE 5 — RELATED PARTY TRANSACTIONS Related Party Transactions Founder Shares On November 16, 2021, the Sponsor received 4,312,500 25,000 1,006,250 3,306,250 The holders of the Founder Shares have agreed, subject to limited exceptions, not to transfer, assign or sell any of the Founder Shares until the earlier to occur of: (A) one year after the completion of a Business Combination and (B) subsequent to a Business Combination, (x) if the last reported sale price of the Class A common stock equals or exceeds $ 12.00 Promissory Note — Related Party On November 4, 2021, the Sponsor issued an unsecured promissory note to the Company (the “Promissory Note”), pursuant to which the Company may borrow up to an aggregate principal amount of $ 300,000 . The Promissory Note is non-interest bearing and payable on the earlier of (i) the consummation of the Initial Public Offering or (ii) the decision not to execute the Initial Public Offering. The balance of this Promissory Note in the amount of $ 177,057 On March 7, 2023, the Company entered into a $ 1.5 300,000 200,000 General and Administrative Services Commencing on the date the Units are first listed on the Nasdaq, the Company has agreed to pay the Sponsor a total of $ 10,000 30,000 20,000 Related Party Loans In order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). Such Working Capital Loans would be evidenced by promissory notes. The notes may be repaid upon completion of a Business Combination, without interest, or, at the lender’s discretion, up to $ 1,500,000 of the notes may be converted upon completion of a Business Combination into units at a price of $ 10.00 per unit. Such units would be identical to the Private Placement Units. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans.	NOTE 5 — RELATED PARTY TRANSACTIONS Related Party Transactions Founder Shares On November 16, 2021, the Sponsor received 4,312,500 25,000 1,006,250 3,306,250 The holders of the Founder Shares have agreed, subject to limited exceptions, not to transfer, assign or sell any of the Founder Shares until the earlier to occur of: (A) one year after the completion of a Business Combination and (B) subsequent to a Business Combination, (x) if the last reported sale price of the Class A common stock equals or exceeds $ 12.00 Promissory Note — Related Party On November 4, 2021, the Sponsor issued an unsecured promissory note to the Company (the “Promissory Note”), pursuant to which the Company may borrow up to an aggregate principal amount of $ 300,000 177,057 1.5 General and Administrative Services Commencing on the date the Units are first listed on the Nasdaq, the Company has agreed to pay the Sponsor a total of $ 10,000 110,000 Related Party Loans In order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). Such Working Capital Loans would be evidenced by promissory notes. The notes may be repaid upon completion of a Business Combination, without interest, or, at the lender’s discretion, up to $ 1,500,000 10.00 no
Conduit Pharmaceuticals Ltd [Member]
Related Party Transactions	10. Related Party Transactions Corvus Capital Limited Corvus Capital Limited (“Corvus”) is a significant investor in the Company through subscribing to 1,000 1.7 1.3 0.6 0.3 0.1 0.2 0.4 33 no During January and February 2023, under the terms of the 2022 Convertible Loan Note Instrument, the Company issued convertible notes payable with an aggregate principal amount of $ 0.5 0.4 20 St George Street Capital St George Street Capital is a significant investor in the Company through subscribing to 225 Ordinary Shares. The Chief Executive Officer of St George Street Capital is also the Chief Executive Officer of Conduit. Further, the Company has an Exclusive Funding Agreement (as defined below) with St George Street Capital. For the periods ended March 31, 2023 and March 31, 2022, the Company did not incur expenses to St George Street Capital. As of March 31, 2023 and December 31, 2022, the Company did not owe any amounts to St George Street Capital. On March 26, 2021, the Company entered into the Exclusive Funding Agreement (“Funding Agreement”) with St George Street Capital. Under the agreement, the Company has the first exclusive right, but not the obligation, to provide or procure funding for the performance or research and development projects undertaken by St George Street Capital. The Funding Agreement entitles the Company to 100% of the net revenue on projects that the Company funds by itself. As of March 31, 2023, the Company has not recognized any net revenue from the Funding Agreement. See Note 1 for discussion on research and development costs.
Conduit Pharmaceuticals Limited [Member]
Related Party Transactions		10. Related Party Transactions Corvus Capital Limited Corvus Capital Limited (“Corvus”) is a significant investor in the Company through holding 1,000 775 1,000 775 1.6 1.3 0.6 0.7 0.4 0.4 0.4 0.4 During January and February 2023, under the terms of the 2022 Convertible Loan Note Instrument, the Company issued convertible notes payable with an aggregate principal amount of $ 0.5 0.4 5% 20% St George Street Capital St George Street Capital is a significant investor in the Company through holding 225 0.3 0.1 On March 26, 2021, the Company entered into the Exclusive Funding Agreement (“Funding Agreement”) with St George Street Capital. Under the agreement, the Company has the first exclusive right, but not the obligation, to provide or procure funding for the performance or research and development projects undertaken by St George Street Capital. The Funding Agreement entitles the Company to 100% of the net revenue on projects that the Company funds by itself. As of December 31, 2022, the Company has not recognized any net revenue from the Funding Agreement. See Note 1 for discussion on research and development costs.

Other Expense, net

Other Expense, net	3 Months Ended
	Mar. 31, 2023
Conduit Pharmaceuticals Ltd [Member]
Other Expense, net	11. Other Expense, net The following table presents other expense, net, for the periods ended March 31, 2023 and 2022 (in thousands): Schedule of Other Expense, Net 2023 2022 For the three months ended March 31, 2023 2022 Other income: Change in fair value of option liability $ 136 $ - Gain on sale of investment in equity securities - 33 Total other income $ 136 $ 33 Other expense: Change in fair value of equity securities receivable - 48 Change in fair value of convertible notes payable 280 1 Realized foreign currency transaction loss 8 - Interest expense on convertible promissory note 5 - Total other expense $ 293 $ 49 Total other income (expense), net $ (157 ) $ (16 )

Subsequent Events

Subsequent Events	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Subsequent Events	NOTE 10 — SUBSEQUENT EVENTS Subsequent Events The Company evaluated subsequent events and transactions that occurred after the balance sheet date through the date the financial statements were issued. Based upon this review, except as disclosed below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements. On April 5, 2023, the Company’s Sponsor advanced $ 200,000 1.5 On April 6, 2023, and May 4, 2023 the Company deposited into the Trust Account $ 78,863 77,688 On May 11, 2023, the Company, Conduit, and Merger Sub entered into a second amendment to the Merger Agreement to provide for (i) removal of the provision that indicates that no tax opinion would be delivered in connection with the closing, (ii) a closing obligation that that the Company either (a) be exempt from the provisions of Rule 419 promulgated under the Securities Act other than through its net tangible assets or (b) have at least $ 5,000,001	NOTE 10 — SUBSEQUENT EVENTS Subsequent Events The Company evaluated subsequent events and transactions that occurred after the balance sheet date through the date the financial statements were issued. Based upon this review, except as disclosed below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements. Initially, the Company was required to complete an initial business combination transaction by 12 months from the consummation of initial public offering or up to 18 months if the Company extended the period of time to consummate a business combination in accordance with the Company’s Certificate of Incorporation. On January 26, 2023, at a special meeting of the Company’s stockholders (the “Special Meeting”), the Company’s stockholders approved a proposal to amend the Company’s certificate of incorporation to allow the Company to extend, at the Company’s election, the date by which the Company has to consummate a business combination up to 12 times, each such extension for an additional one month period, from February 7, 2023, to February 7, 2024. The Company’s stockholders also approved a related proposal to amend the trust agreement allowing the Company to deposit into the Trust Account, for each one-month extension, one-third of 1% In connection with such proposals, the Company’s public stockholders had the right to redeem their shares for cash equal to their pro rata share of the aggregate amount on deposit in the Trust Account as of two days prior to such stockholder vote. The Company’s public stockholders holding 11,037,272 13,979,000 10.33 114 23 As a result of the approval of such proposals, the Company agreed to deposit into the Trust Account one-third of 1% 0.035 77,000 924,000 On March 7, 2023, the Company entered into a $ 1.5 300,000
Conduit Pharmaceuticals Ltd [Member]
Subsequent Events	12. Subsequent Events Vela Option Agreement In April 2023, the Conduit entered into an agreement with Vela which granted Vela the right, but not the obligation, to sell its 8% 0.5 0.4 4.8 4.0 5 15 The option is exercisable in whole at any time from the close of the Merger (the “Effective Time”) until the earlier of (i) the date that is six (6) months from the Effective Time, and (ii) February 7, 2024, the expiration date of the term.
Conduit Pharmaceuticals Limited [Member]
Subsequent Events		12. Subsequent Events The Company has evaluated all events occurring through May 12, 2023, the date on which the financial statements were available to be issued. The Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements, except for the ones described below. Convertible Loan Note Instruments As discussed in Note 10 – Related Party Transactions, during January and February 2023, under the terms of the 2022 Convertible Loan Note Instrument, the Company issued convertible notes payable with an aggregate principal amount of $ 0.5 0.4 During January and February 2023, under the terms of the 2022 Convertible Loan Note Instrument, the Company issued convertible notes payable with an aggregate principal amount of $ 1.3 1.1 During March 2023, the Company issued promissory convertible notes payable with an aggregate principal amount of $ 0.8 18 20% Vela Option Agreement On April 2023, the Company entered into an agreement with Vela which granted Vela the right, but not the obligation, to sell its 8% 0.5 0.4 4.8 4.0 February 7, 2024

Liability Related to the Sale_2

Liability Related to the Sale of Future Royalties	12 Months Ended
	Dec. 31, 2022
Conduit Pharmaceuticals Limited [Member]
Liability Related to the Sale of Future Royalties	4. Liability Related to the Sale of Future Royalties Indirect Investment Regarding the Covid Asset On June 3, 2020, the Company entered into an agreement with St George Street for an indirect investment in the AZ Covid Asset. Under the terms of the agreement, St George Street agreed to pay the Company a royalty of 30 30 0.3 Vela Technologies PLC The Company entered into an Agreement with St George Street to approve funding from Vela Technologies PLC (“Vela”) on October 20, 2020, whereby Vela agreed to provide funding to the Company via a purchase of future royalties an asset related to COVID-19 (the “Covid Asset”) totaling 8 2.9 2.35 1.6 1.25 1.1 1.3 1.6 1.25 During the year ended December 31, 2021, the Company received the 1.1 1.3 1.1 1.2 76 0.3 Share Consideration in Cizzle PLC On February 11, 2022, the Company entered into an agreement with Cizzle PLC (“Cizzle”) whereby Cizzle agreed to provide funding to the Company for the Covid Asset for use in the field through a purchase of a 5% of future revenue earned if the Covid Asset is commercialized. Total consideration under the agreement is specified as $ 1.4 1.2 25.0 22.0 22.0 1.4 The payments received for the sale of future revenue will be classified as deferred income. Under ASC 470-10-25, a seller of future revenue should evaluate whether the proceeds received should be accounted for as debt or deferred income. In assessing the factors that created rebuttable presumption of debt within the guidance, the Company determined that there were factors present to overcome the debt presumption and deferred income classification to be appropriate. The main factors the Company considered were that the transactions in form were sales, and not debt transactions. Each agreement does not guarantee a return to each purchaser, the return is based solely on future performance of the AZ Covid Asset should it reach commercialization, with neither purchaser having an involvement in generating future cash flows from the AZ Covid Asset. The following table presents as of December 31, 2022 the Company’s liability for the sale of future revenue (in thousands): Schedule of Liability for the Sale of Future Revenue Liability related to the sale of future royalties December 31, 2021 $ 2,958 Sale of future royalties 1,439 Foreign currency exchange impact (314 ) December 31, 2022 $ 4,083 On December 15, 2022, the Company entered into an agreement with Cizzle whereby the Company granted Cizzle the option, but not the obligation, to sell its economic interest in the Covid Asset back to the Company. The agreement contained an option period of nine months from the date of the agreement for Cizzle to notify the Company of its intent to exercise the option to sell its economic interest in the Covid Asset. Upon closing of the agreement, Cizzle agreed to pay the Company an option fee of $ 0.1 0.1 3.9 3.25

Other Expense

Other Expense	12 Months Ended
	Dec. 31, 2022
Conduit Pharmaceuticals Limited [Member]
Other Expense	11. Other Expense The following table presents other expense, for the years ended December 31, 2022 and 2021 (in thousands): Schedule of Other Expense, Net 2022 2021 For the year ended December 31, 2022 2021 Other expense: Loss on Cizzle option $ 1,300 $ - Realized foreign currency transaction loss - 8 Loss on sale of investment in equity securities 129 76 Placement fees on sale of investment in equity securities 33 327 Change in fair value of convertible notes payable 265 73 Total other expense $ 1,727 $ 484

DESCRIPTION OF ORGANIZATION, BU

DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND GOING CONCERN	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND GOING CONCERN	NOTE 1 — DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND GOING CONCERN Murphy Canyon Acquisition Corp. (the “Company”) was incorporated in Delaware on October 19, 2021. The Company was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses (the “Business Combination”). The Company is not limited to a particular industry or sector for purposes of consummating a Business Combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies. As of March 31, 2023, the Company had not commenced any operations. All activity for the period from October 19, 2021 (inception), through March 31, 2023, relates to the Company’s formation, the proposed initial public offering (“Initial Public Offering”), which is described below, and searching for an initial Business Combination, as defined below. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income from the proceeds derived from the Initial Public Offering. The Company has selected December 31 as its fiscal year end. The registration statement for the Company’s Initial Public Offering (the “Registration Statement”) was declared effective on February 2, 2022. On February 7, 2022, the Company consummated the Initial Public Offering of 13,225,000 132,250,000 Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 754,000 10.00 7,540,000 Following the closing of the Initial Public Offering on February 7, 2022, an amount of $ 139,790,000 4,895,000 2,000,000 2,895,000 On November 8, 2022, the Company entered into a definitive Business Combination Agreement (the “BCA”) with Conduit Pharmaceuticals Limited, a Cayman Islands exempted company (“Conduit”), and Conduit Merger Sub, Inc., a Cayman Islands exempted company (“Merger Sub”). Merger Sub is a wholly owned subsidiary of the Company. Conduit is a pharmaceutical company led by experienced pharma executives, established to fund the development of successful deprioritized clinical assets licensed from large pharmaceutical companies through its exclusive relationships. The BCA was amended in January 2023 and May 2023. Upon the consummation of the transactions contemplated by the BCA, Merger Sub will merge with and into Conduit, with Conduit surviving as a wholly owned subsidiary of the Company (the “Business Combination”). The Company is expected to be renamed Conduit Pharmaceuticals Inc. at the closing of the Business Combination. Pursuant to the BCA, at the closing, the Company shall issue and deliver to the shareholders of Conduit an aggregate number of shares of the Company’s common stock with an aggregate value equal to $ 650,000,000 10.00 27,000,000 There can be no assurance that the Business Combination or PIPE Financing will occur as planned or at all. The Company’s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. There is no assurance that the Company will be able to complete a Business Combination successfully. The Company must complete one or more initial Business Combinations with one or more operating businesses or assets with a fair market value equal to at least 80% of the net assets held in the Trust Account (as defined below) (excluding the deferred underwriting commissions and taxes payable on the interest earned on the Trust Account). The Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the “Investment Company Act”). Upon the closing of the Initial Public Offering, management has agreed that an amount equal to at least $10.00 per Unit sold in the Initial Public Offering, including proceeds of the Private Placement Warrants, will be held in a trust account (“Trust Account”), located in the United States and invested only in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less or in any open-ended investment company that holds itself out as a money market fund selected by the Company meeting certain conditions of Rule 2a-7 of the Investment Company Act, as determined by the Company, until the earlier of: (i) the completion of a Business Combination and (ii) the distribution of the funds held in the Trust Account, as described below The Company will provide the holders of the outstanding Public Shares (the “Public Stockholders”) with the opportunity to redeem all or a portion of their Public Shares either (i) in connection with a stockholder meeting called to approve the Business Combination or (ii) by means of a tender offer in connection with the Business Combination. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company. The Public Stockholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (net of taxes payable). There will be no redemption rights upon the completion of a Business Combination with respect to the Company’s warrants. All of the Public Shares contain a redemption feature which allows for the redemption of such Public Shares in connection with our liquidation, if there is a stockholder vote or tender offer in connection with our initial business combination and in connection with certain amendments to our amended and restated certificate of incorporation. In accordance with U.S. Securities and Exchange Commission (“SEC”) and its guidance on redeemable equity instruments, which has been codified in ASC 480-10-S99, redemption provisions not solely within the control of a company require common stock subject to redemption to be classified outside of permanent equity. Given that the Public Shares will be issued with other freestanding instruments (i.e., public warrants), the initial carrying value of Class A common stock classified as temporary equity will be the allocated proceeds determined in accordance with ASC 470-20. The Class A common stock is subject to ASC 480-10-S99. If it is probable that the equity instrument will become redeemable, we have the option to either (i) accrete changes in the redemption value over the period from the date of issuance (or from the date that it becomes probable that the instrument will become redeemable, if later) to the earliest redemption date of the instrument or (ii) recognize changes in the redemption value immediately as they occur and adjust the carrying amount of the instrument to equal the redemption value at the end of each reporting period. We have elected to recognize the changes immediately. The accretion or remeasurement will be treated as a deemed dividend (i.e., a reduction to retained earnings, or in absence of retained earnings, additional paid-in capital). The Public Shares are redeemable and will be classified as such on the balance sheet until such date that a redemption event takes place. If the Company seeks stockholder approval of the Business Combination, the Company will proceed with a Business Combination if a majority of the outstanding shares voted are voted in favor of the Business Combination, or such other vote as required by law or stock exchange rule. If a stockholder vote is not required by applicable law or stock exchange listing requirements and the Company does not decide to hold a stockholder vote for business or other reasons, the Company will, pursuant to its amended and restated certificate of incorporation (the “Certificate of Incorporation”), conduct the redemptions pursuant to the tender offer rules of the (“SEC”) and file tender offer documents with the SEC prior to completing a Business Combination. If, however, stockholder approval of the transaction is required by applicable law or stock exchange listing requirements, or the Company decides to obtain stockholder approval for business or other reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. If the Company seeks stockholder approval in connection with a Business Combination, the Sponsor has agreed to vote its Founder Shares (as defined in Note 5) and any Public Shares purchased during or after the Initial Public Offering in favor of approving a Business Combination. Additionally, each Public Stockholder may elect to redeem their Public Shares without voting, and if they do vote, irrespective of whether they vote for or against the proposed transaction. Notwithstanding the foregoing, if the Company seeks stockholder approval of a Business Combination and it does not conduct redemptions pursuant to the tender offer rules, the Certificate of Incorporation provides that a Public Stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% of the Public Shares, without the prior consent of the Company The holders of the Founder Shares have agreed (a) to waive their redemption rights with respect to the Founder Shares and Public Shares held by them in connection with the completion of a Business Combination and (b) not to propose an amendment to the Certificate of Incorporation (i) to modify the substance or timing of the Company’s obligation to allow redemptions in connection with a Business Combination or to redeem 100 If the Company has not completed a Business Combination within 12 months from the consummation of our initial public offering (or up to February 7, 2024 at the election of the Company subject to satisfaction of certain conditions, as amended at the January 2023 Special Meeting, see Note 10) (“Business Combination Period”), the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to pay taxes (less up to $ 100,000 The holders of the Founders Shares have agreed to waive their liquidation rights with respect to the Founder Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the holders of Founder Shares acquire Public Shares in or after the Initial Public Offering, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to their deferred underwriting commission (see Note 6) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the Initial Public Offering price per Unit ($ 10.00 In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below (i) $10.00 per Public Share or (ii) such lesser amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account, if less than $10.00 per public Share due to reductions in the value of the trust assets, in each case net of the amount of interest which may be withdrawn to pay taxes, except as to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims under the Company’s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”) Initially, the Company was required to complete an initial business combination transaction by 12 months from the consummation of initial public offering or up to 18 months if the Company extended the period of time to consummate a business combination in accordance with the Company’s Certificate of Incorporation. On January 26, 2023, at a special meeting of the Company’s stockholders (the “Special Meeting”), the Company’s stockholders approved a proposal to amend the Company’s certificate of incorporation to allow the Company to extend, at the Company’s election, the date by which the Company has to consummate a business combination up to 12 times, each such extension for an additional one month period, from February 7, 2023, to February 7, 2024. The Company’s stockholders also approved a related proposal to amend the trust agreement allowing the Company to deposit into the Trust Account, for each one-month extension, one-third of 1 In connection with such proposals, the Company’s public stockholders had the right to redeem their shares for cash equal to their pro rata share of the aggregate amount on deposit in the Trust Account as of two days prior to such stockholder vote. The Company’s public stockholders holding 11,037,272 13,979,000 10.33 114 24 As a result of the approval of such proposals, the Company agreed to deposit into the Trust Account one-third of 1 0.035 77,000 924,000 155,403 Management’s Plan and Going Concern In connection with the Company’s assessment of going concern considerations in accordance with Accounting Standards Update (“ASU”) 2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” management has determined that the Combination Period is less than one year from the date of the issuance of the financial statements. There is no assurance that the Company’s plans to consummate a Business Combination will be successful within the Combination Period. Additionally, the Company has incurred and expects to continue to incur significant costs in pursuit of its acquisition plans. As a result, these factors raise substantial doubt about the Company’s ability to continue as a going concern for the next twelve months from the issuance of these financial statements. The financial statements do not include any adjustments that might result from the outcome of the uncertainty. Risks and Uncertainties Management is currently evaluating the impact of the COVID-19 pandemic and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position, results of its operations, and search for a target company, the specific impact is not readily determinable as of the date of these financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.	NOTE 1 — DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND GOING CONCERN Murphy Canyon Acquisition Corp. (the “Company”) was incorporated in Delaware on October 19, 2021. The Company was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses (the “Business Combination”). The Company is not limited to a particular industry or sector for purposes of consummating a Business Combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies. As of December 31, 2022, the Company had not commenced any operations. All activity for the period from October 19, 2021 (inception) through December 31, 2022 relates to the Company’s formation, the proposed initial public offering (“Initial Public Offering”), which is described below, and searching for an initial Business Combination, as defined below. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income from the proceeds derived from the Initial Public Offering. The Company has selected December 31 as its fiscal year end. The registration statement for the Company’s Initial Public Offering (the “Registration Statement”) was declared effective on February 2, 2022. On February 7, 2022, the Company consummated the Initial Public Offering of 13,225,000 132,250,000 Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 754,000 10.00 7,540,000 Following the closing of the Initial Public Offering on February 7, 2022, an amount of $ 139,790,000 4,895,000 2,000,000 2,895,000 On November 8, 2022, the Company entered into a definitive Business Combination Agreement (the “BCA”) with Conduit Pharmaceuticals Limited, a Cayman Islands exempted company (“Conduit”), and Conduit Merger Sub, Inc., a Cayman Islands exempted company (“Merger Sub”). Merger Sub is a wholly owned subsidiary of the Company. Conduit is a pharmaceutical company led by experienced pharma executives, established to fund the development of successful deprioritized clinical assets licensed from large pharmaceutical companies through its exclusive relationships. The BCA was amended in January 2023, see Note 10 for additional information. Upon the consummation of the transactions contemplated by the BCA, Merger Sub will merge with and into Conduit, with Conduit surviving as a wholly owned subsidiary of the Company (the “Business Combination”). The Company is expected to be renamed Conduit Pharmaceuticals Inc. at the closing of the Business Combination. Pursuant to the BCA, at the closing, the Company shall issue and deliver to the shareholders of Conduit an aggregate number of shares of the Company’s common stock with an aggregate value equal to $ 650,000,000 10.00 27,000,000 There can be no assurance that the Business Combination or PIPE Financing will occur as planned or at all. The Company’s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. There is no assurance that the Company will be able to complete a Business Combination successfully. The Company must complete one or more initial Business Combinations with one or more operating businesses or assets with a fair market value equal to at least 80% of the net assets held in the Trust Account (as defined below) (excluding the deferred underwriting commissions and taxes payable on the interest earned on the Trust Account). The Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the “Investment Company Act”). Upon the closing of the Initial Public Offering, management has agreed that an amount equal to at least $10.00 per Unit sold in the Initial Public Offering, including proceeds of the Private Placement Warrants, will be held in a trust account (“Trust Account”), located in the United States and invested only in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less or in any open-ended investment company that holds itself out as a money market fund selected by the Company meeting certain conditions of Rule 2a-7 of the Investment Company Act, as determined by the Company, until the earlier of: (i) the completion of a Business Combination and (ii) the distribution of the funds held in the Trust Account, as described below. The Company will provide the holders of the outstanding Public Shares (the “Public Stockholders”) with the opportunity to redeem all or a portion of their Public Shares either (i) in connection with a stockholder meeting called to approve the Business Combination or (ii) by means of a tender offer in connection with the Business Combination. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company. The Public Stockholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (net of taxes payable). There will be no redemption rights upon the completion of a Business Combination with respect to the Company’s warrants. All of the Public Shares contain a redemption feature which allows for the redemption of such Public Shares in connection with our liquidation, if there is a stockholder vote or tender offer in connection with our initial business combination and in connection with certain amendments to our amended and restated certificate of incorporation. In accordance with U.S. Securities and Exchange Commission (“SEC”) and its guidance on redeemable equity instruments, which has been codified in ASC 480-10-S99, redemption provisions not solely within the control of a company require common stock subject to redemption to be classified outside of permanent equity. Given that the Public Shares will be issued with other freestanding instruments (i.e., public warrants), the initial carrying value of Class A common stock classified as temporary equity will be the allocated proceeds determined in accordance with ASC 470-20. The Class A common stock is subject to ASC 480-10-S99. If it is probable that the equity instrument will become redeemable, we have the option to either (i) accrete changes in the redemption value over the period from the date of issuance (or from the date that it becomes probable that the instrument will become redeemable, if later) to the earliest redemption date of the instrument or (ii) recognize changes in the redemption value immediately as they occur and adjust the carrying amount of the instrument to equal the redemption value at the end of each reporting period. We have elected to recognize the changes immediately. The accretion or remeasurement will be treated as a deemed dividend (i.e., a reduction to retained earnings, or in absence of retained earnings, additional paid-in capital). The Public Shares are redeemable and will be classified as such on the balance sheet until such date that a redemption event takes place. If the Company seeks stockholder approval of the Business Combination, the Company will proceed with a Business Combination if a majority of the outstanding shares voted are voted in favor of the Business Combination, or such other vote as required by law or stock exchange rule. If a stockholder vote is not required by applicable law or stock exchange listing requirements and the Company does not decide to hold a stockholder vote for business or other reasons, the Company will, pursuant to its amended and restated certificate of incorporation (the “Certificate of Incorporation”), conduct the redemptions pursuant to the tender offer rules of the (“SEC”) and file tender offer documents with the SEC prior to completing a Business Combination. If, however, stockholder approval of the transaction is required by applicable law or stock exchange listing requirements, or the Company decides to obtain stockholder approval for business or other reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. If the Company seeks stockholder approval in connection with a Business Combination, the Sponsor has agreed to vote its Founder Shares (as defined in Note 5) and any Public Shares purchased during or after the Initial Public Offering in favor of approving a Business Combination. Additionally, each Public Stockholder may elect to redeem their Public Shares without voting, and if they do vote, irrespective of whether they vote for or against the proposed transaction. Notwithstanding the foregoing, if the Company seeks stockholder approval of a Business Combination and it does not conduct redemptions pursuant to the tender offer rules, the Certificate of Incorporation provides that a Public Stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% of the Public Shares, without the prior consent of the Company. The holders of the Founder Shares have agreed (a) to waive their redemption rights with respect to the Founder Shares and Public Shares held by them in connection with the completion of a Business Combination and (b) not to propose an amendment to the Certificate of Incorporation (i) to modify the substance or timing of the Company’s obligation to allow redemptions in connection with a Business Combination or to redeem 100% If the Company has not completed a Business Combination within 12 months from the consummation of our initial public offering (or up to February 7, 2024 at the election of the Company subject to satisfaction of certain conditions, as amended at the January 2023 Special Meeting, see Note 10) (“Business Combination Period”), the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to pay taxes (less up to $ 100,000 The holders of the Founders Shares have agreed to waive their liquidation rights with respect to the Founder Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the holders of Founder Shares acquire Public Shares in or after the Initial Public Offering, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to their deferred underwriting commission (see Note 6) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the Initial Public Offering price per Unit ($ 10.00 In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below (i) $10.00 per Public Share or (ii) such lesser amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account, if less than $10.00 per public Share due to reductions in the value of the trust assets, in each case net of the amount of interest which may be withdrawn to pay taxes, except as to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims under the Company’s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). Management’s Plan and Going Concern In connection with the Company’s assessment of going concern considerations in accordance with Accounting Standards Update (“ASU”) 2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” management has determined that the Combination Period is less than one year from the date of the issuance of the financial statements. There is no assurance that the Company’s plans to consummate a Business Combination will be successful within the Combination Period. Additionally, the Company has incurred and expects to continue to incur significant costs in pursuit of its acquisition plans. As a result, these factors raise substantial doubt about the Company’s ability to continue as a going concern for the next twelve months from the issuance of these financial statements. The financial statements do not include any adjustments that might result from the outcome of the uncertainty. Risks and Uncertainties Management is currently evaluating the impact of the COVID-19 pandemic and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position, results of its operations, and search for a target company, the specific impact is not readily determinable as of the date of these financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) as contained within the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”). Emerging Growth Company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012, as amended (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. Use of Estimates The preparation of financial statements in conformity with US GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had $ 90,606 345,777 Investments Held in Trust Account At March 31, 2023, and December 31, 2022, the Company had $ 23,658,838 136,871,183 Offering Costs Associated With a Public Offering The Company complies with the requirements of FASB ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (“SAB”) Topic 5A — “ Expenses of Offering.” 7,738,161 2,645,000 4,628,750 464,411 1,358,457 19,656 Class A Common Stock Subject to Possible Redemption The Company accounts for its shares of Class A common stock subject to possible redemption in accordance with the guidance enumerated in ASC 480 “ Distinguishing Liabilities from Equity During the three months ended March 31, 2023, 11,037,272 22,861,803 The following table provides a reconciliation of the shares of Class A common stock subject to possible redemption reflected on the balance sheet as of March 31, 2023: SCHEDULE OF COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION Gross proceeds from IPO $ 132,250,000 Less: Proceeds allocated to Public Warrants (23,276,000 ) Class A common stock issuance costs (6,360,054 ) Plus: Remeasurement adjustment of carrying value to redemption value 32,281,054 Class A common stock subject to possible redemption, as of March 31, 2022 134,895,000 Plus: Remeasurement adjustment of carrying value to redemption value 1,876,183 Class A common stock subject to possible redemption as of December 31, 2022 $ 136,771,183 Less: Redemptions during the three months ended March 31, 2023 * (114,068,280 ) Plus: Remeasurement adjustment of carrying value to redemption value 158,900 Class A common stock subject to possible redemption as of March 31, 2023 22,861,803 * As of March 31, 2023, $ 236,350 Excise Tax In accordance with the Inflation Reduction Act of 2022, the Company accrues the expected excise tax obligation at the end of each reporting period as a cost of redeeming any shares as of that date. In connection with the vote to amend the Company’s certificate of incorporation, holders of 11,037,272 114,068,280 1 1,140,683 Net Income (Loss) per Common Share The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share”. Net income (loss) per share of common stock is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding for the period. Accretion associated with the redeemable shares of Class A common stock is excluded from income (loss) per common share as the redemption value approximates fair value. The calculation of diluted income (loss) per share of common stock does not consider the effect of the warrants issued in connection with the (i) Initial Public Offering, and (ii) the private placement since the exercise of the warrants is contingent upon the occurrence of future events. As of March 31, 2023, the Company’s outstanding warrants ( 13,979,000 The following table reflects the calculation of basic and diluted net income (loss) per common share (in dollars, except per share amounts): SCHEDULE OF BASIC AND DILUTED NET INCOME (LOSS) PER COMMON SHARE Three Months Ended March 31, 2023 Class A common stock Class B common stock Basic and diluted net income per common share Numerator: Allocation of net loss $ 76,421 $ 43,848 Denominator: Basic and diluted weighted average shares outstanding 5,762,364 3,306,250 Basic and diluted net income per common share $ 0.01 $ 0.01 For the Three Months Ended March 31, 2022 Class A common stock Class B common stock Basic and diluted net loss per common share Numerator: Allocation of net loss $ (180,478 ) $ (73,058 ) Denominator: Basic and diluted weighted average shares outstanding 8,167,506 3,306,250 Basic and diluted net loss per common share $ (0.02 ) $ (0.02 ) Income Taxes The Company follows the asset and liability method of accounting for income taxes under ASC 740, “ Income Taxes ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of March 31, 2023 or December 31, 2022. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception. The Company has identified the United States and California as its only tax jurisdictions. The Company is subject to income taxation by major taxing authorities since inception. All tax periods are open to examination by tax authorities. These examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. The Company actual tax expense differs from the expected tax expense due to the change in the valuation allowance. Concentration of Credit Risk Financial instruments that potentially subject the Company to credit risk consist principally of cash and investments held in the Trust Account. Cash is maintained in accounts with financial institutions, which, at times may exceed the Federal Depository Insurance Corporation coverage limit of $ 250,000 Investments Held in Trust Account The Company’s Investments held in the Trust Account were $ 23,658,838 136,871,183 The Company’s portfolio of investments is comprised of U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or investments in money market funds that invest in U.S. government securities and generally have a readily determinable fair value, or a combination thereof. When the Company’s investments held in the Trust Account are comprised of U.S. government securities, the investments are classified as trading securities. When the Company’s investments held in the Trust Account are comprised of money market funds, the investments are recognized at fair value. Trading securities and investments in money market funds are presented on the balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities is included in income on investments held in the Trust Account in the accompanying statements of operations. The estimated fair values of investments held in the Trust Account are determined using available market information. Fair Value of Financial Instruments The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC 820, “Fair Value Measurements” approximates the carrying amounts represented in the balance sheet, partially due to their short-term nature. Fair value is defined as the price that would be received for sale of an asset or paid to transfer of a liability, in an orderly transaction between market participants at the measurement date. US GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: ● Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. Derivative Financial Instruments The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging”. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date. Warrant Instruments The Company accounts for warrants in accordance with the guidance contained in FASB ASC 815, “Derivatives and Hedging”. Under ASC 815-40 warrants that meet the criteria for equity treatment are recorded in stockholders’ equity (deficit). The warrants are subject to re-evaluation of the proper classification and accounting treatment at each reporting period. If the warrants no longer meet the criteria for equity treatment, they will be recorded as a liability and remeasured each period with changes recorded in the statement of operations. Recent Accounting Standards Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.	NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) as contained within the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”). Emerging Growth Company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012, as amended (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. Use of Estimates The preparation of financial statements in conformity with US GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had $ 345,777 48,555 Investments Held in Trust Account At December 31, 2022 and 2021, the Company had $ 136,871,183 zero, respectively, Offering Costs Associated With a Public Offering The Company complies with the requirements of FASB ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (“SAB”) Topic 5A — “ Expenses of Offering.” 7,738,161 2,645,000 4,628,750 464,411 1,358,457 19,656 Class A Common Stock Subject to Possible Redemption The Company accounts for its shares of Class A common stock subject to possible redemption in accordance with the guidance enumerated in ASC 480 “ Distinguishing Liabilities from Equity 136,771,183 As of December 31, 2022, the Class A common stock subject to possible redemption reflected on the balance sheet are reconciled in the following table: SCHEDULE OF COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION Gross proceeds from IPO $ 132,250,000 Less: Proceeds allocated to Public Warrants (23,276,000 ) Class A common stock issuance costs (6,360,054 ) Plus: Remeasurement adjustment of carrying value to redemption value 32,281,054 Class A common stock subject to possible redemption, as of March 31, 2022 134,895,000 Plus: Remeasurement adjustment of carrying value to redemption value 101,767 Class A common stock subject to possible redemption as of June 30, 2022 134,996,767 Plus: Remeasurement adjustment of carrying value to redemption value 609,920 Class A common stock subject to possible redemption as of September 30, 2022 135,606,687 Plus: Remeasurement adjustment of carrying value to redemption value 1,164,496 Class A common stock subject to possible redemption as of December 31, 2022 $ 136,771,183 Net Income (Loss) per Common Share The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share”. Net income (loss) per share of common stock is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding for the period. Accretion associated with the redeemable shares of Class A common stock is excluded from income (loss) per common share as the redemption value approximates fair value. The calculation of diluted income (loss) per share of common stock does not consider the effect of the warrants issued in connection with the (i) Initial Public Offering, and (ii) the private placement since the exercise of the warrants is contingent upon the occurrence of future events. As of December 31, 2022, the Company’s outstanding warrants ( 13,979,000 The following table reflects the calculation of basic and diluted net income (loss) per common share (in dollars, except per share amounts): SCHEDULE OF BASIC AND DILUTED NET INCOME (LOSS) PER COMMON SHARE For the Period Since Inception to December 31, 2021 Class A common stock Class B common stock Basic and diluted net income per common share Numerator: Allocation of net loss $ - $ (4,381 ) Denominator: Basic and diluted weighted average shares outstanding - 2,875,000 Basic and diluted net income per common share $ - $ (0.00 ) For the Year Ended December 31, 2022 Class A common stock Class B common stock Basic and diluted net loss per common share Numerator: Allocation of net income $ 315,560 $ 83,079 Denominator: Basic and diluted weighted average shares outstanding 12,558,058 3,306,250 Basic and diluted net loss per common share $ 0.03 $ 0.03 Income Taxes The Company follows the asset and liability method of accounting for income taxes under ASC 740, “ Income Taxes ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no no The Company has identified the United States and California as its only tax jurisdictions. The Company is subject to income taxation by major taxing authorities since inception. All tax periods are open to examination by tax authorities. These examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. The Company actual tax expense differs from the expected tax expense due to the change in the valuation allowance. Concentration of Credit Risk Financial instruments that potentially subject the Company to credit risk consist principally of cash and investments held in the Trust Account. Cash is maintained in accounts with financial institutions, which, at times may exceed the Federal Depository Insurance Corporation coverage limit of $ 250,000 Investments Held in Trust Account The Company’s Investments held in the Trust Account were $ 136,871,183 zero The Company’s portfolio of investments is comprised of U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or investments in money market funds that invest in U.S. government securities and generally have a readily determinable fair value, or a combination thereof. When the Company’s investments held in the Trust Account are comprised of U.S. government securities, the investments are classified as trading securities. When the Company’s investments held in the Trust Account are comprised of money market funds, the investments are recognized at fair value. Trading securities and investments in money market funds are presented on the balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities is included in income on investments held in the Trust Account in the accompanying statements of operations. The estimated fair values of investments held in the Trust Account are determined using available market information. Fair Value of Financial Instruments The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC 820, “Fair Value Measurements” approximates the carrying amounts represented in the balance sheet, partially due to their short-term nature. Fair value is defined as the price that would be received for sale of an asset or paid to transfer of a liability, in an orderly transaction between market participants at the measurement date. US GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: ● Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. Derivative Financial Instruments The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging”. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date. Warrant Instruments The Company accounts for warrants in accordance with the guidance contained in FASB ASC 815, “Derivatives and Hedging”. Under ASC 815-40 warrants that meet the criteria for equity treatment are recorded in stockholders’ equity (deficit). The warrants are subject to re-evaluation of the proper classification and accounting treatment at each reporting period. If the warrants no longer meet the criteria for equity treatment, they will be recorded as a liability and remeasured each period with changes recorded in the statement of operations. Recent Accounting Standards Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.

INITIAL PUBLIC OFFERING

INITIAL PUBLIC OFFERING	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Initial Public Offering
INITIAL PUBLIC OFFERING	NOTE 3 — INITIAL PUBLIC OFFERING Pursuant to the Initial Public Offering, the Company sold 13,225,000 10.00 11.50	NOTE 3 — INITIAL PUBLIC OFFERING Pursuant to the Initial Public Offering, the Company sold 13,225,000 10.00 11.50

PRIVATE PLACEMENTS

PRIVATE PLACEMENTS	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Private Placements
PRIVATE PLACEMENTS	NOTE 4 — PRIVATE PLACEMENTS Simultaneously with the closing of the Initial Public Offering, the Company consummated the private sale to the Sponsor of 754,000 10.00 7,540,000 11.50 15,000	NOTE 4 — PRIVATE PLACEMENTS Simultaneously with the closing of the Initial Public Offering, the Company consummated the private sale to the Sponsor of 754,000 10.00 7,540,000 11.50 15,000

STOCKHOLDERS_ DEFICIT

STOCKHOLDERS’ DEFICIT	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Equity [Abstract]
STOCKHOLDERS’ DEFICIT	NOTE 7 — STOCKHOLDERS’ DEFICIT Preferred Stock 1,000,000 0.0001 no Class A Common Stock 100,000,000 0.0001 Holders of Class A common stock are entitled to one vote for each share 754,000 2,187,728 13,225,000 11,037,272 114,068,280 10.33 Class B Common Stock 10,000,000 0.0001 3,306,250 Only holders of the Class B common stock will have the right to vote on the election of directors prior to the Business Combination. Holders of Class A common stock and holders of Class B common stock will vote together as a single class on all matters submitted to a vote of our shareholders except as otherwise required by law. In connection with our initial business combination, we may enter into a stockholders agreement or other arrangements with the stockholders of the target or other investors to provide for voting or other corporate governance arrangements that differ from those in effect upon completion of this offering. The shares of Class B common stock will automatically convert into Class A common stock at the time of a Business Combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment. In the case that additional shares of Class A common stock, or equity-linked securities, are issued or deemed issued in excess of the amounts issued in the Initial Public Offering and related to the closing of a Business Combination, the ratio at which shares of Class B common stock shall convert into shares of Class A common stock will be adjusted (unless the holders of a majority of the then-outstanding shares of Class B common stock agree to waive such adjustment with respect to any such issuance or deemed issuance) so that the number of shares of Class A common stock issuable upon conversion of all shares of Class B common stock will equal, in the aggregate, on an as-converted basis, 20% of the sum of the total number of all shares of common stock outstanding upon the completion of Initial Public Offering plus all shares of Class A common stock and equity-linked securities issued or deemed issued in connection with a Business Combination (net of the number of shares of Class A common stock redeemed in connection with a Business Combination), excluding any shares or equity-linked securities issued or issuable to any seller of an interest in the target to us in a Business Combination. Only holders of the Class B common stock will have the right to vote on the election of directors prior to the Business Combination. Holders of Class B common stock will vote together as a single class on all matters submitted to a vote of our shareholders except as otherwise required by law. In connection with our initial business combination, we may enter into a stockholders agreement or other arrangements with the stockholders of the target or other investors to provide for voting or other corporate governance arrangements that differ from those in effect upon completion of this offering. Warrants The Company will not be obligated to deliver any shares of Class A common stock pursuant to the exercise of a warrant and will have no obligation to settle such warrant exercise unless a registration statement under the Securities Act covering the issuance of the shares of Class A common stock issuable upon exercise of the warrants is then effective and a current prospectus relating to those shares of Class A common stock is available, subject to the Company satisfying its obligations with respect to registration, or a valid exemption from registration is available. No warrant will be exercisable for cash or on a cashless basis, and the Company will not be obligated to issue any shares to holders seeking to exercise their warrants, unless the issuance of the shares upon such exercise is registered or qualified under the securities laws of the state of residence of the exercising holder, or an exemption from registration is available. The Company has agreed that as soon as practicable, but in no event later than 15 business days after the closing of a Business Combination, the Company will use its commercially reasonable efforts to file, and within 60 business days following a Business Combination to have declared effective, a registration statement covering the issuance of the shares of Class A common stock issuable upon exercise of the warrants and to maintain a current prospectus relating to those shares of Class A common stock until the warrants expire or are redeemed. Notwithstanding the above, if the Class A common stock is at the time of any exercise of a warrant not listed on a national securities exchange such that it satisfies the definition of a “covered security” under Section 18(b)(1) of the Securities Act, the Company may, at its option, require holders of Public Warrants who exercise their warrants to do so on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act and, in the event the Company so elects, the Company will not be required to file or maintain in effect a registration statement, but will use its commercially reasonable efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. Redemption of Warrants When the Price per Share of Class A Common Stock Equals or Exceeds $18.00 ● in whole and not in part; ● at a price of $ 0.01 ● upon a minimum of 30 days’ prior written notice of redemption, or the 30-day redemption period to each warrant holder; and ● if, and only if, the last reported sale price of the Class A common stock equals or exceeds $ 18.00 If and when the warrants become redeemable by the Company, the Company may exercise its redemption right even if it is unable to register or qualify the underlying securities for sale under all applicable state securities laws. If the Company calls the Public Warrants for redemption, as described above, its management will have the option to require any holder that wishes to exercise the Public Warrants to do so on a “cashless basis,” as described in the warrant agreement. The exercise price and number of common stock issuable upon exercise of the Public Warrants may be adjusted in certain circumstances including in the event of a stock dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation. However, except as described below, the Public Warrants will not be adjusted for issuances of common stock at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the Public Warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of Public Warrants will not receive any of such funds with respect to their Public Warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with respect to such Public Warrants. Accordingly, the Public Warrants may expire worthless. The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering. The Private Placement Warrants and Public Warrants are recorded in stockholders’ equity (deficit) as they qualify for equity treatment under ASC 815. The key assumptions used to value the Public Warrants, which was determined to be $ 23,276,000 ● Term – 5 ● Volatility – 22 ● Dividends – 0 ● Discount rate – 1.76	NOTE 7 — STOCKHOLDERS’ EQUITY (DEFICIT) Preferred Stock 1,000,000 0.0001 no Class A Common Stock 100,000,000 0.0001 Holders of Class A common stock are entitled to one vote for each share. 754,000 zero 13,225,000 Class B Common Stock 10,000,000 0.0001 3,306,250 Only holders of the Class B common stock will have the right to vote on the election of directors prior to the Business Combination. Holders of Class A common stock and holders of Class B common stock will vote together as a single class on all matters submitted to a vote of our shareholders except as otherwise required by law. In connection with our initial business combination, we may enter into a stockholders agreement or other arrangements with the stockholders of the target or other investors to provide for voting or other corporate governance arrangements that differ from those in effect upon completion of this offering. The shares of Class B common stock will automatically convert into Class A common stock at the time of a Business Combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment. In the case that additional shares of Class A common stock, or equity-linked securities, are issued or deemed issued in excess of the amounts issued in the Initial Public Offering and related to the closing of a Business Combination, the ratio at which shares of Class B common stock shall convert into shares of Class A common stock will be adjusted (unless the holders of a majority of the then-outstanding shares of Class B common stock agree to waive such adjustment with respect to any such issuance or deemed issuance) so that the number of shares of Class A common stock issuable upon conversion of all shares of Class B common stock will equal, in the aggregate, on an as-converted basis, 20% of the sum of the total number of all shares of common stock outstanding upon the completion of Initial Public Offering plus all shares of Class A common stock and equity-linked securities issued or deemed issued in connection with a Business Combination (net of the number of shares of Class A common stock redeemed in connection with a Business Combination), excluding any shares or equity-linked securities issued or issuable to any seller of an interest in the target to us in a Business Combination. Only holders of the Class B common stock will have the right to vote on the election of directors prior to the Business Combination. Holders of Class B common stock will vote together as a single class on all matters submitted to a vote of our shareholders except as otherwise required by law. In connection with our initial business combination, we may enter into a stockholders agreement or other arrangements with the stockholders of the target or other investors to provide for voting or other corporate governance arrangements that differ from those in effect upon completion of this offering. Warrants The Company will not be obligated to deliver any shares of Class A common stock pursuant to the exercise of a warrant and will have no obligation to settle such warrant exercise unless a registration statement under the Securities Act covering the issuance of the shares of Class A common stock issuable upon exercise of the warrants is then effective and a current prospectus relating to those shares of Class A common stock is available, subject to the Company satisfying its obligations with respect to registration, or a valid exemption from registration is available. No warrant will be exercisable for cash or on a cashless basis, and the Company will not be obligated to issue any shares to holders seeking to exercise their warrants, unless the issuance of the shares upon such exercise is registered or qualified under the securities laws of the state of residence of the exercising holder, or an exemption from registration is available. The Company has agreed that as soon as practicable, but in no event later than 15 business days after the closing of a Business Combination, the Company will use its commercially reasonable efforts to file, and within 60 business days following a Business Combination to have declared effective, a registration statement covering the issuance of the shares of Class A common stock issuable upon exercise of the warrants and to maintain a current prospectus relating to those shares of Class A common stock until the warrants expire or are redeemed. Notwithstanding the above, if the Class A common stock is at the time of any exercise of a warrant not listed on a national securities exchange such that it satisfies the definition of a “covered security” under Section 18(b)(1) of the Securities Act, the Company may, at its option, require holders of Public Warrants who exercise their warrants to do so on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act and, in the event the Company so elects, the Company will not be required to file or maintain in effect a registration statement, but will use its commercially reasonable efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. Redemption of Warrants When the Price per Share of Class A Common Stock Equals or Exceeds $18.00 ● in whole and not in part; ● at a price of $ 0.01 ● upon a minimum of 30 days’ prior written notice of redemption, or the 30-day redemption period to each warrant holder; and ● if, and only if, the last reported sale price of the Class A common stock equals or exceeds $ 18.00 If and when the warrants become redeemable by the Company, the Company may exercise its redemption right even if it is unable to register or qualify the underlying securities for sale under all applicable state securities laws. If the Company calls the Public Warrants for redemption, as described above, its management will have the option to require any holder that wishes to exercise the Public Warrants to do so on a “cashless basis,” as described in the warrant agreement. The exercise price and number of common stock issuable upon exercise of the Public Warrants may be adjusted in certain circumstances including in the event of a stock dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation. However, except as described below, the Public Warrants will not be adjusted for issuances of common stock at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the Public Warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of Public Warrants will not receive any of such funds with respect to their Public Warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with respect to such Public Warrants. Accordingly, the Public Warrants may expire worthless. The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering. The Private Placement Warrants and Public Warrants are recorded in stockholders’ equity (deficit) as they qualify for equity treatment under ASC 815. The key assumptions used to value the Public Warrants, which was determined to be $ 23,276,000 ● Term – 5 ● Volatility – 22 ● Dividends – 0 ● Discount rate – 1.76

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	NOTE 8 — FAIR VALUE MEASUREMENTS The Company follows the guidance in ASC 820 for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and non-financial assets and liabilities that are re-measured and reported at fair value at least annually. The fair value of the Company’s financial assets and liabilities reflects management’s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities: Level 1: Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. Level 2: Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active. Level 3: Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability. The following table presents information about the Company’s assets and liabilities that are measured at fair value at March 31, 2023 and December 31, 2022, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: SCHEDULE OF FAIR VALUE OF ASSETS AND LIABILITIES Description Level March 31, 2023 Assets: Investments held in Trust Account 1 $ 23,658,838 Description Level December 31, 2022 Assets: Investments held in Trust Account 1 $ 136,871,183	NOTE 8 — FAIR VALUE MEASUREMENTS The following table presents information about the Company’s assets and liabilities that are measured at fair value at December 31, 2022, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: SCHEDULE OF FAIR VALUE OF ASSETS AND LIABILITIES Description Level December 31, 2022 Assets: Investments held in Trust Account 1 $ 136,871,183 As of December 31, 2021, there were no

TAXES

TAXES	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
TAXES	NOTE 9 — TAXES The expected tax expense based on the statutory rate is reconciled with actual tax expense as follows: The effective tax rate differs from the statutory tax rate of 21 23.3	NOTE 9 — TAXES The expected tax expense based on the statutory rate is reconciled with actual tax expense as follows: SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION For the Year Ended December 31, 2022 U.S. federal statutory rate 21.0 % State taxes, net of federal benefit 0.1 % Change in valuation allowance 27.36 % Income tax provision 48.46 % The effective tax rate differs from the statutory tax rate of 21 Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets and liabilities and the change in valuation are as follows at December 31: SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES 2022 Deferred tax assets: Startup costs 211,627 Total deferred tax assets 211,627 Valuation Allowance (211,627 ) Net deferred tax asset $ — SCHEDULE OF CHANGE IN VALUATION 2022 Federal Current $ 374,862 Deferred (211,627 ) State and Local Current - Deferred - Change in valuation 211,627 Income Tax Provision $ 374,862 In assessing the realization of the deferred tax assets, management considers whether it is more likely than not that some portion of all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is independent upon the generation of future taxable income during the periods in which temporary differences representing net future deductible amounts become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. After consideration of all of the information available, management believes that significant uncertainty exists with respect to future realization of the deferred tax assets and has therefore established a full valuation allowance. For the year ended December 31,2021, the change in the valuation allowance was zero.

STOCKHOLDERS_ EQUITY (DEFICIT)

STOCKHOLDERS’ EQUITY (DEFICIT)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Equity [Abstract]
STOCKHOLDERS’ EQUITY (DEFICIT)	NOTE 7 — STOCKHOLDERS’ DEFICIT Preferred Stock 1,000,000 0.0001 no Class A Common Stock 100,000,000 0.0001 Holders of Class A common stock are entitled to one vote for each share 754,000 2,187,728 13,225,000 11,037,272 114,068,280 10.33 Class B Common Stock 10,000,000 0.0001 3,306,250 Only holders of the Class B common stock will have the right to vote on the election of directors prior to the Business Combination. Holders of Class A common stock and holders of Class B common stock will vote together as a single class on all matters submitted to a vote of our shareholders except as otherwise required by law. In connection with our initial business combination, we may enter into a stockholders agreement or other arrangements with the stockholders of the target or other investors to provide for voting or other corporate governance arrangements that differ from those in effect upon completion of this offering. The shares of Class B common stock will automatically convert into Class A common stock at the time of a Business Combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment. In the case that additional shares of Class A common stock, or equity-linked securities, are issued or deemed issued in excess of the amounts issued in the Initial Public Offering and related to the closing of a Business Combination, the ratio at which shares of Class B common stock shall convert into shares of Class A common stock will be adjusted (unless the holders of a majority of the then-outstanding shares of Class B common stock agree to waive such adjustment with respect to any such issuance or deemed issuance) so that the number of shares of Class A common stock issuable upon conversion of all shares of Class B common stock will equal, in the aggregate, on an as-converted basis, 20% of the sum of the total number of all shares of common stock outstanding upon the completion of Initial Public Offering plus all shares of Class A common stock and equity-linked securities issued or deemed issued in connection with a Business Combination (net of the number of shares of Class A common stock redeemed in connection with a Business Combination), excluding any shares or equity-linked securities issued or issuable to any seller of an interest in the target to us in a Business Combination. Only holders of the Class B common stock will have the right to vote on the election of directors prior to the Business Combination. Holders of Class B common stock will vote together as a single class on all matters submitted to a vote of our shareholders except as otherwise required by law. In connection with our initial business combination, we may enter into a stockholders agreement or other arrangements with the stockholders of the target or other investors to provide for voting or other corporate governance arrangements that differ from those in effect upon completion of this offering. Warrants The Company will not be obligated to deliver any shares of Class A common stock pursuant to the exercise of a warrant and will have no obligation to settle such warrant exercise unless a registration statement under the Securities Act covering the issuance of the shares of Class A common stock issuable upon exercise of the warrants is then effective and a current prospectus relating to those shares of Class A common stock is available, subject to the Company satisfying its obligations with respect to registration, or a valid exemption from registration is available. No warrant will be exercisable for cash or on a cashless basis, and the Company will not be obligated to issue any shares to holders seeking to exercise their warrants, unless the issuance of the shares upon such exercise is registered or qualified under the securities laws of the state of residence of the exercising holder, or an exemption from registration is available. The Company has agreed that as soon as practicable, but in no event later than 15 business days after the closing of a Business Combination, the Company will use its commercially reasonable efforts to file, and within 60 business days following a Business Combination to have declared effective, a registration statement covering the issuance of the shares of Class A common stock issuable upon exercise of the warrants and to maintain a current prospectus relating to those shares of Class A common stock until the warrants expire or are redeemed. Notwithstanding the above, if the Class A common stock is at the time of any exercise of a warrant not listed on a national securities exchange such that it satisfies the definition of a “covered security” under Section 18(b)(1) of the Securities Act, the Company may, at its option, require holders of Public Warrants who exercise their warrants to do so on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act and, in the event the Company so elects, the Company will not be required to file or maintain in effect a registration statement, but will use its commercially reasonable efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. Redemption of Warrants When the Price per Share of Class A Common Stock Equals or Exceeds $18.00 ● in whole and not in part; ● at a price of $ 0.01 ● upon a minimum of 30 days’ prior written notice of redemption, or the 30-day redemption period to each warrant holder; and ● if, and only if, the last reported sale price of the Class A common stock equals or exceeds $ 18.00 If and when the warrants become redeemable by the Company, the Company may exercise its redemption right even if it is unable to register or qualify the underlying securities for sale under all applicable state securities laws. If the Company calls the Public Warrants for redemption, as described above, its management will have the option to require any holder that wishes to exercise the Public Warrants to do so on a “cashless basis,” as described in the warrant agreement. The exercise price and number of common stock issuable upon exercise of the Public Warrants may be adjusted in certain circumstances including in the event of a stock dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation. However, except as described below, the Public Warrants will not be adjusted for issuances of common stock at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the Public Warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of Public Warrants will not receive any of such funds with respect to their Public Warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with respect to such Public Warrants. Accordingly, the Public Warrants may expire worthless. The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering. The Private Placement Warrants and Public Warrants are recorded in stockholders’ equity (deficit) as they qualify for equity treatment under ASC 815. The key assumptions used to value the Public Warrants, which was determined to be $ 23,276,000 ● Term – 5 ● Volatility – 22 ● Dividends – 0 ● Discount rate – 1.76	NOTE 7 — STOCKHOLDERS’ EQUITY (DEFICIT) Preferred Stock 1,000,000 0.0001 no Class A Common Stock 100,000,000 0.0001 Holders of Class A common stock are entitled to one vote for each share. 754,000 zero 13,225,000 Class B Common Stock 10,000,000 0.0001 3,306,250 Only holders of the Class B common stock will have the right to vote on the election of directors prior to the Business Combination. Holders of Class A common stock and holders of Class B common stock will vote together as a single class on all matters submitted to a vote of our shareholders except as otherwise required by law. In connection with our initial business combination, we may enter into a stockholders agreement or other arrangements with the stockholders of the target or other investors to provide for voting or other corporate governance arrangements that differ from those in effect upon completion of this offering. The shares of Class B common stock will automatically convert into Class A common stock at the time of a Business Combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment. In the case that additional shares of Class A common stock, or equity-linked securities, are issued or deemed issued in excess of the amounts issued in the Initial Public Offering and related to the closing of a Business Combination, the ratio at which shares of Class B common stock shall convert into shares of Class A common stock will be adjusted (unless the holders of a majority of the then-outstanding shares of Class B common stock agree to waive such adjustment with respect to any such issuance or deemed issuance) so that the number of shares of Class A common stock issuable upon conversion of all shares of Class B common stock will equal, in the aggregate, on an as-converted basis, 20% of the sum of the total number of all shares of common stock outstanding upon the completion of Initial Public Offering plus all shares of Class A common stock and equity-linked securities issued or deemed issued in connection with a Business Combination (net of the number of shares of Class A common stock redeemed in connection with a Business Combination), excluding any shares or equity-linked securities issued or issuable to any seller of an interest in the target to us in a Business Combination. Only holders of the Class B common stock will have the right to vote on the election of directors prior to the Business Combination. Holders of Class B common stock will vote together as a single class on all matters submitted to a vote of our shareholders except as otherwise required by law. In connection with our initial business combination, we may enter into a stockholders agreement or other arrangements with the stockholders of the target or other investors to provide for voting or other corporate governance arrangements that differ from those in effect upon completion of this offering. Warrants The Company will not be obligated to deliver any shares of Class A common stock pursuant to the exercise of a warrant and will have no obligation to settle such warrant exercise unless a registration statement under the Securities Act covering the issuance of the shares of Class A common stock issuable upon exercise of the warrants is then effective and a current prospectus relating to those shares of Class A common stock is available, subject to the Company satisfying its obligations with respect to registration, or a valid exemption from registration is available. No warrant will be exercisable for cash or on a cashless basis, and the Company will not be obligated to issue any shares to holders seeking to exercise their warrants, unless the issuance of the shares upon such exercise is registered or qualified under the securities laws of the state of residence of the exercising holder, or an exemption from registration is available. The Company has agreed that as soon as practicable, but in no event later than 15 business days after the closing of a Business Combination, the Company will use its commercially reasonable efforts to file, and within 60 business days following a Business Combination to have declared effective, a registration statement covering the issuance of the shares of Class A common stock issuable upon exercise of the warrants and to maintain a current prospectus relating to those shares of Class A common stock until the warrants expire or are redeemed. Notwithstanding the above, if the Class A common stock is at the time of any exercise of a warrant not listed on a national securities exchange such that it satisfies the definition of a “covered security” under Section 18(b)(1) of the Securities Act, the Company may, at its option, require holders of Public Warrants who exercise their warrants to do so on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act and, in the event the Company so elects, the Company will not be required to file or maintain in effect a registration statement, but will use its commercially reasonable efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. Redemption of Warrants When the Price per Share of Class A Common Stock Equals or Exceeds $18.00 ● in whole and not in part; ● at a price of $ 0.01 ● upon a minimum of 30 days’ prior written notice of redemption, or the 30-day redemption period to each warrant holder; and ● if, and only if, the last reported sale price of the Class A common stock equals or exceeds $ 18.00 If and when the warrants become redeemable by the Company, the Company may exercise its redemption right even if it is unable to register or qualify the underlying securities for sale under all applicable state securities laws. If the Company calls the Public Warrants for redemption, as described above, its management will have the option to require any holder that wishes to exercise the Public Warrants to do so on a “cashless basis,” as described in the warrant agreement. The exercise price and number of common stock issuable upon exercise of the Public Warrants may be adjusted in certain circumstances including in the event of a stock dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation. However, except as described below, the Public Warrants will not be adjusted for issuances of common stock at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the Public Warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of Public Warrants will not receive any of such funds with respect to their Public Warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with respect to such Public Warrants. Accordingly, the Public Warrants may expire worthless. The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering. The Private Placement Warrants and Public Warrants are recorded in stockholders’ equity (deficit) as they qualify for equity treatment under ASC 815. The key assumptions used to value the Public Warrants, which was determined to be $ 23,276,000 ● Term – 5 ● Volatility – 22 ● Dividends – 0 ● Discount rate – 1.76

Nature of the Business, Basis_2

Nature of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Policies)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had $ 90,606 345,777	Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had $ 345,777 48,555
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with US GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.	Use of Estimates The preparation of financial statements in conformity with US GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.
Income Taxes	Income Taxes The Company follows the asset and liability method of accounting for income taxes under ASC 740, “ Income Taxes ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of March 31, 2023 or December 31, 2022. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception. The Company has identified the United States and California as its only tax jurisdictions. The Company is subject to income taxation by major taxing authorities since inception. All tax periods are open to examination by tax authorities. These examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. The Company actual tax expense differs from the expected tax expense due to the change in the valuation allowance.	Income Taxes The Company follows the asset and liability method of accounting for income taxes under ASC 740, “ Income Taxes ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no no The Company has identified the United States and California as its only tax jurisdictions. The Company is subject to income taxation by major taxing authorities since inception. All tax periods are open to examination by tax authorities. These examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. The Company actual tax expense differs from the expected tax expense due to the change in the valuation allowance.
Net Loss per Ordinary Share Attributable to Ordinary Shareholders	Net Income (Loss) per Common Share The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share”. Net income (loss) per share of common stock is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding for the period. Accretion associated with the redeemable shares of Class A common stock is excluded from income (loss) per common share as the redemption value approximates fair value. The calculation of diluted income (loss) per share of common stock does not consider the effect of the warrants issued in connection with the (i) Initial Public Offering, and (ii) the private placement since the exercise of the warrants is contingent upon the occurrence of future events. As of March 31, 2023, the Company’s outstanding warrants ( 13,979,000 The following table reflects the calculation of basic and diluted net income (loss) per common share (in dollars, except per share amounts): SCHEDULE OF BASIC AND DILUTED NET INCOME (LOSS) PER COMMON SHARE Three Months Ended March 31, 2023 Class A common stock Class B common stock Basic and diluted net income per common share Numerator: Allocation of net loss $ 76,421 $ 43,848 Denominator: Basic and diluted weighted average shares outstanding 5,762,364 3,306,250 Basic and diluted net income per common share $ 0.01 $ 0.01 For the Three Months Ended March 31, 2022 Class A common stock Class B common stock Basic and diluted net loss per common share Numerator: Allocation of net loss $ (180,478 ) $ (73,058 ) Denominator: Basic and diluted weighted average shares outstanding 8,167,506 3,306,250 Basic and diluted net loss per common share $ (0.02 ) $ (0.02 )	Net Income (Loss) per Common Share The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share”. Net income (loss) per share of common stock is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding for the period. Accretion associated with the redeemable shares of Class A common stock is excluded from income (loss) per common share as the redemption value approximates fair value. The calculation of diluted income (loss) per share of common stock does not consider the effect of the warrants issued in connection with the (i) Initial Public Offering, and (ii) the private placement since the exercise of the warrants is contingent upon the occurrence of future events. As of December 31, 2022, the Company’s outstanding warrants ( 13,979,000 The following table reflects the calculation of basic and diluted net income (loss) per common share (in dollars, except per share amounts): SCHEDULE OF BASIC AND DILUTED NET INCOME (LOSS) PER COMMON SHARE For the Period Since Inception to December 31, 2021 Class A common stock Class B common stock Basic and diluted net income per common share Numerator: Allocation of net loss $ - $ (4,381 ) Denominator: Basic and diluted weighted average shares outstanding - 2,875,000 Basic and diluted net income per common share $ - $ (0.00 ) For the Year Ended December 31, 2022 Class A common stock Class B common stock Basic and diluted net loss per common share Numerator: Allocation of net income $ 315,560 $ 83,079 Denominator: Basic and diluted weighted average shares outstanding 12,558,058 3,306,250 Basic and diluted net loss per common share $ 0.03 $ 0.03
Recently Adopted Accounting Pronouncements	Recent Accounting Standards Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.	Recent Accounting Standards Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.
Conduit Pharmaceuticals Ltd [Member]
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents are primarily maintained with major financial institutions in the United Kingdom and Switzerland. The Company considers cash equivalents to be short-term, highly liquid investments that (a) are readily convertible into known amounts of cash, (b) are traded and held for cash management purposes, and (c) have original maturities of three months or less at the time of purchase. The Switzerland bank accounts holding cash balances are uninsured. The Company has not experienced any losses on this account through the period ended March 31, 2023. As of March 31, 2023, the Company held immaterial cash equivalents. As of December 31, 2022, the Company did not hold any cash equivalents.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and related disclosures of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting period. Estimates are based on several factors including the facts and circumstances available at the time the estimates are made, historical experience, risk of loss, general economic conditions and trends, and the assessment of the probable future outcome. Subjective and significant estimates include, but are not necessarily limited to, the inputs used to determine the fair value of convertible notes payable, the Cizzle option and the amount to reserve for the related party loan receivable. Actual results could differ materially from such estimates. Estimates and assumptions are reviewed periodically by management and changes in estimates are made as management becomes aware of changes in circumstances surrounding the estimates. The effects of changes are reflected in the financial statements in the period that they are determined.
Fair Value Measurements	Fair Value Measurements Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurements and Disclosures, defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. Fair value is to be determined based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants. In determining fair value, the Company used various valuation approaches. A fair value hierarchy has been established for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are those that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs reflect the Company’s assumption about the inputs that market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The fair value hierarchy is categorized into three levels, based on the inputs, as follows: ● Level 1—Valuations based on quoted prices for identical instruments in active markets. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these instruments does not entail a significant degree of judgment. ● Level 2— Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for either similar instruments in active markets, identical or similar instruments in markets that are not active, or model-derived valuations whose inputs or significant value drivers are observable or can be corroborated by observable market data. ● Level 3—Valuations based on inputs that are unobservable. These valuations require significant judgment. The Company’s Level 1 assets consist of cash and cash equivalents in the accompanying balance sheets and the value of accrued expenses and other current liabilities approximate fair value due to the short-term nature of these assets and liabilities. As of March 31, 2023, the Company has two financial liabilities, convertible notes that are adjusted to fair value on a recurring basis as well as an option liability for which the fair value is determined based on Level 3 inputs as such inputs are not readily observable. See Note 2, Note 4 and Note 5 for further information on the Company’s financial liability held at fair value.
Research and Development and Funding	Research and Development and Funding Research and development expenses consist primarily of costs incurred in connection with the research and development of our product candidates and programs. Funding expenses consist primarily of costs incurred in connection with the Company providing funding to St George Street Capital (“SGSC”) to carry out its research and development activities. SGSC holds all licenses to conduct clinical research through third party pharmaceutical companies. The Company expenses research and development costs and intangible assets acquired that have no alternative future use as incurred. These expenses include: ● expenses incurred under agreements with organizations that support the Company’s drug discovery and development activities; ● expenses incurred in connection with the preclinical and clinical development of the Company’s product candidates and programs, including under agreements with contract research organizations, or CROs; ● costs related to contract manufacturing organizations, or CMOs, that are primarily engaged to provide drug substance and product for our clinical trials, research and development programs, as well as investigative sites and consultants that conduct the Company’s clinical trials, nonclinical studies and other scientific development services; ● the costs of acquiring and manufacturing nonclinical and clinical trial materials, including manufacturing registration and validation batches; ● employee-related expenses, including salaries, related benefits and equity-based compensation expense, for employees engaged in research and development functions; ● costs related to compliance with quality and regulatory requirements; ● payments made under third-party licensing agreements; and ● direct and allocated costs related to facilities, information technology, personnel and other overhead. Advance payments that we make for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such amounts are recognized as an expense as the goods are delivered or consumed or the related services are performed, or until it is no longer expected that the goods will be delivered, or the services rendered.
General and Administrative Expenses	General and Administrative Expenses General and administrative expenses consist primarily of salaries and related costs for personnel in executive management, finance, corporate and business development, and administrative functions. General and administrative expenses also include legal fees relating to patent and corporate matters; professional fees for accounting, auditing, tax, and administrative consulting services; insurance costs; administrative travel expenses and other operating costs The Company has incurred increased accounting, audit, legal, regulatory, compliance and director and officer insurance costs as well as investor and public relations expenses associated with being a public company. The Company anticipates that its general and administrative expenses will increase in the future as it increases its headcount to support development of its product candidates and programs and with continued research and development activities.
Income Taxes	Income Taxes ASC Topic 740, Income Taxes The Company is exempt from income tax in the Cayman Islands.
Net Loss per Ordinary Share Attributable to Ordinary Shareholders	Net Loss per Ordinary Share Attributable to Ordinary Shareholders The Company calculates net loss per share attributable to ordinary shareholders – basic and diluted using the two-class method under ASC Topic 260, Earnings Per Share
Investments in Equity Securities	Investments in Equity Securities Investments in equity securities that have a readily determinable fair value are reported at fair value. Changes in fair value between accounting periods are recorded in other expense, net, in the statements of operations and comprehensive loss. Realized gains or losses upon sale are recorded in other expense, net, in the statements of operations and comprehensive loss. The Company did not hold any available for sale or trading securities at the period ended March 31, 2023 or at the year ended December 31, 2022.
Intangible Assets	Intangible Assets Intangible assets subject to amortization include a developed patent. The Company qualitatively evaluates intangible assets for impairment annually or whenever events or changes in circumstances indicate that it is more likely than not the carrying amount of intangible assets may excess their implied fair values. The company recorded an immaterial amount for the intangible asset and an immaterial amount of amortization expense for the periods ended March 31, 2023 and March 31, 2022. As of March 31, 2023 and December 31, 2022, no indicators of impairment of the intangible asset were identified.
Related Party Loan	Related Party Loan The loan made to a related party is stated at the principal amount of $ 0.6 0.6
Foreign Currency Translation	Foreign Currency Translation Monetary assets and liabilities in the functional currency are re-measured into the reporting currency at the rates of exchange prevailing at the reporting date. Income and expense transactions in the functional currency are re-measured into the reporting currency at the average exchange rate prevailing during the reporting period. Non-monetary items in functional currency are re-measured into the reporting currency at the historical exchange rate (i.e., the rate of exchange at the date of the transaction). The gains or losses resulting from foreign currency translation are included in the statements of operations and comprehensive loss.
Emerging Growth Company Status	Emerging Growth Company Status The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that: (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. If the Business Combination were to be consummated, the surviving company will remain an emerging growth company, as defined by the Jumpstart Our Business Startups act of 2012, until the earliest of (i) the last day of the combined entity’s first fiscal year following the fifth anniversary of the completion of MURF’s initial public offering, (ii) the last day of the fiscal year in which the combined entity has total annual gross revenue of at least $1.235 billion, (iii) the last day of the fiscal year in which the combined entity is deemed to be a large accelerated filer, which means the market value of the combined entity’s common stock that is held by non-affiliates exceeds $700.0 million as of the prior December 31 st
Conduit Pharmaceuticals Limited [Member]
Cash and Cash Equivalents		Cash and Cash Equivalents Cash and cash equivalents are primarily maintained with major financial institutions in the United Kingdom and Switzerland. The Company considers cash equivalents to be short-term, highly liquid investments that (a) are readily convertible into known amounts of cash, (b) are traded and held for cash management purposes, and (c) have original maturities of three months or less at the time of purchase. The Switzerland bank accounts holding cash balances are uninsured. The Company has not experienced any losses on this account through the year ended December 31, 2022. As of December 31, 2022 and 2021, the Company did not hold any cash equivalents.
Use of Estimates		Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and related disclosures of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting period. Estimates are based on several factors including the facts and circumstances available at the time the estimates are made, historical experience, risk of loss, general economic conditions and trends, and the assessment of the probable future outcome. Subjective and significant estimates include, but are not necessarily limited to, the inputs used to determine the fair value of convertible notes payable and the amount to reserve for the related party loan receivable. Actual results could differ materially from such estimates. Estimates and assumptions are reviewed periodically by management and changes in estimates are made as management becomes aware of changes in circumstances surrounding the estimates. The effects of changes are reflected in the financial statements in the period that they are determined.
Fair Value Measurements		Fair Value Measurements Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurements and Disclosures, defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. Fair value is to be determined based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants. In determining fair value, the Company used various valuation approaches. A fair value hierarchy has been established for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are those that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs reflect the Company’s assumption about the inputs that market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The fair value hierarchy is categorized into three levels, based on the inputs, as follows: ● Level 1—Valuations based on quoted prices for identical instruments in active markets. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these instruments does not entail a significant degree of judgment. ● Level 2— Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for either similar instruments in active markets, identical or similar instruments in markets that are not active, or model-derived valuations whose inputs or significant value drivers are observable or can be corroborated by observable market data. ● Level 3—Valuations based on inputs that are unobservable. These valuations require significant judgment. The Company’s Level 1 assets consist of cash and cash equivalents in the accompanying balance sheets and the value of accrued expenses and other current liabilities approximate fair value due to the short-term nature of these assets and liabilities. As of December 31, 2022 and 2021, the Company has two financial liabilities, convertible notes that are adjusted to fair value on a recurring basis as well as an option liability for which the fair value is determined based on Level 3 inputs as such inputs are not readily observable. See Note 2 and Note 5 for further information on the Company’s financial liability held at fair value.
Research and Development and Funding		Research and Development and Funding Research and development expenses consist primarily of costs incurred in connection with the research and development of our product candidates and programs. Funding expenses consist primarily of costs incurred in connection with the Company providing funding to St George Street Capital (“St George Street”) to carry out its research and development activities. St George Street holds all licenses to conduct clinical research through third party pharmaceutical companies. The Company expenses research and development costs and intangible assets acquired that have no alternative future use as incurred. These expenses include: ● expenses incurred under agreements with organizations that support the Company’s drug discovery and development activities; ● expenses incurred in connection with the preclinical and clinical development of the Company’s product candidates and programs, including under agreements with contract research organizations, or CROs; ● costs related to contract manufacturing organizations, or CMOs, that are primarily engaged to provide drug substance and product for our clinical trials, research and development programs, as well as investigative sites and consultants that conduct the Company’s clinical trials, nonclinical studies and other scientific development services; ● the costs of acquiring and manufacturing nonclinical and clinical trial materials, including manufacturing registration and validation batches; ● employee-related expenses, including salaries, related benefits and equity-based compensation expense, for employees engaged in research and development functions; ● costs related to compliance with quality and regulatory requirements; ● payments made under third-party licensing agreements; and ● direct and allocated costs related to facilities, information technology, personnel and other overhead. Advance payments that we make for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such amounts are recognized as an expense as the goods are delivered or consumed or the related services are performed, or until it is no longer expected that the goods will be delivered, or the services rendered.
General and Administrative Expenses		General and Administrative Expenses General and administrative expenses consist primarily of salaries and related costs for personnel in executive management, finance, corporate and business development, and administrative functions. General and administrative expenses also include legal fees relating to patent and corporate matters; professional fees for accounting, auditing, tax, and administrative consulting services; insurance costs; administrative travel expenses and other operating costs. The Company has incurred increased accounting, audit, legal, regulatory, compliance and director and officer insurance costs as well as investor and public relations expenses associated with being a public company. The Company anticipates that its general and administrative expenses will increase in the future as it increases its headcount to support the development of its product candidates and programs and with continued research and development activities.
Income Taxes		Income Taxes ASC Topic 740, Income Taxes The Company is exempt from income tax in the Cayman Islands.
Net Loss per Ordinary Share Attributable to Ordinary Shareholders		Net Loss per Ordinary Share Attributable to Ordinary Shareholders The Company calculates net loss per share attributable to ordinary shareholders – basic and diluted using the two-class method under ASC Topic 260, Earnings Per Share
Investments in Equity Securities		Investments in Equity Securities Investments in equity securities that have a readily determinable fair value are reported at fair value. Changes in fair value between accounting periods are recorded in other income, net, in the statements of operations and comprehensive loss. Realized gains or losses upon sale are recorded in other income, net, in the statements of operations and comprehensive loss. The Company did not hold any available for sale or trading securities at the years ended December 31, 2022 and December 31, 2021.
Intangible Assets		Intangible Assets Intangible assets subject to amortization include a developed patent. The Company qualitatively evaluates intangible assets for impairment annually or whenever events or changes in circumstances indicate that it is more likely than not the carrying amount of intangible assets may excess their implied fair values. The company recorded an immaterial amount for the intangible asset and an immaterial amount of amortization expense for the year ended December 31, 2022. As of December 31, 2022, no indicators of impairment of the intangible asset were identified.
Related Party Loan		Related Party Loan The loan made to a related party is stated at the principal amount of $ 0.3 0.3
Foreign Currency Translation		Foreign Currency Translation Monetary assets and liabilities in the functional currency are re-measured into the reporting currency at the rates of exchange prevailing at the reporting date. Income and expense transactions in the functional currency are re-measured into the reporting currency at the average exchange rate prevailing during the reporting period. Non-monetary items in functional currency are re-measured into the reporting currency at the historical exchange rate (i.e., the rate of exchange at the date of the transaction). The gains or losses resulting from foreign currency translation are included in the statements of operations and comprehensive loss.
Emerging Growth Company Status		Emerging Growth Company Status The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that: (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. If the Business Combination (see Note 1) were to be consummated, the surviving company will remain an emerging growth company, as defined by the Jumpstart Our Business Startups act of 2012, until the earliest of (i) the last day of the combined entity’s first fiscal year following the fifth anniversary of the completion of MURF’s initial public offering, (ii) the last day of the fiscal year in which the combined entity has total annual gross revenue of at least $1.235 billion, (iii) the last day of the fiscal year in which the combined entity is deemed to be a large accelerated filer, which means the market value of the combined entity’s common stock that is held by non-affiliates exceeds $700.0 million as of the prior December 31 st
Recently Adopted Accounting Pronouncements		Recently Adopted Accounting Pronouncements Effective January 1, 2021, the Company adopted ASU No. 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40) In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842).” Topic 842 was subsequently amended by ASU 2018-10, “Codification Improvements to Topic 842, Leases” and ASU 2018-11, “Leases (Topic 842)”. The amendments in this update increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. For leases with a term of 12 months or less, the amendments permit lessees to make an accounting policy election by class of underlying assets not to recognize lease assets and lease liabilities. For finance leases, the amendments in this update require a lessee to (1) recognize a right-of-use asset and lease liability, initially measured at the present value of the lease payments, on the balance sheet; (2) recognize interest on the lease liability separately from amortization of the right-of-use asset in the statement of operations; (3) classify repayments of the principal portion of the lease liability within financing activities and payments of interest on the lease liability and variable lease payments within operating activities in the statement of cash flows. For operating leases, the amendments in this update require a lessee to (1) recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments, on the balance sheet; (2) recognize a single lease cost, calculated so that the cost of the lease is allocated over the lease term on a generally straight-line basis; (3) classify all cash payments within operating activities in the statement of cash flows. On October 16, 2019, the FASB approved the proposal to delay the effective date for this standard for private and all other entities. Due to the Company’s extended transition period election, the amendments are effective for fiscal years beginning after December 15, 2020. In June 2020, the FASB issued ASU No. 2020-05, Coronavirus Disease 2019 (“COVID-19”) in response to the pandemic which has adversely affected the global economy and caused significant and widespread business and capital market disruptions. The FASB is committed to supporting and assisting stakeholders during this difficult time. The FASB issued ASU 2020-05 as a limited deferral of the effective dates of certain ASUs, including ASU 2016-02 (including amendments issued after the issuance of the original) to provide immediate, near-term relief for certain entities for whom these ASUs are either currently effective or imminently effective. This update is effective for annual periods beginning January 1, 2022, and interim periods beginning January 1, 2023, with early adoption permitted. The Company is in the process of evaluating its impact. The Company did not have any lease agreements as of the years ended December 31, 2022 and 2021 and does not believe the new standard will have a material impact on the financial statements. The Company adopted the standard on January 1, 2022. The adoption of ASU No. 2016-02 did not have a material impact on the Company’s financial statements.
Recent Accounting Pronouncements Not Yet Adopted		Recent Accounting Pronouncements Not Yet Adopted In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740) In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) as contained within the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”).	Basis of Presentation The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) as contained within the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”).
Emerging Growth Company	Emerging Growth Company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012, as amended (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.	Emerging Growth Company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012, as amended (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with US GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.	Use of Estimates The preparation of financial statements in conformity with US GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had $ 90,606 345,777	Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had $ 345,777 48,555
Investments Held in Trust Account	Investments Held in Trust Account At March 31, 2023, and December 31, 2022, the Company had $ 23,658,838 136,871,183	Investments Held in Trust Account At December 31, 2022 and 2021, the Company had $ 136,871,183 zero, respectively,
Offering Costs Associated With a Public Offering	Offering Costs Associated With a Public Offering The Company complies with the requirements of FASB ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (“SAB”) Topic 5A — “ Expenses of Offering.” 7,738,161 2,645,000 4,628,750 464,411 1,358,457 19,656	Offering Costs Associated With a Public Offering The Company complies with the requirements of FASB ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (“SAB”) Topic 5A — “ Expenses of Offering.” 7,738,161 2,645,000 4,628,750 464,411 1,358,457 19,656
Class A Common Stock Subject to Possible Redemption	Class A Common Stock Subject to Possible Redemption The Company accounts for its shares of Class A common stock subject to possible redemption in accordance with the guidance enumerated in ASC 480 “ Distinguishing Liabilities from Equity During the three months ended March 31, 2023, 11,037,272 22,861,803 The following table provides a reconciliation of the shares of Class A common stock subject to possible redemption reflected on the balance sheet as of March 31, 2023: SCHEDULE OF COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION Gross proceeds from IPO $ 132,250,000 Less: Proceeds allocated to Public Warrants (23,276,000 ) Class A common stock issuance costs (6,360,054 ) Plus: Remeasurement adjustment of carrying value to redemption value 32,281,054 Class A common stock subject to possible redemption, as of March 31, 2022 134,895,000 Plus: Remeasurement adjustment of carrying value to redemption value 1,876,183 Class A common stock subject to possible redemption as of December 31, 2022 $ 136,771,183 Less: Redemptions during the three months ended March 31, 2023 * (114,068,280 ) Plus: Remeasurement adjustment of carrying value to redemption value 158,900 Class A common stock subject to possible redemption as of March 31, 2023 22,861,803 * As of March 31, 2023, $ 236,350	Class A Common Stock Subject to Possible Redemption The Company accounts for its shares of Class A common stock subject to possible redemption in accordance with the guidance enumerated in ASC 480 “ Distinguishing Liabilities from Equity 136,771,183 As of December 31, 2022, the Class A common stock subject to possible redemption reflected on the balance sheet are reconciled in the following table: SCHEDULE OF COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION Gross proceeds from IPO $ 132,250,000 Less: Proceeds allocated to Public Warrants (23,276,000 ) Class A common stock issuance costs (6,360,054 ) Plus: Remeasurement adjustment of carrying value to redemption value 32,281,054 Class A common stock subject to possible redemption, as of March 31, 2022 134,895,000 Plus: Remeasurement adjustment of carrying value to redemption value 101,767 Class A common stock subject to possible redemption as of June 30, 2022 134,996,767 Plus: Remeasurement adjustment of carrying value to redemption value 609,920 Class A common stock subject to possible redemption as of September 30, 2022 135,606,687 Plus: Remeasurement adjustment of carrying value to redemption value 1,164,496 Class A common stock subject to possible redemption as of December 31, 2022 $ 136,771,183
Excise Tax	Excise Tax In accordance with the Inflation Reduction Act of 2022, the Company accrues the expected excise tax obligation at the end of each reporting period as a cost of redeeming any shares as of that date. In connection with the vote to amend the Company’s certificate of incorporation, holders of 11,037,272 114,068,280 1 1,140,683
Net Income (Loss) per Common Share	Net Income (Loss) per Common Share The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share”. Net income (loss) per share of common stock is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding for the period. Accretion associated with the redeemable shares of Class A common stock is excluded from income (loss) per common share as the redemption value approximates fair value. The calculation of diluted income (loss) per share of common stock does not consider the effect of the warrants issued in connection with the (i) Initial Public Offering, and (ii) the private placement since the exercise of the warrants is contingent upon the occurrence of future events. As of March 31, 2023, the Company’s outstanding warrants ( 13,979,000 The following table reflects the calculation of basic and diluted net income (loss) per common share (in dollars, except per share amounts): SCHEDULE OF BASIC AND DILUTED NET INCOME (LOSS) PER COMMON SHARE Three Months Ended March 31, 2023 Class A common stock Class B common stock Basic and diluted net income per common share Numerator: Allocation of net loss $ 76,421 $ 43,848 Denominator: Basic and diluted weighted average shares outstanding 5,762,364 3,306,250 Basic and diluted net income per common share $ 0.01 $ 0.01 For the Three Months Ended March 31, 2022 Class A common stock Class B common stock Basic and diluted net loss per common share Numerator: Allocation of net loss $ (180,478 ) $ (73,058 ) Denominator: Basic and diluted weighted average shares outstanding 8,167,506 3,306,250 Basic and diluted net loss per common share $ (0.02 ) $ (0.02 )	Net Income (Loss) per Common Share The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share”. Net income (loss) per share of common stock is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding for the period. Accretion associated with the redeemable shares of Class A common stock is excluded from income (loss) per common share as the redemption value approximates fair value. The calculation of diluted income (loss) per share of common stock does not consider the effect of the warrants issued in connection with the (i) Initial Public Offering, and (ii) the private placement since the exercise of the warrants is contingent upon the occurrence of future events. As of December 31, 2022, the Company’s outstanding warrants ( 13,979,000 The following table reflects the calculation of basic and diluted net income (loss) per common share (in dollars, except per share amounts): SCHEDULE OF BASIC AND DILUTED NET INCOME (LOSS) PER COMMON SHARE For the Period Since Inception to December 31, 2021 Class A common stock Class B common stock Basic and diluted net income per common share Numerator: Allocation of net loss $ - $ (4,381 ) Denominator: Basic and diluted weighted average shares outstanding - 2,875,000 Basic and diluted net income per common share $ - $ (0.00 ) For the Year Ended December 31, 2022 Class A common stock Class B common stock Basic and diluted net loss per common share Numerator: Allocation of net income $ 315,560 $ 83,079 Denominator: Basic and diluted weighted average shares outstanding 12,558,058 3,306,250 Basic and diluted net loss per common share $ 0.03 $ 0.03
Income Taxes	Income Taxes The Company follows the asset and liability method of accounting for income taxes under ASC 740, “ Income Taxes ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of March 31, 2023 or December 31, 2022. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception. The Company has identified the United States and California as its only tax jurisdictions. The Company is subject to income taxation by major taxing authorities since inception. All tax periods are open to examination by tax authorities. These examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. The Company actual tax expense differs from the expected tax expense due to the change in the valuation allowance.	Income Taxes The Company follows the asset and liability method of accounting for income taxes under ASC 740, “ Income Taxes ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no no The Company has identified the United States and California as its only tax jurisdictions. The Company is subject to income taxation by major taxing authorities since inception. All tax periods are open to examination by tax authorities. These examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. The Company actual tax expense differs from the expected tax expense due to the change in the valuation allowance.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to credit risk consist principally of cash and investments held in the Trust Account. Cash is maintained in accounts with financial institutions, which, at times may exceed the Federal Depository Insurance Corporation coverage limit of $ 250,000	Concentration of Credit Risk Financial instruments that potentially subject the Company to credit risk consist principally of cash and investments held in the Trust Account. Cash is maintained in accounts with financial institutions, which, at times may exceed the Federal Depository Insurance Corporation coverage limit of $ 250,000
Investments Held in Trust Account	Investments Held in Trust Account The Company’s Investments held in the Trust Account were $ 23,658,838 136,871,183 The Company’s portfolio of investments is comprised of U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or investments in money market funds that invest in U.S. government securities and generally have a readily determinable fair value, or a combination thereof. When the Company’s investments held in the Trust Account are comprised of U.S. government securities, the investments are classified as trading securities. When the Company’s investments held in the Trust Account are comprised of money market funds, the investments are recognized at fair value. Trading securities and investments in money market funds are presented on the balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities is included in income on investments held in the Trust Account in the accompanying statements of operations. The estimated fair values of investments held in the Trust Account are determined using available market information.	Investments Held in Trust Account The Company’s Investments held in the Trust Account were $ 136,871,183 zero The Company’s portfolio of investments is comprised of U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or investments in money market funds that invest in U.S. government securities and generally have a readily determinable fair value, or a combination thereof. When the Company’s investments held in the Trust Account are comprised of U.S. government securities, the investments are classified as trading securities. When the Company’s investments held in the Trust Account are comprised of money market funds, the investments are recognized at fair value. Trading securities and investments in money market funds are presented on the balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities is included in income on investments held in the Trust Account in the accompanying statements of operations. The estimated fair values of investments held in the Trust Account are determined using available market information.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC 820, “Fair Value Measurements” approximates the carrying amounts represented in the balance sheet, partially due to their short-term nature. Fair value is defined as the price that would be received for sale of an asset or paid to transfer of a liability, in an orderly transaction between market participants at the measurement date. US GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: ● Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.	Fair Value of Financial Instruments The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC 820, “Fair Value Measurements” approximates the carrying amounts represented in the balance sheet, partially due to their short-term nature. Fair value is defined as the price that would be received for sale of an asset or paid to transfer of a liability, in an orderly transaction between market participants at the measurement date. US GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: ● Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.
Derivative Financial Instruments	Derivative Financial Instruments The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging”. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date.	Derivative Financial Instruments The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging”. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date.
Warrant Instruments	Warrant Instruments The Company accounts for warrants in accordance with the guidance contained in FASB ASC 815, “Derivatives and Hedging”. Under ASC 815-40 warrants that meet the criteria for equity treatment are recorded in stockholders’ equity (deficit). The warrants are subject to re-evaluation of the proper classification and accounting treatment at each reporting period. If the warrants no longer meet the criteria for equity treatment, they will be recorded as a liability and remeasured each period with changes recorded in the statement of operations.	Warrant Instruments The Company accounts for warrants in accordance with the guidance contained in FASB ASC 815, “Derivatives and Hedging”. Under ASC 815-40 warrants that meet the criteria for equity treatment are recorded in stockholders’ equity (deficit). The warrants are subject to re-evaluation of the proper classification and accounting treatment at each reporting period. If the warrants no longer meet the criteria for equity treatment, they will be recorded as a liability and remeasured each period with changes recorded in the statement of operations.
Recent Accounting Standards	Recent Accounting Standards Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.	Recent Accounting Standards Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.

Fair Value (Tables)

Fair Value (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Conduit Pharmaceuticals Ltd [Member]
Schedule of Liabilities Subject to Measurement at Fair Value on Recurring Basis	The following table presents as of March 31, 2023 the Company’s liabilities subject to measurement at fair value on a recurring basis (in thousands): Schedule of Liabilities Subject to Measurement at Fair Value on Recurring Basis Fair Value Measurements as of March 31, 2023 In thousands Level 1 Level 2 Level 3 Total Liabilities: Convertible notes payable $ - $ - $ 3,620 $ 3,620 Option liability $ - $ - $ 1,309 $ 1,309 Total Liabilities $ - $ - $ 4,929 $ 4,929 The following table presents as of December 31, 2022 the Company’s liabilities subject to measurement at fair value on a recurring basis (in thousands): Fair Value Measurements as of December 31, 2022 In thousands Level 1 Level 2 Level 3 Total Liabilities: Convertible notes payable $ - $ - $ 1,835 $ 1,835 Option liability $ - $ - $ 1,417 $ 1,417 Total Liabilities $ - $ - $ 3,252 $ 3,252
Schedule of Additional Information About the Financial Liabilities Subject To Measurement at Fair Value	The following table presents additional information about the financial liabilities subject to measurement at fair value on a recurring basis for which the Company used significant unobservable inputs (Level 3) (in thousands): Schedule of Additional Information About the Financial Liabilities Subject To Measurement at Fair Value Amount Balance as of December 31, 2022 $ 1,835 Issuance of debt 1,459 Change in fair value 280 Foreign currency exchange impact 46 Balance as of March 31, 2023 $ 3,620
Schedule of Fair Value Significant Unobservable Inputs	Schedule of Fair Value Significant Unobservable Inputs Assumption Unobservable input - Change of control 2023 2022 Probabilities of conversion provisions 10 90 % 10 90 % Estimated timing of conversion 0.33 1.59 0.25 1.41 Time period to maturity 1.41 1.41 Risk-adjusted discount rate 6.3 % 6.1 %
Schedule of Additional Information About the Option Liability Subject to Measurement at Fair Value	The following table presents additional information about the option liability subject to measurement at fair value on a recurring basis for which the Company used significant unobservable inputs (Level 3) (in thousands): Schedule of Additional Information About the Option Liability Subject to Measurement at Fair Value Amount Balance, beginning of period $ 1,417 Option issued - Change in fair value (136 ) Foreign currency exchange impact 28 Balance, end of period $ 1,309
Conduit Pharmaceuticals Limited [Member]
Schedule of Liabilities Subject to Measurement at Fair Value on Recurring Basis		The following tables present as of December 31, 2022 and 2021 respectively, the Company’s liabilities subject to measurement at fair value on a recurring basis (in thousands): Schedule of Liabilities Subject to Measurement at Fair Value on Recurring Basis Fair Value Measurements as of December 31, 2022 In thousands Level 1 Level 2 Level 3 Total Liabilities: Convertible notes payable $ - $ - $ 1,835 $ 1,835 Option liability $ - $ - $ 1,404 $ 1,404 Total Liabilities $ - $ - $ 3,239 $ 3,239 Fair Value Measurements as of December 31, 2021 In thousands Level 1 Level 2 Level 3 Total Liabilities: Convertible notes payable $ - $ - $ 749 $ 749 Total Liabilities $ - $ - $ 749 $ 749
Schedule of Additional Information About the Financial Liabilities Subject To Measurement at Fair Value		The following table presents additional information about the convertible notes payable subject to measurement at fair value on a recurring basis for which the Company used significant unobservable inputs (Level 3) (in thousands): Schedule of Additional Information About the Financial Liabilities Subject To Measurement at Fair Value Amount Balance, beginning of period $ 749 Notes issued 908 Change in fair value 264 Foreign currency exchange impact (86 ) Balance, end of period $ 1,835
Schedule of Fair Value Significant Unobservable Inputs		Schedule of Fair Value Significant Unobservable Inputs Assumption Unobservable input - Change of control 2022 2021 Probabilities of conversion provisions 10 90 5 67.5 Estimated timing of conversion 0.25 1.41 0.75 2.41 Time period to maturity 1.41 2.41 Risk-adjusted discount rate 6.1 % 2.9 %
Schedule of Additional Information About the Option Liability Subject to Measurement at Fair Value		The following table presents additional information about the option liability subject to measurement at fair value on recurring basis for which the Company used significant unobservable inputs (Level 3) (in thousands): Schedule of Additional Information About the Option Liability Subject to Measurement at Fair Value Amount Balance, beginning of period $ - Option issued 1,404 Change in fair value - Foreign currency exchange impact - Balance, end of period $ 1,404
Schedule of Fair Value of the Covid Asset Option		The following table presents the inputs to the Black-Scholes model as of December 31, 2022 to determine the fair value of the Covid Asset option (in thousands where applicable): Schedule of Fair Value of the Covid Asset Option Black-Scholes Inputs Assumption Underlying asset price $ 2,812 Strike Price $ 3,960 Volatility 90 % Risk-free rate 4.68 % Dividend yield 0 % Option term .71

Accrued Expenses (Tables)

Accrued Expenses (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Conduit Pharmaceuticals Ltd [Member]
Schedule of Accrued Expenses	Accrued expenses consisted of the following as of March 31, 2023 and December 31, 2022 (in thousands): Schedule of Accrued Expenses March 31, December 31, 2023 2022 Accrued expenses: Professional service fees $ 2,419 $ 2,246 Payroll 25 338 Total accrued expenses and other current liabilities $ 2,444 $ 2,584
Conduit Pharmaceuticals Limited [Member]
Schedule of Accrued Expenses		Accrued expenses consisted of the following as of December 31, 2022 and 2021 (in thousands): Schedule of Accrued Expenses 2022 2021 December 31, 2022 2021 Accrued expenses: Professional service fees $ 2,246 $ 1,308 Payroll 338 921 Other current liabilities: Other - 6 Total accrued expenses and other current liabilities $ 2,584 $ 2,235

Liability Related to the Sale_3

Liability Related to the Sale of Future Revenue (Tables)	3 Months Ended
	Mar. 31, 2023
Conduit Pharmaceuticals Ltd [Member]
Schedule of Liability for the Sale of Future Revenue	The following table presents as of March 31, 2023 the Company’s liability for the sale of future revenue (in thousands): Schedule of Liability for the Sale of Future Revenue Liability related to the sale of future royalties December 31, 2022 $ 4,083 Sale of future royalties - Foreign currency exchange impact 90 March 31, 2023 $ 4,173

Net Loss Per Share Attributab_2

Net Loss Per Share Attributable to Ordinary Shareholders (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Schedule of Basic and Diluted Net Loss Per Share	The following table reflects the calculation of basic and diluted net income (loss) per common share (in dollars, except per share amounts): SCHEDULE OF BASIC AND DILUTED NET INCOME (LOSS) PER COMMON SHARE Three Months Ended March 31, 2023 Class A common stock Class B common stock Basic and diluted net income per common share Numerator: Allocation of net loss $ 76,421 $ 43,848 Denominator: Basic and diluted weighted average shares outstanding 5,762,364 3,306,250 Basic and diluted net income per common share $ 0.01 $ 0.01 For the Three Months Ended March 31, 2022 Class A common stock Class B common stock Basic and diluted net loss per common share Numerator: Allocation of net loss $ (180,478 ) $ (73,058 ) Denominator: Basic and diluted weighted average shares outstanding 8,167,506 3,306,250 Basic and diluted net loss per common share $ (0.02 ) $ (0.02 )	The following table reflects the calculation of basic and diluted net income (loss) per common share (in dollars, except per share amounts): SCHEDULE OF BASIC AND DILUTED NET INCOME (LOSS) PER COMMON SHARE For the Period Since Inception to December 31, 2021 Class A common stock Class B common stock Basic and diluted net income per common share Numerator: Allocation of net loss $ - $ (4,381 ) Denominator: Basic and diluted weighted average shares outstanding - 2,875,000 Basic and diluted net income per common share $ - $ (0.00 ) For the Year Ended December 31, 2022 Class A common stock Class B common stock Basic and diluted net loss per common share Numerator: Allocation of net income $ 315,560 $ 83,079 Denominator: Basic and diluted weighted average shares outstanding 12,558,058 3,306,250 Basic and diluted net loss per common share $ 0.03 $ 0.03
Conduit Pharmaceuticals Ltd [Member]
Schedule of Basic and Diluted Net Loss Per Share	The following table presents the calculation of basic and diluted net loss per share attributable to holders of the Ordinary Shares (in thousands, except share amounts and per share data): Schedule of Basic and Diluted Net Loss Per Share 2023 2022 March 31, 2023 2022 Numerator: Net loss and comprehensive loss $ (2,165 ) $ (307 ) Denominator: Weighted average number of ordinary shares outstanding - basic and diluted 2,000 1,000 Net loss per share - basic and diluted $ (1,082 ) $ (307 )
Schedule of Potentially Dilutive Securities	Potentially dilutive securities (upon conversion) that were not included in the diluted per share calculations because they would have been anti-dilutive were as follows: Schedule of Potentially Dilutive Securities March 31, 2023 Ordinary Shares potentially issuable upon conversion of convertible notes payable 3,070,000 Total 3,070,000 March 31, 2022 Ordinary Shares potentially issuable upon conversion of convertible notes payable 500,000 Total 500,000
Conduit Pharmaceuticals Limited [Member]
Schedule of Basic and Diluted Net Loss Per Share		The following table presents the calculation of basic and diluted net loss per share attributable to holders of the Ordinary Shares (in thousands, except share amounts and per share data): Schedule of Basic and Diluted Net Loss Per Share 2022 2021 December 31, 2022 2021 Numerator: Net loss $ (4,887 ) $ (3,657 ) Denominator: Weighted-average shares outstanding used in calculating net loss per share – basic and diluted 2,000 1,000 Net loss per share attributable to ordinary shareholders – basic and diluted $ (2,444 ) $ (3,657 )
Schedule of Potentially Dilutive Securities		Potentially dilutive securities (upon conversion) that were not included in the diluted per share calculations because they would have been anti-dilutive were as follows: Schedule of Potentially Dilutive Securities December 31, 2022 Ordinary Shares potentially issuable upon conversion of convertible notes payable 1,250,000 Total 1,250,000 December 31, 2021 Ordinary Shares potentially issuable upon conversion of convertible notes payable 500,000 Total 500,000

Other Expense, net (Tables)

Other Expense, net (Tables)	3 Months Ended
	Mar. 31, 2023
Conduit Pharmaceuticals Ltd [Member]
Schedule of Other Expense, Net	The following table presents other expense, net, for the periods ended March 31, 2023 and 2022 (in thousands): Schedule of Other Expense, Net 2023 2022 For the three months ended March 31, 2023 2022 Other income: Change in fair value of option liability $ 136 $ - Gain on sale of investment in equity securities - 33 Total other income $ 136 $ 33 Other expense: Change in fair value of equity securities receivable - 48 Change in fair value of convertible notes payable 280 1 Realized foreign currency transaction loss 8 - Interest expense on convertible promissory note 5 - Total other expense $ 293 $ 49 Total other income (expense), net $ (157 ) $ (16 )

Liability Related to the Sale_4

Liability Related to the Sale of Future Royalties (Tables)	12 Months Ended
	Dec. 31, 2022
Conduit Pharmaceuticals Limited [Member]
Schedule of Liability for the Sale of Future Revenue	The following table presents as of December 31, 2022 the Company’s liability for the sale of future revenue (in thousands): Schedule of Liability for the Sale of Future Revenue Liability related to the sale of future royalties December 31, 2021 $ 2,958 Sale of future royalties 1,439 Foreign currency exchange impact (314 ) December 31, 2022 $ 4,083

Other Expense (Tables)

Other Expense (Tables)	12 Months Ended
	Dec. 31, 2022
Conduit Pharmaceuticals Limited [Member]
Schedule of Other Expense, Net	The following table presents other expense, for the years ended December 31, 2022 and 2021 (in thousands): Schedule of Other Expense, Net 2022 2021 For the year ended December 31, 2022 2021 Other expense: Loss on Cizzle option $ 1,300 $ - Realized foreign currency transaction loss - 8 Loss on sale of investment in equity securities 129 76 Placement fees on sale of investment in equity securities 33 327 Change in fair value of convertible notes payable 265 73 Total other expense $ 1,727 $ 484

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Accounting Policies [Abstract]
SCHEDULE OF COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION	The following table provides a reconciliation of the shares of Class A common stock subject to possible redemption reflected on the balance sheet as of March 31, 2023: SCHEDULE OF COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION Gross proceeds from IPO $ 132,250,000 Less: Proceeds allocated to Public Warrants (23,276,000 ) Class A common stock issuance costs (6,360,054 ) Plus: Remeasurement adjustment of carrying value to redemption value 32,281,054 Class A common stock subject to possible redemption, as of March 31, 2022 134,895,000 Plus: Remeasurement adjustment of carrying value to redemption value 1,876,183 Class A common stock subject to possible redemption as of December 31, 2022 $ 136,771,183 Less: Redemptions during the three months ended March 31, 2023 * (114,068,280 ) Plus: Remeasurement adjustment of carrying value to redemption value 158,900 Class A common stock subject to possible redemption as of March 31, 2023 22,861,803 * As of March 31, 2023, $ 236,350	As of December 31, 2022, the Class A common stock subject to possible redemption reflected on the balance sheet are reconciled in the following table: SCHEDULE OF COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION Gross proceeds from IPO $ 132,250,000 Less: Proceeds allocated to Public Warrants (23,276,000 ) Class A common stock issuance costs (6,360,054 ) Plus: Remeasurement adjustment of carrying value to redemption value 32,281,054 Class A common stock subject to possible redemption, as of March 31, 2022 134,895,000 Plus: Remeasurement adjustment of carrying value to redemption value 101,767 Class A common stock subject to possible redemption as of June 30, 2022 134,996,767 Plus: Remeasurement adjustment of carrying value to redemption value 609,920 Class A common stock subject to possible redemption as of September 30, 2022 135,606,687 Plus: Remeasurement adjustment of carrying value to redemption value 1,164,496 Class A common stock subject to possible redemption as of December 31, 2022 $ 136,771,183
SCHEDULE OF BASIC AND DILUTED NET INCOME (LOSS) PER COMMON SHARE	The following table reflects the calculation of basic and diluted net income (loss) per common share (in dollars, except per share amounts): SCHEDULE OF BASIC AND DILUTED NET INCOME (LOSS) PER COMMON SHARE Three Months Ended March 31, 2023 Class A common stock Class B common stock Basic and diluted net income per common share Numerator: Allocation of net loss $ 76,421 $ 43,848 Denominator: Basic and diluted weighted average shares outstanding 5,762,364 3,306,250 Basic and diluted net income per common share $ 0.01 $ 0.01 For the Three Months Ended March 31, 2022 Class A common stock Class B common stock Basic and diluted net loss per common share Numerator: Allocation of net loss $ (180,478 ) $ (73,058 ) Denominator: Basic and diluted weighted average shares outstanding 8,167,506 3,306,250 Basic and diluted net loss per common share $ (0.02 ) $ (0.02 )	The following table reflects the calculation of basic and diluted net income (loss) per common share (in dollars, except per share amounts): SCHEDULE OF BASIC AND DILUTED NET INCOME (LOSS) PER COMMON SHARE For the Period Since Inception to December 31, 2021 Class A common stock Class B common stock Basic and diluted net income per common share Numerator: Allocation of net loss $ - $ (4,381 ) Denominator: Basic and diluted weighted average shares outstanding - 2,875,000 Basic and diluted net income per common share $ - $ (0.00 ) For the Year Ended December 31, 2022 Class A common stock Class B common stock Basic and diluted net loss per common share Numerator: Allocation of net income $ 315,560 $ 83,079 Denominator: Basic and diluted weighted average shares outstanding 12,558,058 3,306,250 Basic and diluted net loss per common share $ 0.03 $ 0.03

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Fair Value Disclosures [Abstract]
SCHEDULE OF FAIR VALUE OF ASSETS AND LIABILITIES	The following table presents information about the Company’s assets and liabilities that are measured at fair value at March 31, 2023 and December 31, 2022, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: SCHEDULE OF FAIR VALUE OF ASSETS AND LIABILITIES Description Level March 31, 2023 Assets: Investments held in Trust Account 1 $ 23,658,838 Description Level December 31, 2022 Assets: Investments held in Trust Account 1 $ 136,871,183	The following table presents information about the Company’s assets and liabilities that are measured at fair value at December 31, 2022, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: SCHEDULE OF FAIR VALUE OF ASSETS AND LIABILITIES Description Level December 31, 2022 Assets: Investments held in Trust Account 1 $ 136,871,183

STOCKHOLDERS_ EQUITY (DEFICIT)

STOCKHOLDERS’ EQUITY (DEFICIT) (Tables)	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION	The expected tax expense based on the statutory rate is reconciled with actual tax expense as follows: SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION For the Year Ended December 31, 2022 U.S. federal statutory rate 21.0 % State taxes, net of federal benefit 0.1 % Change in valuation allowance 27.36 % Income tax provision 48.46 %
SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES	SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES 2022 Deferred tax assets: Startup costs 211,627 Total deferred tax assets 211,627 Valuation Allowance (211,627 ) Net deferred tax asset $ —
SCHEDULE OF CHANGE IN VALUATION	SCHEDULE OF CHANGE IN VALUATION 2022 Federal Current $ 374,862 Deferred (211,627 ) State and Local Current - Deferred - Change in valuation 211,627 Income Tax Provision $ 374,862

Nature of the Business, Basis_3

Nature of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative) - USD ($)	2 Months Ended	3 Months Ended			12 Months Ended
	Dec. 31, 2021	Mar. 31, 2023	Dec. 31, 2022	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Nov. 08, 2022
Accumulated deficit	$ 4,381	$ 5,479,806	$ 4,300,492		$ 4,300,492	$ 4,381
Net losses	4,381	(120,269)		$ 253,536	(398,639)
Cash used in operating activities	5,995	599,818		692,485	1,311,310
Conduit Pharmaceuticals Ltd [Member]
Accumulated deficit		12,929,000	10,764,000		10,764,000
Net losses		2,165,000		307,000
Cash used in operating activities		1,969,000		$ 788,000
Private placement aggregated amount, common stock
Description of emerging growth company status		the surviving company will remain an emerging growth company, as defined by the Jumpstart Our Business Startups act of 2012, until the earliest of (i) the last day of the combined entity’s first fiscal year following the fifth anniversary of the completion of MURF’s initial public offering, (ii) the last day of the fiscal year in which the combined entity has total annual gross revenue of at least $1.235 billion, (iii) the last day of the fiscal year in which the combined entity is deemed to be a large accelerated filer, which means the market value of the combined entity’s common stock that is held by non-affiliates exceeds $700.0 million as of the prior December 31st or (iv) the date on which the combined entity has issued more than $1.0 billion in non-convertible debt securities during the prior three year period.
Conduit Pharmaceuticals Ltd [Member] | Related Party [Member]
Related party principal amount		$ 600,000
Related party allowance		$ 600,000
Conduit Pharmaceuticals Ltd [Member] | Convertible Notes Payable [Member]
Convertible notes			3,700,000		3,700,000
Convertible notes issued			1,800,000
Conduit Pharmaceuticals Ltd [Member] | Convertible Notes Payable [Member] | Private Placement [Member]
Private placement aggregated amount, common stock							$ 27,000,000
Conduit Pharmaceuticals Limited [Member]
Accumulated deficit	5,877,000		10,764,000		10,764,000	5,877,000
Net losses					4,887,000	3,657,000
Cash used in operating activities					2,266,000	2,151,000
Private placement aggregated amount, common stock
Description of emerging growth company status					the surviving company will remain an emerging growth company, as defined by the Jumpstart Our Business Startups act of 2012, until the earliest of (i) the last day of the combined entity’s first fiscal year following the fifth anniversary of the completion of MURF’s initial public offering, (ii) the last day of the fiscal year in which the combined entity has total annual gross revenue of at least $1.235 billion, (iii) the last day of the fiscal year in which the combined entity is deemed to be a large accelerated filer, which means the market value of the combined entity’s common stock that is held by non-affiliates exceeds $700.0 million as of the prior December 31st or (iv) the date on which the combined entity has issued more than $1.0 billion in non-convertible debt securities during the prior three year period
Conduit Pharmaceuticals Limited [Member] | Related Party [Member]
Related party principal amount					$ 300,000
Related party allowance			300,000		300,000
Conduit Pharmaceuticals Limited [Member] | Private Placement [Member]
Private placement aggregated amount, common stock							$ 27,000,000
Conduit Pharmaceuticals Limited [Member] | Convertible Notes Payable [Member]
Convertible notes			3,600,000		$ 3,600,000
Convertible notes issued			$ 1,800,000

Schedule of Liabilities Subject

Schedule of Liabilities Subject to Measurement at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Conduit Pharmaceuticals Ltd [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Convertible notes payable	$ 3,620	$ 1,835
Option liability	1,309	1,417
Total Liabilities	4,929	3,252
Conduit Pharmaceuticals Limited [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Convertible notes payable		1,835	$ 749
Option liability		1,404
Total Liabilities		3,239	749
Fair Value, Inputs, Level 1 [Member] | Conduit Pharmaceuticals Ltd [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Convertible notes payable
Option liability
Total Liabilities
Fair Value, Inputs, Level 1 [Member] | Conduit Pharmaceuticals Limited [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Convertible notes payable
Option liability
Total Liabilities
Fair Value, Inputs, Level 2 [Member] | Conduit Pharmaceuticals Ltd [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Convertible notes payable
Option liability
Total Liabilities
Fair Value, Inputs, Level 2 [Member] | Conduit Pharmaceuticals Limited [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Convertible notes payable
Option liability
Total Liabilities
Fair Value, Inputs, Level 3 [Member] | Conduit Pharmaceuticals Ltd [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Convertible notes payable	3,620	1,835
Option liability	1,309	1,417
Total Liabilities	$ 4,929	3,252
Fair Value, Inputs, Level 3 [Member] | Conduit Pharmaceuticals Limited [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Convertible notes payable		1,835	749
Option liability		1,404
Total Liabilities		$ 3,239	$ 749

Schedule of Additional Informat

Schedule of Additional Information About the Financial Liabilities Subject To Measurement at Fair Value (Details) - USD ($) $ in Thousands	3 Months Ended			12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Conduit Pharmaceuticals Ltd [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning balance, fair value	$ 1,835
Change in fair value	280	$ 1
Ending balance, fair value	3,620			$ 1,835
Conduit Pharmaceuticals Limited [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning balance, fair value	1,835	749		749
Change in fair value			$ 73	265	$ 73
Ending balance, fair value				1,835	749
Fair Value, Inputs, Level 3 [Member] | Conduit Pharmaceuticals Ltd [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning balance, fair value	1,835
Issuance of debt	1,459
Change in fair value	280
Foreign currency exchange impact	46
Ending balance, fair value	3,620			1,835
Fair Value, Inputs, Level 3 [Member] | Conduit Pharmaceuticals Limited [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning balance, fair value	$ 1,835	$ 749		749
Issuance of debt				908
Change in fair value				264
Foreign currency exchange impact				(86)
Ending balance, fair value				$ 1,835	$ 749

Schedule of Fair Value Signific

Schedule of Fair Value Significant Unobservable Inputs (Details)	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Probabilities of Conversion Provisions [Member] | Minimum [Member] | Conduit Pharmaceuticals Ltd [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Risk-adjusted discount rate	10	10
Probabilities of Conversion Provisions [Member] | Minimum [Member] | Conduit Pharmaceuticals Limited [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Risk-adjusted discount rate		10	5
Probabilities of Conversion Provisions [Member] | Maximum [Member] | Conduit Pharmaceuticals Ltd [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Risk-adjusted discount rate	90	90
Probabilities of Conversion Provisions [Member] | Maximum [Member] | Conduit Pharmaceuticals Limited [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Risk-adjusted discount rate		90	67.5
Measurement Input, Expected Term [Member] | Conduit Pharmaceuticals Ltd [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Time period to maturity, years	1 year 4 months 28 days	1 year 4 months 28 days
Measurement Input, Expected Term [Member] | Conduit Pharmaceuticals Limited [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Time period to maturity, years		1 year 4 months 28 days	2 years 4 months 28 days
Measurement Input, Expected Term [Member] | Minimum [Member] | Conduit Pharmaceuticals Ltd [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Estimated timing of conversion, years	3 months 29 days	3 months
Measurement Input, Expected Term [Member] | Minimum [Member] | Conduit Pharmaceuticals Limited [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Estimated timing of conversion, years		3 months	9 months
Measurement Input, Expected Term [Member] | Maximum [Member] | Conduit Pharmaceuticals Ltd [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Estimated timing of conversion, years	1 year 7 months 2 days	1 year 4 months 28 days
Measurement Input, Expected Term [Member] | Maximum [Member] | Conduit Pharmaceuticals Limited [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Estimated timing of conversion, years		1 year 4 months 28 days	2 years 4 months 28 days
Measurement Input, Discount Rate [Member] | Conduit Pharmaceuticals Ltd [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Risk-adjusted discount rate	6.3	6.1
Measurement Input, Discount Rate [Member] | Conduit Pharmaceuticals Limited [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Risk-adjusted discount rate		6.1	2.9

Schedule of Additional Inform_2

Schedule of Additional Information About the Option Liability Subject to Measurement at Fair Value (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Conduit Pharmaceuticals Ltd [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning balance, option liability	$ 1,417
Change in fair value, option liability	136
Ending balance, option liability	1,309		$ 1,417
Conduit Pharmaceuticals Limited [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning balance, option liability	1,404
Ending balance, option liability			1,404
Fair Value, Inputs, Level 3 [Member] | Conduit Pharmaceuticals Ltd [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning balance, option liability	1,417
Option issued
Change in fair value, option liability	(136)
Foreign currency exchange impact	28
Ending balance, option liability	1,309		1,417
Fair Value, Inputs, Level 3 [Member] | Conduit Pharmaceuticals Limited [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning balance, option liability	$ 1,404
Option issued			1,404
Change in fair value, option liability
Foreign currency exchange impact
Ending balance, option liability			$ 1,404

Fair Value (Details Narrative)

Fair Value (Details Narrative) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Conduit Pharmaceuticals Ltd [Member]
Phase transition success rates	52.70%
Covid asset value	$ 2,800
Fair value of covid asset	1,300	$ 1,400
Option liability	$ 1,309	$ 1,417
Conduit Pharmaceuticals Limited [Member]
Phase transition success rates		52.70%
Covid asset value		$ 2,800
Fair value of covid asset		1,400
Option liability		$ 1,404

Schedule of Accrued Expenses (D

Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Conduit Pharmaceuticals Ltd [Member]
Professional service fees	$ 2,419	$ 2,246
Payroll	25	338
Total accrued expenses and other current liabilities	$ 2,444	2,584
Conduit Pharmaceuticals Limited [Member]
Professional service fees		2,246	$ 1,308
Payroll		338	921
Total accrued expenses and other current liabilities		2,584	2,235
Other			$ 6

Schedule of Liability for the S

Schedule of Liability for the Sale of Future Revenue (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Conduit Pharmaceuticals Ltd [Member]
Beginning balance, deferred revenue	$ 4,083
Sale of future royalties
Foreign currency exchange impact	90
Ending balance, deferred revenue	4,173	$ 4,083
Conduit Pharmaceuticals Limited [Member]
Beginning balance, deferred revenue	$ 4,083	2,958
Sale of future royalties		1,439
Foreign currency exchange impact		(314)
Ending balance, deferred revenue		$ 4,083

Liability Related to the Sale_5

Liability Related to the Sale of Future Revenue (Details Narrative) £ in Thousands, shares in Millions										2 Months Ended		3 Months Ended	12 Months Ended
	Dec. 15, 2022 USD ($)	Dec. 15, 2022 GBP (£)	Feb. 11, 2022 USD ($) shares	Feb. 11, 2022 GBP (£) shares	Sep. 10, 2021 USD ($)	Oct. 20, 2020 USD ($)	Oct. 20, 2020 GBP (£)	Jun. 03, 2020 USD ($)	Jun. 03, 2020 GBP (£)	Dec. 31, 2021 USD ($)	[1],[2]	Mar. 31, 2022 USD ($)	Dec. 31, 2022 USD ($) shares	Dec. 31, 2020 USD ($)	Dec. 31, 2020 GBP (£)	Mar. 31, 2023 USD ($)	Dec. 15, 2022 GBP (£)
Issuance of shares, value										$ 25,000		$ 7,520,350	$ 7,520,350
Conduit Pharmaceuticals Ltd [Member]
Percentage of royalty expenses								30%	30%
Covid asset								$ 24,500,000	£ 19,200
Funding amount																$ 300,000
Conduit Pharmaceuticals Ltd [Member] | Cizzle [Member]
Total consideration			$ 1,600,000	£ 1,200
Stock issued during period, shares, new issues | shares			25	25
Shares issued | shares			22	22									22
Deferred revenue																$ 1,400,000
Option fee	$ 100,000																£ 100
Issuance of shares, value	$ 3,900,000	£ 3,250
Conduit Pharmaceuticals Ltd [Member] | Vela Agreement [Member]
Percentage of future revenue earned						8%	8%
Total consideration						$ 2,900,000	£ 2,350
Cash consideration						1,600,000	£ 1,250
Stock issued during period, value, acquisitions					$ 1,300,000	$ 1,100,000,000
Conduit Pharmaceuticals Ltd [Member] | Vela Agreement [Member] | Vela Technologies PLC [Member]
Cash consideration														$ 1,600,000	£ 1,250
[1]Includes an aggregate of up to 431,250 1,006,250 3,306,250

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative)	3 Months Ended			12 Months Ended
	Mar. 31, 2023 USD ($)	Mar. 31, 2022 USD ($)	Mar. 31, 2021 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Mar. 07, 2023 USD ($)	Feb. 28, 2023 USD ($)	Feb. 28, 2023 GBP (£)	Dec. 31, 2022 GBP (£)	Nov. 16, 2022 USD ($)	Nov. 16, 2022 GBP (£)	Nov. 01, 2022 USD ($)	Nov. 01, 2022 GBP (£)	Oct. 06, 2022 USD ($)	Oct. 06, 2022 GBP (£)	Aug. 26, 2022 USD ($)	Aug. 26, 2022 GBP (£)	Nov. 04, 2021 USD ($)	Jun. 12, 2021 USD ($)	Jun. 12, 2021 GBP (£)	Jun. 11, 2021 USD ($)	Jun. 11, 2021 GBP (£)	May 27, 2021 USD ($)	May 27, 2021 GBP (£)
Principal amount						$ 1,500,000												$ 300,000
Conduit Pharmaceuticals Ltd [Member]
Principal amount												$ 3,300,000	£ 3,000,000										$ 1,400,000	£ 1,000,000
Interest rate												5%	5%										5%	5%
Convertible notes payable	$ 3,620,000			$ 1,835,000										$ 67,000	£ 50,000	$ 500,000	£ 400,000
Convertible loan notes issued														1,300,000	950,000
Convertible loan notes outstanding														1,300,000	950,000
Change in fair value of convertible notes payable	280,000	$ 1,000
Conduit Pharmaceuticals Ltd [Member] | Convertible Promissory Notes Payable [Member]
Principal amount	$ 800,000
Interest rate	20%
Conduit Pharmaceuticals Ltd [Member] | Other Income [Member]
Change in fair value of convertible notes payable	$ 300,000
Conduit Pharmaceuticals Ltd [Member] | Nonrelated Party [Member]
Principal amount							$ 900,000	£ 800,000
Conduit Pharmaceuticals Ltd [Member] | Chief Executive Officer [Member] | Related Party [Member]
Principal amount							500,000	400,000
Conduit Pharmaceuticals Ltd [Member] | 2022 Convertible Loan Note Instrument [Member] | Chief Executive Officer [Member]
Convertible notes payable							500,000	400,000		$ 400,000	£ 300,000
Conduit Pharmaceuticals Limited [Member]
Principal amount												$ 3,300,000	£ 3,000,000										$ 1,400,000	£ 1,000,000
Interest rate												5%	5%										5%	5%
Convertible notes payable				1,835,000	$ 749,000					$ 400,000	£ 300,000
Convertible loan notes issued				1,100,000					£ 950,000
Convertible loan notes outstanding				1,100,000					950,000
Change in fair value of convertible notes payable			$ 73,000	265,000	$ 73,000
Conversion price interest rate												20%	20%										20%	20%
Issuance of convertible notes				$ 67,000					£ 50,000
Conduit Pharmaceuticals Limited [Member] | Investor One [Member]
Convertible notes payable														67,000	50,000	500,000	400,000				$ 300,000	£ 250,000
Conduit Pharmaceuticals Limited [Member] | Investor Two [Member]
Convertible notes payable														$ 67,000	£ 50,000	$ 500,000	£ 400,000		$ 300,000	£ 250,000
Conduit Pharmaceuticals Limited [Member] | 2022 Convertible Loan Note Instrument [Member] | Chief Executive Officer [Member]
Convertible notes payable							$ 500,000	£ 400,000

Loans Payable (Details Narrativ

Loans Payable (Details Narrative) £ in Thousands, $ in Thousands	May 01, 2022 USD ($)	Mar. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	May 01, 2022 GBP (£)
Conduit Pharmaceuticals Ltd [Member]
Loan payable	$ 200	$ 200	$ 200
Conduit Pharmaceuticals Ltd [Member] | Tranche One [Member]
Loan payable	33			£ 30
Conduit Pharmaceuticals Ltd [Member] | Tranche Two [Member]
Loan payable	33			30
Conduit Pharmaceuticals Ltd [Member] | Tranche Three [Member]
Loan payable	28			25
Conduit Pharmaceuticals Limited [Member]
Loan payable	200		$ 200
Conduit Pharmaceuticals Limited [Member] | Tranche One [Member]
Loan payable	33			30
Conduit Pharmaceuticals Limited [Member] | Tranche Two [Member]
Loan payable	33			30
Conduit Pharmaceuticals Limited [Member] | Tranche Three [Member]
Loan payable	28			£ 25
Loan Agreements [Member] | Conduit Pharmaceuticals Ltd [Member]
Loan payable	$ 200
Loans maturity years description	The Loans mature two years from the date of the agreement
Loan Agreements [Member] | Conduit Pharmaceuticals Limited [Member]
Loan payable	$ 200
Loans maturity years description	The Loans mature two years from the date of the agreement

Ordinary Shares (Details Narrat

Ordinary Shares (Details Narrative)			12 Months Ended
	Mar. 31, 2023 USD ($) $ / shares shares	Mar. 31, 2022 USD ($)	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares	Mar. 31, 2023 £ / shares shares	Dec. 31, 2022 £ / shares shares	Nov. 04, 2022 shares
Conduit Pharmaceuticals Ltd [Member]
Subsidiary or Equity Method Investee [Line Items]
Common stock, shares authorized	400,000,000		400,000,000		400,000,000	400,000,000
Common stock, par value | (per share)	$ 0.0001		$ 0.0001		£ 0.0001	£ 0.0001
Common stock, shares issued	2,000		2,000		2,000	2,000
Common stock, shares outstanding	2,000		2,000		2,000	2,000
Conduit Pharmaceuticals Ltd [Member] | Dividend Declared [Member]
Subsidiary or Equity Method Investee [Line Items]
Cash dividends common stock | $	$ 0	$ 0
Conduit Pharmaceuticals Ltd [Member] | Dividend Paid [Member]
Subsidiary or Equity Method Investee [Line Items]
Cash dividends common stock | $	$ 0	$ 0
Conduit Pharmaceuticals Ltd [Member] | Corvus Capital Limited [Member]
Subsidiary or Equity Method Investee [Line Items]
Common stock, shares issued							1,000
Common stock shares transferred to other investors							775
Conduit Pharmaceuticals Limited [Member]
Subsidiary or Equity Method Investee [Line Items]
Common stock, shares authorized			400,000,000	400,000,000		400,000,000
Common stock, par value | $ / shares			$ 0.0001	$ 0.0001
Common stock, shares issued			2,000	1,000		2,000
Common stock, shares outstanding			2,000	1,000		2,000
Conduit Pharmaceuticals Limited [Member] | Common Stock [Member]
Subsidiary or Equity Method Investee [Line Items]
Common stock, shares issued			1,000	0		1,000
Conduit Pharmaceuticals Limited [Member] | Dividend Declared [Member]
Subsidiary or Equity Method Investee [Line Items]
Cash dividends common stock | $			$ 0	$ 0
Conduit Pharmaceuticals Limited [Member] | Dividend Paid [Member]
Subsidiary or Equity Method Investee [Line Items]
Cash dividends common stock | $			$ 0	$ 0

Schedule of Basic and Diluted N

Schedule of Basic and Diluted Net Loss Per Share (Details) - USD ($)	2 Months Ended	3 Months Ended		12 Months Ended
	Dec. 31, 2021	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021
Net loss	$ (4,381)	$ 120,269	$ (253,536)	$ 398,639
Conduit Pharmaceuticals Ltd [Member]
Net loss		$ (2,165,000)	$ (307,000)
Weighted-average shares outstanding used in calculating net loss per share – basic and diluted		2,000	1,000
Net loss per share attributable to ordinary shareholders – basic and diluted		$ (1,082)	$ (307)
Conduit Pharmaceuticals Limited [Member]
Net loss				$ (4,887,000)	$ (3,657,000)
Weighted-average shares outstanding used in calculating net loss per share – basic and diluted				2,000,000	1,000,000
Net loss per share attributable to ordinary shareholders – basic and diluted				$ (2,444)	$ (3,657)

Schedule of Potentially Dilutiv

Schedule of Potentially Dilutive Securities (Details) - shares	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021
Conduit Pharmaceuticals Ltd [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	3,070,000	500,000
Conduit Pharmaceuticals Ltd [Member] | Ordinary Shares Potentially Issuable Upon Conversion of Convertible Notes Payable [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	3,070,000	500,000
Conduit Pharmaceuticals Limited [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total			1,250,000	500,000
Conduit Pharmaceuticals Limited [Member] | Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total			1,250,000	500,000

Related Party Transactions (Det

Related Party Transactions (Details Narrative) $ / shares in Units, £ in Thousands												1 Months Ended	2 Months Ended			3 Months Ended		9 Months Ended		12 Months Ended
	Apr. 05, 2023 USD ($)	Mar. 07, 2023 USD ($)	Mar. 07, 2023 USD ($)	Dec. 15, 2022 USD ($)	Dec. 15, 2022 GBP (£)	Feb. 10, 2022 USD ($)	Feb. 10, 2022 USD ($)	Jan. 26, 2022 shares	Jan. 26, 2022 shares	Nov. 16, 2021 USD ($) $ / shares shares	Nov. 16, 2021 $ / shares	Mar. 31, 2023 USD ($) $ / shares shares	Feb. 28, 2023 USD ($)	Dec. 31, 2021 USD ($) shares		Mar. 31, 2023 USD ($) $ / shares shares	Mar. 31, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2021 GBP (£)	Nov. 30, 2023 shares	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($) shares	Dec. 31, 2021 GBP (£)	Mar. 06, 2023 USD ($)	Feb. 28, 2023 GBP (£)	Nov. 16, 2022 USD ($)	Nov. 16, 2022 GBP (£)	Nov. 04, 2022 shares	Nov. 01, 2022 USD ($)	Nov. 01, 2022 GBP (£)	Oct. 06, 2022 USD ($)	Oct. 06, 2022 GBP (£)	Aug. 26, 2022 USD ($)	Aug. 26, 2022 GBP (£)	Nov. 04, 2021 USD ($)	May 27, 2021 USD ($)	May 27, 2021 GBP (£)
Number of shares issued to sponsor, value														$ 25,000	[1],[2]		$ 7,520,350				$ 7,520,350
Stock surrendered and forfeited during period shares | shares																11,037,272
Related Party Transaction, Description of Transaction											(A) one year after the completion of a Business Combination and (B) subsequent to a Business Combination, (x) if the last reported sale price of the Class A common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after a Business Combination, or (y) the date on which the Company completes a liquidation, merger, capital stock exchange or other similar transaction that results in all of the Public Stockholders having the right to exchange their shares of common stock for cash, securities or other property. However, our sponsor has agreed to transfer, but has not yet transferred, 15,000 placement units to each of our director nominees.
Principal amount		$ 1,500,000	$ 1,500,000																																$ 300,000
Monthly payment for office space																$ 10,000					10,000
Administration fee related party														4,381		$ 477,406	243,718				1,092,682
Notes payable converted																					$ 1,500,000
Conversion price | $ / shares												$ 10				$ 10					$ 10
Notes payable, current												$ 300,000		177,057		$ 300,000						$ 177,057
Sponsor fees						$ 1,500,000
Administration fee related party																30,000	20,000				110,000
Working capital loans														$ 0							$ 0	$ 0
Maximum [Member]
Notes payable converted																$ 1,500,000
Subsequent Event [Member]
Principal amount																								$ 1,500,000
Proceeds from note payable	$ 200,000	300,000
Unsecured Promissory Note [Member]
Principal amount																																			$ 300,000
Payment of promissory not							$ 177,057
Promissory Note [Member]
Principal amount		$ 1,500,000	1,500,000
Proceeds from note payable			$ 300,000
Promissory Note [Member] | Subsequent Event [Member]
Proceeds from note payable	$ 200,000
Common Class B [Member]
Ordinary shares issued | shares												3,306,250		3,306,250		3,306,250					3,306,250	3,306,250
Common Class A [Member]
Ordinary shares issued | shares												754,000		0		754,000					754,000	0
Sale of stock price per share | $ / shares										$ 12	$ 12
Sponsor [Member]
Stock surrendered and forfeited during period shares | shares									1,006,250
Stock issued during period on hold | shares								3,306,250	3,306,250
Sponsor [Member] | Common Class B [Member]
Number of shares issued to sponsor | shares										4,312,500
Number of shares issued to sponsor, value										$ 25,000
Conduit Pharmaceuticals Ltd [Member]
Convertible notes payable aggregate princpal												$ 3,620,000				$ 3,620,000					$ 1,835,000										$ 67,000	£ 50	$ 500,000	£ 400
Ordinary shares issued | shares												2,000				2,000					2,000
Principal amount																													$ 3,300,000	£ 3,000						$ 1,400,000	£ 1,000
Administration fee related party																$ 2,008,000	291,000
Conduit Pharmaceuticals Ltd [Member] | Chief Executive Officer [Member] | 2022 Convertible Loan Note Instrument [Member]
Convertible notes payable aggregate princpal													$ 500,000												£ 400	$ 400,000	£ 300
Conduit Pharmaceuticals Limited [Member]
Convertible notes payable aggregate princpal														$ 749,000							$ 1,835,000	$ 749,000				$ 400,000	£ 300
Ordinary shares issued | shares														1,000							2,000	1,000
Number of shares issued to sponsor, value				$ 3,900,000	£ 3,250
Principal amount																													$ 3,300,000	£ 3,000						$ 1,400,000	£ 1,000
Administration fee related party																					$ 3,049,000	$ 2,890,000
Conduit Pharmaceuticals Limited [Member] | Chief Executive Officer [Member] | 2022 Convertible Loan Note Instrument [Member]
Convertible notes payable aggregate princpal													$ 500,000												400
Bearer interest													5%
Conversion price													20%
Conduit Pharmaceuticals Limited [Member] | Chief Executive Officer [Member] | 2022 Convertible Loan Note Instrument [Member] | Subsequent Event [Member]
Convertible notes payable aggregate princpal													$ 500,000												400
Conversion price												20%
Corvus Capital Limited [Member] | Conduit Pharmaceuticals Ltd [Member]
Ordinary shares subscribed | shares												1,000				1,000
Corvus Capital Limited [Member] | Conduit Pharmaceuticals Ltd [Member] | Chief Executive Officer [Member]
Directors fees payable												$ 300,000				$ 300,000	100,000
Corvus Capital Limited [Member] | Conduit Pharmaceuticals Ltd [Member] | Chief Executive Officers Family [Member]
Amount paid to CEO's family member																	33,000
Corvus Capital Limited [Member] | Conduit Pharmaceuticals Ltd [Member] | Other Current Liabilities [Member]
Advisory fees																600,000					600,000
Corvus Capital Limited [Member] | Conduit Pharmaceuticals Ltd [Member] | Accrued Expenses and Other Current Liabilities [Member] | Chief Executive Officer [Member]
Directors fees paid																200,000					$ 400,000
Corvus Capital Limited [Member] | Conduit Pharmaceuticals Ltd [Member] | General and Administrative Expense [Member]
Advisory fees																		$ 1,700,000	£ 1,300
Corvus Capital Limited [Member] | Conduit Pharmaceuticals Limited [Member]
Ordinary shares subscribed | shares														775							1,000	775
Ordinary shares issued | shares																												1,000
Ordinary shares converted | shares																				775
Corvus Capital Limited [Member] | Conduit Pharmaceuticals Limited [Member] | Chief Executive Officer [Member]
Directors fees payable														$ 400,000							$ 400,000	$ 400,000
Corvus Capital Limited [Member] | Conduit Pharmaceuticals Limited [Member] | Other Current Liabilities [Member]
Advisory fees																					600,000	700,000
Corvus Capital Limited [Member] | Conduit Pharmaceuticals Limited [Member] | Accrued Expenses and Other Current Liabilities [Member] | Chief Executive Officer [Member]
Directors fees paid																					400,000	400,000
Corvus Capital Limited [Member] | Conduit Pharmaceuticals Limited [Member] | General and Administrative Expense [Member]
Advisory fees																						1,600,000	£ 1,300
St George Street Capital [Member] | Conduit Pharmaceuticals Limited [Member]
Ordinary shares held																					225
Capital														$ 100,000							$ 300,000	$ 100,000
Related Party [Member]
Administration fee related party																$ 30,000	$ 20,000
Related Party [Member] | Conduit Pharmaceuticals Ltd [Member] | Chief Executive Officer [Member]
Principal amount													$ 500,000												£ 400
[1]Includes an aggregate of up to 431,250 1,006,250 3,306,250

Schedule of Other Expense, Net

Schedule of Other Expense, Net (Details) - USD ($) $ in Thousands	3 Months Ended			12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Conduit Pharmaceuticals Ltd [Member]
Change in fair value of option liability	$ 136
Gain on sale of investment in equity securities		33
Total other income	136	33
Change in fair value of equity securities receivable		48
Change in fair value of convertible notes payable	280	1
Realized foreign currency transaction loss	8
Interest expense on convertible promissory note	5
Total other expense	293	49
Total other income (expense), net	$ (157)	$ (16)
Conduit Pharmaceuticals Limited [Member]
Change in fair value of convertible notes payable			$ 73	$ 265	$ 73
Realized foreign currency transaction loss			8
Total other expense			484	1,727
Total other income (expense), net				(1,727)	$ (484)
Loss on Cizzle option				1,300
Loss on sale of investment in equity securities			76	129
Placement fees on sale of investment in equity securities			$ 327	$ 33

Schedule of Fair Value of the C

Schedule of Fair Value of the Covid Asset Option (Details) - Conduit Pharmaceuticals Limited [Member] $ / shares in Thousands	12 Months Ended
	Dec. 31, 2022 $ / shares
Measurement Input Price Underlying Asset Price [Member]
Dividend yield	2,812
Measurement Input Price Strike Price [Member]
Dividend yield	3,960
Measurement Input, Price Volatility [Member]
Dividend yield	0.90
Measurement Input, Risk Free Interest Rate [Member]
Dividend yield	0.0468
Measurement Input, Expected Dividend Rate [Member]
Dividend yield	0
Measurement Input, Expected Term [Member]
Debt Instrument, Term	8 months 15 days

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) $ / shares in Units, £ in Thousands					1 Months Ended			2 Months Ended	3 Months Ended			12 Months Ended
	Apr. 05, 2023 USD ($)	Mar. 07, 2023 USD ($)	Jan. 26, 2023 USD ($) $ / shares shares	Jan. 26, 2023 USD ($) $ / shares shares	Apr. 30, 2023 USD ($) $ / shares	Apr. 30, 2023 GBP (£)	Mar. 31, 2023 USD ($) $ / shares shares	Feb. 28, 2023 USD ($)	Mar. 31, 2023 USD ($) $ / shares shares		Dec. 31, 2022 USD ($) $ / shares	Dec. 31, 2022 USD ($) $ / shares	May 11, 2023 USD ($)	May 04, 2023 USD ($)	Apr. 30, 2023 GBP (£)	Apr. 06, 2023 USD ($)	Mar. 31, 2023 GBP (£) shares	Mar. 06, 2023 USD ($)	Feb. 28, 2023 GBP (£)	Nov. 16, 2022 USD ($)	Nov. 16, 2022 GBP (£)	Nov. 01, 2022 USD ($)	Nov. 01, 2022 GBP (£)	Oct. 31, 2022 shares	Oct. 06, 2022 USD ($)	Oct. 06, 2022 GBP (£)	Aug. 26, 2022 USD ($)	Aug. 26, 2022 GBP (£)	Feb. 11, 2022 shares	Dec. 31, 2021 USD ($)	Nov. 16, 2021 $ / shares	Nov. 04, 2021 USD ($)	May 27, 2021 USD ($)	May 27, 2021 GBP (£)
Subsequent Event [Line Items]
Debt instrument, face amount		$ 1,500,000																														$ 300,000
Percentage of deposit in trust account			1%
Redemption price per share | $ / shares							$ 10.45		$ 10.45		$ 10.34	$ 10.34
Number of stock redeemed, value			$ 114,000,000						$ 114,068,280	[1]	$ 1,876,183	$ 1,876,183
Investments held in trust account			$ 24,000,000	$ 24,000,000			$ 23,658,838		$ 23,658,838		136,871,183	136,871,183
Price per share | $ / shares			$ 0.035	$ 0.035
Aggregate of deposit			$ 77,000	$ 77,000
Proceeds from business combination			$ 924,000
Common Class A [Member]
Subsequent Event [Line Items]
Price per share | $ / shares																															$ 12
Percentage of deposit in trust account			1%
Stock issued | shares							13,979,000		13,979,000								13,979,000
Number of stock redeemed, value									$ 114,068,280
Price per share | $ / shares							$ 10.33		$ 10.33
Conduit Pharmaceuticals Ltd [Member]
Subsequent Event [Line Items]
Convertible notes payable aggregate princpal							$ 3,620,000		$ 3,620,000		1,835,000	1,835,000													$ 67,000	£ 50	$ 500,000	£ 400
Debt instrument, face amount																						$ 3,300,000	£ 3,000										$ 1,400,000	£ 1,000
Conduit Pharmaceuticals Ltd [Member] | Nonrelated Party [Member]
Subsequent Event [Line Items]
Debt instrument, face amount								$ 900,000											£ 800
Conduit Pharmaceuticals Limited [Member]
Subsequent Event [Line Items]
Convertible notes payable aggregate princpal											$ 1,835,000	$ 1,835,000								$ 400,000	£ 300									$ 749,000
Debt instrument, face amount																						$ 3,300,000	£ 3,000										$ 1,400,000	£ 1,000
Stock issued | shares																								22,000,000					22,000,000
2022 Convertible Loan Note Instrument [Member] | Conduit Pharmaceuticals Ltd [Member] | Chief Executive Officer [Member]
Subsequent Event [Line Items]
Convertible notes payable aggregate princpal								500,000											400	$ 400,000	£ 300
2022 Convertible Loan Note Instrument [Member] | Conduit Pharmaceuticals Limited [Member] | Chief Executive Officer [Member]
Subsequent Event [Line Items]
Convertible notes payable aggregate princpal								$ 500,000											400
Conversion price								20%
Subsequent Event [Member]
Subsequent Event [Line Items]
Sponsor advanced amount	$ 200,000	$ 300,000
Debt instrument, face amount																		$ 1,500,000
Deposit														$ 77,688		$ 78,863
Percentage of deposit in trust account				1%
Number of stock redeemed, value				$ 114
Investments held in trust account			$ 23	$ 23
Price per share | $ / shares			$ 0.035	$ 0.035
Aggregate of deposit			$ 77,000	$ 77,000
Proceeds from business combination				$ 924,000
Subsequent Event [Member] | Common Class A [Member]
Subsequent Event [Line Items]
Percentage of deposit in trust account				1%
Stock issued during period on hold | shares				11,037,272
Stock issued | shares			13,979,000	13,979,000
Redemption price per share | $ / shares			$ 10.33	$ 10.33
Subsequent Event [Member] | Conduit Pharmaceuticals Limited [Member] | Nonrelated Party [Member]
Subsequent Event [Line Items]
Convertible notes payable aggregate princpal | £																	£ 800
Subsequent Event [Member] | Vela Option Agreement [Member] | Conduit Pharmaceuticals Ltd [Member]
Subsequent Event [Line Items]
Royalty percentage					8%	8%
Option fee					$ 500,000	£ 400
Description of option agreement					The option is exercisable in whole at any time from the close of the Merger (the “Effective Time”) until the earlier of (i) the date that is six (6) months from the Effective Time, and (ii) February 7, 2024, the expiration date of the term.	The option is exercisable in whole at any time from the close of the Merger (the “Effective Time”) until the earlier of (i) the date that is six (6) months from the Effective Time, and (ii) February 7, 2024, the expiration date of the term.
Subsequent Event [Member] | Vela Option Agreement [Member] | Conduit Pharmaceuticals Ltd [Member] | Minimum [Member]
Subsequent Event [Line Items]
Price per share | $ / shares					$ 5
Subsequent Event [Member] | Vela Option Agreement [Member] | Conduit Pharmaceuticals Ltd [Member] | Maximum [Member]
Subsequent Event [Line Items]
Price per share | $ / shares					$ 15
Subsequent Event [Member] | Vela Option Agreement [Member] | Conduit Pharmaceuticals Ltd [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Total consideration paid					$ 4,800,000										£ 4,000
Subsequent Event [Member] | Vela Option Agreement [Member] | Conduit Pharmaceuticals Limited [Member]
Subsequent Event [Line Items]
Royalty percentage					8%	8%
Option fee					$ 500,000	£ 400
Maturity term							18 months		18 months								18 months
Expiration date					Feb. 07, 2024	Feb. 07, 2024
Subsequent Event [Member] | Vela Option Agreement [Member] | Conduit Pharmaceuticals Limited [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Total consideration paid					$ 4,800,000										£ 4,000
Subsequent Event [Member] | 2022 Convertible Loan Note Instrument [Member] | Conduit Pharmaceuticals Limited [Member] | Nonrelated Party [Member]
Subsequent Event [Line Items]
Convertible notes payable aggregate princpal								$ 1,300,000											1,100
Subsequent Event [Member] | 2022 Convertible Loan Note Instrument [Member] | Conduit Pharmaceuticals Limited [Member] | Chief Executive Officer [Member]
Subsequent Event [Line Items]
Convertible notes payable aggregate princpal								$ 500,000											£ 400
Conversion price							20%
Subsequent Event [Member] | Merger Agreement [Member]
Subsequent Event [Line Items]
Net tangible asset													$ 5,000,001
[1]As of March 31, 2023, $ 236,350

Liability Related to the Sale_6

Liability Related to the Sale of Future Royalties (Details Narrative) £ in Thousands									2 Months Ended		3 Months Ended	12 Months Ended
	Dec. 15, 2022 USD ($)	Dec. 15, 2022 GBP (£)	Feb. 11, 2022 USD ($) shares	Feb. 11, 2022 GBP (£) shares	Sep. 10, 2021 USD ($)	Oct. 20, 2020 USD ($)	Oct. 20, 2020 GBP (£)	Jun. 03, 2020	Dec. 31, 2021 USD ($)	[1],[2]	Mar. 31, 2022 USD ($)	Dec. 31, 2022 USD ($) shares	Dec. 31, 2021 USD ($) shares	Dec. 31, 2020 USD ($)	Dec. 31, 2020 GBP (£)	Dec. 15, 2022 GBP (£)	Oct. 31, 2022 shares
Sale of Private Placement Units, net of offering costs									$ 25,000		$ 7,520,350	$ 7,520,350
Conduit Pharmaceuticals Limited [Member]
Percentage of royalty expenses								30%
Funding amount												300,000
Sale of Private Placement Units, net of offering costs	$ 3,900,000	£ 3,250
Total consideration			$ 1,400,000	£ 1,200
Shares issued | shares			22,000,000	22,000,000													22,000,000
Deferred revenue												$ 1,400,000
Option fee	$ 100,000															£ 100
Conduit Pharmaceuticals Limited [Member] | Common Stock [Member]
Stock issued during period, shares, new issues | shares												1,000
Sale of Private Placement Units, net of offering costs
Conduit Pharmaceuticals Limited [Member] | Vela Agreement [Member]
Percentage of future revenue earned						8%	8%
Total consideration						$ 2,900,000	£ 2,350
Stock issued during period, value, acquisitions					$ 1,300,000	1,100,000,000
Stock issued during period, shares, new issues | shares			25	25									1,100,000,000
Equity securities fair value													$ 1,300,000
Sale of Private Placement Units, net of offering costs													1,200,000,000
Loss on sale of investment													76,000
Placement fees													$ 300,000
Conduit Pharmaceuticals Limited [Member] | Vela Agreement [Member] | Common Stock [Member]
Stock issued during period, shares, new issues | shares													1,100,000,000
Conduit Pharmaceuticals Limited [Member] | Vela Agreement [Member] | Vela Technologies PLC [Member]
Cash consideration						$ 1,600,000	£ 1,250							$ 1,600,000	£ 1,250
[1]Includes an aggregate of up to 431,250 1,006,250 3,306,250

DESCRIPTION OF ORGANIZATION, _2

DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND GOING CONCERN (Details Narrative) - USD ($)				2 Months Ended	3 Months Ended				6 Months Ended	12 Months Ended
	Jan. 26, 2023	Nov. 08, 2022	Feb. 07, 2022	Dec. 31, 2021	Mar. 31, 2023		Dec. 31, 2022	Mar. 31, 2022	Jun. 30, 2022	Dec. 31, 2022	Nov. 16, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from isssuance								$ 132,250,000	$ 132,250,000	$ 132,250,000
Offering costs					$ 4,628,750		$ 4,628,750			$ 4,628,750
Shares issued	$ 924,000
Share issued price per share	$ 0.035
Business combination description of transaction					The Company must complete one or more initial Business Combinations with one or more operating businesses or assets with a fair market value equal to at least 80% of the net assets held in the Trust Account (as defined below) (excluding the deferred underwriting commissions and taxes payable on the interest earned on the Trust Account). The Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the “Investment Company Act”). Upon the closing of the Initial Public Offering, management has agreed that an amount equal to at least $10.00 per Unit sold in the Initial Public Offering, including proceeds of the Private Placement Warrants, will be held in a trust account (“Trust Account”), located in the United States and invested only in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less or in any open-ended investment company that holds itself out as a money market fund selected by the Company meeting certain conditions of Rule 2a-7 of the Investment Company Act, as determined by the Company, until the earlier of: (i) the completion of a Business Combination and (ii) the distribution of the funds held in the Trust Account, as described below					The Company must complete one or more initial Business Combinations with one or more operating businesses or assets with a fair market value equal to at least 80% of the net assets held in the Trust Account (as defined below) (excluding the deferred underwriting commissions and taxes payable on the interest earned on the Trust Account). The Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the “Investment Company Act”). Upon the closing of the Initial Public Offering, management has agreed that an amount equal to at least $10.00 per Unit sold in the Initial Public Offering, including proceeds of the Private Placement Warrants, will be held in a trust account (“Trust Account”), located in the United States and invested only in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less or in any open-ended investment company that holds itself out as a money market fund selected by the Company meeting certain conditions of Rule 2a-7 of the Investment Company Act, as determined by the Company, until the earlier of: (i) the completion of a Business Combination and (ii) the distribution of the funds held in the Trust Account, as described below.
Retained earnings restrictions					the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% of the Public Shares, without the prior consent of the Company					the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% of the Public Shares, without the prior consent of the Company.
Debt instrument redemption price percentage					100%					100%
Interest expense					$ 100,000					$ 100,000
Percentage of deposit in trust account	1%
Redemption price per share					$ 10.45		$ 10.34			$ 10.34
Number of stock redeemed, value	$ 114,000,000				$ 114,068,280	[1]	$ 1,876,183			$ 1,876,183
Investments held in trust account	24,000,000				23,658,838		$ 136,871,183			$ 136,871,183
Aggregate of deposit	$ 77,000
Payments to Acquire Investments to be Held in Decommissioning Trust Fund					$ 155,403
Common Class A [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sale of stock price per share											$ 12
Share issued price per share					$ 10.33
Percentage of deposit in trust account	1%
Stock issued					13,979,000
Number of stock redeemed, value					$ 114,068,280
Common Class A [Member] | Public Stockholder [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock issued during period shares on hold	11,037,272
Stock issued	13,979,000
Redemption price per share	$ 10.33
Business Combination Agreement [Member] | Conduit Pharmaceuticals Limited [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Shares issued		$ 650,000,000
Share issued price per share		$ 10
Subscription Agreements [Member] | Conduit Pharmaceuticals Limited [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Shares issued		$ 27,000,000
Transaction Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Business combination description of transaction					(i) $10.00 per Public Share or (ii) such lesser amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account, if less than $10.00 per public Share due to reductions in the value of the trust assets, in each case net of the amount of interest which may be withdrawn to pay taxes, except as to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims under the Company’s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”)					(i) $10.00 per Public Share or (ii) such lesser amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account, if less than $10.00 per public Share due to reductions in the value of the trust assets, in each case net of the amount of interest which may be withdrawn to pay taxes, except as to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims under the Company’s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”).
IPO [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sale of private placement units, net of offering costs			13,225,000
Proceeds from isssuance			$ 132,250,000
Sale of stock					13,225,000					13,225,000
Sale of stock price per share					$ 10		$ 10			$ 10
Net proceeds from sale of equity			$ 139,790,000
Share issued price per share					$ 10		10			$ 10
Private Placement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sale of stock			754,000		754,000					754,000
Sale of stock price per share			$ 10		$ 10		$ 10			$ 10
Gross proceeds from shares issuance			$ 7,540,000
Overfunding of trust account			4,895,000
Operating cash account			2,000,000
Offering costs			2,895,000
Overfunding of the trust account			$ 4,895,000
[1]As of March 31, 2023, $ 236,350

SCHEDULE OF COMMON STOCK SUBJEC

SCHEDULE OF COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION (Details) - USD ($)		2 Months Ended	3 Months Ended						6 Months Ended	12 Months Ended
	Jan. 26, 2023	Dec. 31, 2021	Mar. 31, 2023		Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2022	Dec. 31, 2022
Accounting Policies [Abstract]
Proceeds from Issuance Initial Public Offering								$ 132,250,000	$ 132,250,000	$ 132,250,000
Proceeds allocated to Public Warrants								(23,276,000)
Class A common stock issuance costs								(6,360,054)	(6,360,054)
Remeasurement adjustment of carrying value to redemption value			158,900		$ 1,164,496	$ 609,920	$ 101,767	32,281,054
Common stock subject to possible redemption, ending			136,771,183		135,606,687	134,996,767	134,895,000
Remeasurement adjustment of carrying value to redemption value	$ 114,000,000		114,068,280	[1]	1,876,183					1,876,183
Remeasurement adjustment of carrying value to redemption value	$ (114,000,000)		(114,068,280)	[1]	(1,876,183)					(1,876,183)
Common stock subject to possible redemption, ending			$ 22,861,803		$ 136,771,183	$ 135,606,687	$ 134,996,767	$ 134,895,000	134,996,767	$ 136,771,183
Proceeds allocated to Public Warrants									(23,276,000)
Remeasurement adjustment of carrying value to redemption value									$ 32,281,054
[1]As of March 31, 2023, $ 236,350

SCHEDULE OF COMMON STOCK SUBJ_2

SCHEDULE OF COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION (Details) (Parenthetical)	Mar. 31, 2023 USD ($)
Accounting Policies [Abstract]
Cash account in trust account	$ 236,350

SCHEDULE OF BASIC AND DILUTED_2

SCHEDULE OF BASIC AND DILUTED NET INCOME (LOSS) PER COMMON SHARE (Details) - USD ($)	2 Months Ended		3 Months Ended		12 Months Ended
	Dec. 31, 2021		Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Common Class A [Member]
Allocation of net loss			$ 76,421	$ (180,478)	$ 315,560
Basic and diluted weighted average shares outstanding			5,762,364	8,167,506	12,558,058
Basic and diluted net loss per common share			$ 0.01	$ (0.02)	$ 0.03
Common Class B [Member]
Allocation of net loss	$ (4,381)		$ 43,848	$ (73,058)	$ 83,079
Basic and diluted weighted average shares outstanding	2,875,000	[1],[2]	3,306,250	3,306,250	3,306,250
Basic and diluted net loss per common share	$ 0		$ 0.01	$ (0.02)	$ 0.03
[1]Excludes an aggregate of up to 431,250 1,006,250 3,306,250

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022	Jan. 26, 2023	Dec. 31, 2021
Cash and cash equivalents	$ 90,606	$ 345,777		$ 48,555
Assets held-in-trust, noncurrent	23,658,838	136,871,183	$ 24,000,000
Offering costs	7,738,161	7,738,161
Underwriting fees	2,645,000	2,645,000
Deferred underwriting fee	4,628,750	4,628,750
Initial public offering costs	$ 464,411	464,411
Stock redeemed, during period shares	11,037,272
Temporary equity, carrying amount, attributable to parent	$ 22,861,803	136,771,183
Accrued Excise Tax Redemptions	(1,140,683)
Federal deposit insurance corporation premium expense	250,000	250,000
Investments held in trust	$ 23,658,838	$ 136,871,183		0
Outstanding warrants		13,979,000
Unrecognized tax benefits		$ 0		0
Income tax penalties and interest accrued		0		$ 0
Common Class A [Member]
Stock Issued During Period Shares Stock Options Exercised	11,037,272
Stock Issued During Period Value Stock Options Exercised	$ 114,068,280
Exercise tax liability	1%
Accrued Excise Tax Redemptions	$ 1,140,683
Stock issued	13,979,000
Public Warrants [Member]
Warrant issuance cost	$ 1,358,457	1,358,457
Private Placement Warrants [Member]
Warrant issuance cost	$ 19,656	$ 19,656

INITIAL PUBLIC OFFERING (Detail

INITIAL PUBLIC OFFERING (Details Narrative) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022	Jan. 26, 2023	Nov. 16, 2021
Shares issued price per share			$ 0.035
Common Class A [Member]
Sale of stock price per share				$ 12
Shares issued price per share	$ 10.33
IPO [Member]
Sale of stock	13,225,000	13,225,000
Sale of stock price per share	$ 10	$ 10
Shares issued price per share	10	10
IPO [Member] | Common Class A [Member] | Public Warrant [Member]
Shares issued price per share	$ 11.50	$ 11.50

PRIVATE PLACEMENTS (Details Nar

PRIVATE PLACEMENTS (Details Narrative) - USD ($)		2 Months Ended	3 Months Ended		12 Months Ended
	Feb. 07, 2022	Dec. 31, 2021	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Proceeds from issuance of private placement				$ 7,540,000	$ 7,540,000
Exercise price of warrants			$ 0.01		$ 0.01
Option exercised date			Feb. 07, 2022		Feb. 07, 2022
Cash underwriting discount			$ 0.20		$ 0.20
Underwriting discount			$ 2,645,000		$ 2,645,000
Deferred fee per share			$ 0.35		$ 0.35
Deferred fee			$ 4,628,750		$ 4,628,750
Underwriter expenses			$ 150,000		$ 150,000
Director [Member]
Sale of private placement units, net of offering costs			15,000		15,000
Private Placement [Member]
Number of shares issued for private sale	754,000		754,000		754,000
Sale of stock price per share	$ 10		$ 10		$ 10
Proceeds from issuance of private placement			$ 7,540,000		$ 7,540,000
Deferred fee	$ 2,895,000
Private Placement [Member] | Capital Unit, Class A [Member]
Exercise price of warrants			$ 11.50		$ 11.50
Over-Allotment Option [Member]
Sale of private placement units, net of offering costs					1,725,000
Over-Allotment Option [Member] | Maximum [Member]
Sale of private placement units, net of offering costs			1,725,000
Underwriter [Member]
Advance payment for underwriter expenses			$ 50,000		$ 50,000

STOCKHOLDERS_ DEFICIT (Details

STOCKHOLDERS’ DEFICIT (Details Narrative)		3 Months Ended			12 Months Ended
	Jan. 26, 2023 USD ($) $ / shares	Mar. 31, 2023 USD ($) $ / shares shares		Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2021 $ / shares shares
Class of Stock [Line Items]
Preferred stock, shares authorized		1,000,000		1,000,000	1,000,000	1,000,000
Preferred stock, par value | $ / shares		$ 0.0001		$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, shares issued		0		0	0	0
Preferred stock, shares outstanding		0		0	0	0
Shares subject to possible redemption		2,187,728		13,225,000	13,225,000
Number of shares redeemed		11,037,272
Stock redeemed, value | $	$ 114,000,000	$ 114,068,280	[1]	$ 1,876,183	$ 1,876,183
Price per share | $ / shares	$ 0.035
Warrant exercise price | $ / shares		$ 0.01		$ 0.01	$ 0.01
Warrant [Member]
Class of Stock [Line Items]
Share price per shares | $ / shares		$ 18		$ 18	$ 18
Private Placement Warrants And Public Warrants [Member]
Class of Stock [Line Items]
Warrants outstanding, value | $		$ 23,276,000		$ 23,276,000	$ 23,276,000
Private Placement Warrants And Public Warrants [Member] | Measurement Input, Expected Term [Member]
Class of Stock [Line Items]
Warrant expected term		5 years		5 years	5 years
Private Placement Warrants And Public Warrants [Member] | Measurement Input, Price Volatility [Member]
Class of Stock [Line Items]
Warrant measurement inputs		22		22	22
Private Placement Warrants And Public Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]
Class of Stock [Line Items]
Warrant measurement inputs		0		0	0
Private Placement Warrants And Public Warrants [Member] | Measurement Input, Discount Rate [Member]
Class of Stock [Line Items]
Warrant measurement inputs		1.76		1.76	1.76
Common Class A [Member]
Class of Stock [Line Items]
Common stock, shares authorized		100,000,000		100,000,000	100,000,000	100,000,000
Common stock, par value | $ / shares		$ 0.0001		$ 0.0001	$ 0.0001	$ 0.0001
Voting rights		Holders of Class A common stock are entitled to one vote for each share			Holders of Class A common stock are entitled to one vote for each share.
Common stock, shares issued		754,000		754,000	754,000	0
Common stock, shares outstanding		754,000		754,000	754,000	0
Shares subject to possible redemption		2,187,728		13,225,000	13,225,000	13,225,000
Stock redeemed, value | $		$ 114,068,280
Price per share | $ / shares		$ 10.33
Common Class B [Member]
Class of Stock [Line Items]
Common stock, shares authorized		10,000,000		10,000,000	10,000,000	10,000,000
Common stock, par value | $ / shares		$ 0.0001		$ 0.0001	$ 0.0001	$ 0.0001
Common stock, shares issued		3,306,250		3,306,250	3,306,250	3,306,250
Common stock, shares outstanding		3,306,250		3,306,250	3,306,250	3,306,250
[1]As of March 31, 2023, $ 236,350

SCHEDULE OF FAIR VALUE OF ASSET

SCHEDULE OF FAIR VALUE OF ASSETS AND LIABILITIES (Details) - USD ($)	Mar. 31, 2023	Jan. 26, 2023	Dec. 31, 2022	Dec. 31, 2021
Assets:
Investments held in Trust Account	$ 23,658,838	$ 24,000,000	$ 136,871,183
Fair Value, Inputs, Level 1 [Member]
Assets:
Investments held in Trust Account	$ 23,658,838		$ 136,871,183

TAXES (Details Narrative)

TAXES (Details Narrative)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Effective income tax rate		21%	21%
Change in valuation allowance, rate	23.30%	27.36%

SCHEDULE OF EFFECTIVE INCOME TA

SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION (Details)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Equity [Abstract]
U.S. federal statutory rate		21%	21%
State taxes, net of federal benefit		0.10%
Change in valuation allowance	23.30%	27.36%
Income tax provision		48.46%

SCHEDULE OF DEFERRED TAX ASSETS

SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)	Dec. 31, 2022 USD ($)
Deferred tax assets:
Startup costs	$ 211,627
Total deferred tax assets	211,627
Valuation Allowance	(211,627)
Net deferred tax asset

SCHEDULE OF CHANGE IN VALUATION

SCHEDULE OF CHANGE IN VALUATION (Details) - USD ($)	2 Months Ended	3 Months Ended		12 Months Ended
	Dec. 31, 2021	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Equity [Abstract]
Current				$ 374,862
Deferred				(211,627)
Current
Deferred
Change in valuation				211,627
Income Tax Provision		$ 36,557		$ 374,862

STOCKHOLDERS_ EQUITY (DEFICIT_2

STOCKHOLDERS’ EQUITY (DEFICIT) (Details Narrative)	3 Months Ended	12 Months Ended
	Mar. 31, 2023 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) $ / shares shares	Jan. 26, 2023 USD ($)	Dec. 31, 2021 USD ($) $ / shares shares
Class of Stock [Line Items]
Preferred Stock, Shares Authorized	1,000,000	1,000,000		1,000,000
Preferred stock, par value | $ / shares	$ 0.0001	$ 0.0001		$ 0.0001
Preferred stock shares issued	0	0		0
Preferred stock shares outstanding	0	0		0
Shares subject to possible redemption	2,187,728	13,225,000
Warrant exercise price | $ / shares	$ 0.01	$ 0.01
Investments held in trust account | $	$ 23,658,838	$ 136,871,183	$ 24,000,000
Financial Service [Member]
Class of Stock [Line Items]
Investments held in trust account | $				$ 0
Warrant [Member]
Class of Stock [Line Items]
Share price per shares | $ / shares	$ 18	$ 18
Private Placement Warrants And Public Warrants [Member]
Class of Stock [Line Items]
Warrants | $	$ 23,276,000	$ 23,276,000
Private Placement Warrants And Public Warrants [Member] | Measurement Input, Expected Term [Member]
Class of Stock [Line Items]
Warrant expected term	5 years	5 years
Private Placement Warrants And Public Warrants [Member] | Measurement Input, Price Volatility [Member]
Class of Stock [Line Items]
Warrant measurement inputs	22	22
Private Placement Warrants And Public Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]
Class of Stock [Line Items]
Warrant measurement inputs	0	0
Private Placement Warrants And Public Warrants [Member] | Measurement Input, Discount Rate [Member]
Class of Stock [Line Items]
Warrant measurement inputs	1.76	1.76
Common Class A [Member]
Class of Stock [Line Items]
Common stock, shares authorized	100,000,000	100,000,000		100,000,000
Common stock, par value | $ / shares	$ 0.0001	$ 0.0001		$ 0.0001
Voting rights	Holders of Class A common stock are entitled to one vote for each share	Holders of Class A common stock are entitled to one vote for each share.
Common stock, shares issued	754,000	754,000		0
Common stock, shares outstanding	754,000	754,000		0
Shares subject to possible redemption	2,187,728	13,225,000		13,225,000
Common Class B [Member]
Class of Stock [Line Items]
Common stock, shares authorized	10,000,000	10,000,000		10,000,000
Common stock, par value | $ / shares	$ 0.0001	$ 0.0001		$ 0.0001
Common stock, shares issued	3,306,250	3,306,250		3,306,250
Common stock, shares outstanding	3,306,250	3,306,250		3,306,250